Senti Biosciences (SNTI) S-1 28 Jun 22 IPO registration Financial data

Cover Page

Cover Page	3 Months Ended
	Mar. 31, 2022
Document Information [Line Items]
Document Type	S-1
Amendment Flag	false
Entity Registrant Name	SENTI BIOSCIENCES, INC.
Entity Central Index Key	0001854270
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Current assets
Cash and cash equivalents	$ 38,140,000	$ 56,034,000	$ 30,537,000
Prepaid expenses and other current assets	1,003,000	798,000
Trade and other receivables Current	430,000	483,000	88,000
Prepaid expense and other current assets	6,048,000	3,676,000	1,084,000
Total current assets	44,618,000	60,193,000	31,709,000
Restricted Cash, Noncurrent	3,257,000	3,257,000	497,000
Property, Plant and Equipment, Net	24,067,000	12,368,000	3,312,000
Operating Lease, Right-of-Use Asset	20,178,000	20,708,000	12,827,000
Other long-term assets	186,000	176,000	0
TOTAL ASSETS	92,306,000	96,702,000	48,345,000
Current liabilities:
Accounts payable	5,657,000	5,187,000	914,000
Early exercise liability, current portion	325,000	626,000	0
Preferred stock tranche liability		0	435,000
Deferred revenue	1,379,000	1,656,000	0
Accrued expenses and other current liabilities	8,979,000	5,331,000	1,998,000
Operating lease liabilities	1,799,000	1,743,000	1,519,000
Total current liabilities	18,139,000	14,543,000	4,866,000
Operating lease liabilities, net of current portion	23,596,000	20,988,000	12,530,000
Deferred revenue, net of current portion	0	176,000	0
Early exercise liability, net of current portion	545,000	619,000	0
Total Liabilities	42,280,000	36,326,000	17,396,000
Commitments and Contingencies
Redeemable convertible preferred stock	171,833,000	171,833,000	89,662,000
Stockholders' Deficit
Common Stock	1,000	1,000	1,000
Additional paid-in capital	5,076,000	3,618,000	1,043,000
Other comprehensive income	0	0	0
Accumulated deficit	(126,884,000)	(115,076,000)	(59,757,000)
Total Stockholders' Deficit	(121,807,000)	(111,457,000)	(58,713,000)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	92,306,000	96,702,000	$ 48,345,000
DYNAMICS SPECIAL PURPOSE [Member]
Current assets
Cash and cash equivalents	396,693	889,323
Prepaid expenses and other current assets	430,459	408,042
Total current assets	827,152	1,297,365
Prepaid expenses - noncurrent	56,764	150,514
Investments held in Trust Account	230,031,946	230,008,784
TOTAL ASSETS	230,915,862	231,456,663
Current liabilities:
Accounts payable and other current liabilities	32,861	39,520
Accrued professional fees and other expenses	3,968,324	3,078,822
Franchise tax payable	50,044	163,839
Total current liabilities	4,051,229	3,282,181
Deferred underwriting fee payable	7,050,000	7,050,000
Total Liabilities	11,101,229	10,332,181
Commitments and Contingencies
Redeemable convertible preferred stock	230,000,000	230,000,000
Stockholders' Deficit
Preferred stock, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding	0	0
Additional paid-in capital	0	0
Accumulated deficit	(10,186,014)	(8,876,165)
Total Stockholders' Deficit	(10,185,367)	(8,875,518)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	230,915,862	231,456,663
DYNAMICS SPECIAL PURPOSE [Member] | Common Class A [Member]
Stockholders' Deficit
Common Stock	72	72
DYNAMICS SPECIAL PURPOSE [Member] | Common Class B [Member]
Stockholders' Deficit
Common Stock	$ 575	$ 575

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Common stock, par value	$ 0.0001	$ 0.0001	$ 0.0001
Common stock, shares authorized	138,000,000	138,000,000	138,000,000
Common stock, shares issued	16,804,476	15,189,091	14,504,193
Common stock, shares outstanding	16,804,476	15,189,091	14,504,193
Shares subject to possible redemption	99,734,543	99,734,543	58,948,067
Temporary Equity, Par or Stated Value Per Share	$ 0.0001	$ 0.0001	$ 0.0001
Temporary Equity, Shares Authorized	99,734,554	99,734,554	99,734,554
Temporary Equity, Shares Issued	99,734,543	99,734,543	58,948,067
Temporary Equity, Liquidation Preference	$ 163,834	$ 163,834	$ 96,834
DYNAMICS SPECIAL PURPOSE [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
DYNAMICS SPECIAL PURPOSE [Member] | Common Class A [Member]
Per share subject to possible redemption	$ 10	$ 10
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	23,715,500	23,715,500
Common stock, shares outstanding	715,500	715,500
Shares subject to possible redemption	23,000,000	23,000,000
Shares Issued, Price Per Share	$ 10	$ 10
DYNAMICS SPECIAL PURPOSE [Member] | Common Class B [Member]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	10,000,000	10,000,000
Common stock, shares issued	5,750,000	5,750,000
Common stock, shares outstanding	5,750,000	5,750,000
Shares subject to possible redemption		5,750,000

Condensed Consolidated Statemen

Condensed Consolidated Statements Of Operations And Comprehensive Loss - USD ($)	1 Months Ended	3 Months Ended		10 Months Ended	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Revenue:
Contract revenue		$ 854,000	$ 44,000		$ 2,291,000	$ 394,000
Grant income		250,000	28,000		470,000	172,000
Total revenue		1,104,000	72,000		2,761,000	566,000
Operating expenses:
Research and development		7,603,000	4,903,000		21,957,000	15,956,000
General and administrative		5,259,000	4,311,000		21,250,000	9,304,000
Total operating expenses		12,862,000	9,214,000		43,207,000	25,260,000
Loss from operations		(11,758,000)	(9,142,000)		(40,446,000)	(24,694,000)
Other income (expense):
Interest income, net		4,000	1,000		11,000	88,000
Change in fair value of convertible notes					0	(720,000)
Change in preferred stock tranche liability		0	(11,824,000)		(14,742,000)	5,748,000
Loss on impairment of fixed assets		0	0		(22,000)	(238,000)
Other expense		(54,000)	(37,000)		(120,000)	(46,000)
Total other income (expense), net		(50,000)	(11,860,000)		(14,873,000)	4,832,000
Net loss		$ (11,808,000)	$ (21,002,000)		(55,319,000)	(19,862,000)
Other comprehensive gain (loss):
Unrealized gain (loss) on investments					0	(13,000)
Comprehensive loss					$ (55,319,000)	$ (19,875,000)
Net loss per share, basic and diluted		$ (0.73)	$ (1.44)		$ (3.72)	$ (1.43)
Weighted-average shares outstanding, basic and diluted		16,204,614	14,602,926		14,881,325	13,862,582
DYNAMICS SPECIAL PURPOSE [Member]
Operating expenses:
Professional fees and other expenses				$ 3,702,033
Professional fees and other expenses	$ 0	$ 1,282,742
Franchise tax expense	0	50,269		163,839
Operating and formation costs	1,178	0
Loss from operations	(1,178)	(1,333,011)		(3,865,872)
Other income (expense):
Interest and dividend income on investments held in Trust Account	0	23,162		8,784
Net loss	$ (1,178)	$ (1,309,849)		$ (3,857,088)
Common Class A [Member] | DYNAMICS SPECIAL PURPOSE [Member]
Other comprehensive gain (loss):
Net loss per share, basic and diluted	$ 0	$ (0.04)		$ (0.17)
Weighted-average shares outstanding, basic and diluted	0	23,715,500		16,872,995
Common Class B [Member] | DYNAMICS SPECIAL PURPOSE [Member]
Other comprehensive gain (loss):
Net loss per share, basic and diluted	$ 0	$ (0.04)		$ (0.17)
Weighted-average shares outstanding, basic and diluted	5,000,000	5,750,000		5,418,853

Condensed Consolidated Statem_2

Condensed Consolidated Statements Of Operations And Comprehensive Loss (Parenthetical)	1 Months Ended
	Mar. 31, 2021 shares
DYNAMICS SPECIAL PURPOSE [Member] | Common Class B [Member]
Common Stock Shares Forfeiture	750,000

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) - USD ($)		Total	Common Stock [Member]	Preferred Stock [Member] Redeemable Convertible Preferred Stock [Member]	Preferred Stock [Member] Redeemable Convertible Preferred Stock [Member] Conversion Of Convertible Debt Into Redeemable Convertible Preferred Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Other Comprehensive Income	DYNAMICS SPECIAL PURPOSE [Member]	DYNAMICS SPECIAL PURPOSE [Member] Common Class A [Member]	DYNAMICS SPECIAL PURPOSE [Member] Common Class B [Member]	DYNAMICS SPECIAL PURPOSE [Member] Common Stock [Member] Common Class A [Member]	DYNAMICS SPECIAL PURPOSE [Member] Common Stock [Member] Common Class B [Member]	DYNAMICS SPECIAL PURPOSE [Member] Additional Paid-in Capital [Member]	DYNAMICS SPECIAL PURPOSE [Member] Accumulated Deficit [Member]
Balance at beginning period, Temporary equity at Dec. 31, 2019				$ 57,408,000
Balance at beginning period, Shares, Temporary equity at Dec. 31, 2019				35,199,610
Balance at beginning period at Dec. 31, 2019		$ (39,443,000)	$ 1,000			$ 438,000	$ (39,895,000)	$ 13,000
Balance at beginning period, Shares at Dec. 31, 2019			13,679,638
Issuance of Series B redeemable convertible preferred stock, Value				$ 24,314,000	$ 7,940,000
Issuance of Series B redeemable convertible preferred stock, Shares				18,262,599	5,485,858
Stock-based compensation		272,000				272,000
Unrealized loss on investments		$ (13,000)						(13,000)
Issuance of common stock, Shares		(3,103,769)	824,555
Issuance of common stock		$ 333,000				333,000
Net loss		(19,862,000)					(19,862,000)
Balance at end of period, Shares at Dec. 31, 2020			14,504,193
Balance at end of period at Dec. 31, 2020		$ (58,713,000)	$ 1,000			1,043,000	(59,757,000)	0
Balance at end of period, Temporary equity at Dec. 31, 2020				$ 89,662,000
Balance at end of period, Shares, Temporary equity at Dec. 31, 2020		58,948,067		58,948,067
Issuance of Series B redeemable convertible preferred stock, Value				$ 2,294,000
Issuance of Series B redeemable convertible preferred stock, Shares				1,420,426
Stock-based compensation		$ 372,000				372,000
Issuance of common stock, Shares			2,879,206
Issuance of common stock		1,432,000				1,432,000
Early exercise of common stock options, Shares			(2,619,677)
Early exercise of common stock options		(1,329,000)				(1,329,000)
Net loss		(21,002,000)					(21,002,000)
Balance at end of period, Shares at Mar. 31, 2021			14,763,722									0	5,750,000
Balance at end of period at Mar. 31, 2021		$ (79,240,000)	$ 1,000			1,518,000	(80,759,000)		$ 23,822			$ 0	$ 575	$ 24,425	$ (1,178)
Balance at end of period, Temporary equity at Mar. 31, 2021				$ 91,956,000
Balance at end of period, Shares, Temporary equity at Mar. 31, 2021				60,368,493
Balance at beginning period, Temporary equity at Dec. 31, 2020				$ 89,662,000
Balance at beginning period, Shares, Temporary equity at Dec. 31, 2020		58,948,067		58,948,067
Balance at beginning period at Dec. 31, 2020		$ (58,713,000)	$ 1,000			1,043,000	(59,757,000)	0
Balance at beginning period, Shares at Dec. 31, 2020			14,504,193
Issuance of Series B redeemable convertible preferred stock, Value				$ 82,171,000
Issuance of Series B redeemable convertible preferred stock, Shares				40,786,476
Stock-based compensation		2,295,000				2,295,000
Unrealized loss on investments		0
Issuance of common stock, Shares			3,103,769
Issuance of common stock		1,525,000				1,525,000
Early exercise of common stock options, Shares			(2,619,677)
Early exercise of common stock options		(1,329,000)				(1,329,000)
Vesting of early exercise of common stock options, Shares			200,806
Vesting of early exercise of common stock options		84,000				84,000
Net loss		(55,319,000)					(55,319,000)
Balance at end of period, Shares at Dec. 31, 2021			15,189,091									715,500	5,750,000
Balance at end of period at Dec. 31, 2021		$ (111,457,000)	$ 1,000			3,618,000	(115,076,000)	0	(8,875,518)			$ 72	$ 575	0	(8,876,165)
Balance at end of period, Temporary equity at Dec. 31, 2021				$ 171,833,000					230,000,000
Balance at end of period, Shares, Temporary equity at Dec. 31, 2021		99,734,543		99,734,543						23,000,000	5,750,000
Balance at beginning period at Feb. 28, 2021									0			$ 0	$ 0	0	0
Balance at beginning period, Shares at Feb. 28, 2021												0	0
Net loss									(1,178)			$ 0	$ 0	0	(1,178)
Issuance of Class B common stock to Sponsor	[1]								25,000			$ 0	$ 575	24,425	0
Issuance of Class B common stock to Sponsor, Shares	[1]											0	5,750,000
Balance at end of period, Shares at Mar. 31, 2021			14,763,722									0	5,750,000
Balance at end of period at Mar. 31, 2021		$ (79,240,000)	$ 1,000			1,518,000	(80,759,000)		23,822			$ 0	$ 575	24,425	(1,178)
Balance at end of period, Temporary equity at Mar. 31, 2021				$ 91,956,000
Balance at end of period, Shares, Temporary equity at Mar. 31, 2021				60,368,493
Balance at beginning period at Feb. 28, 2021									0			$ 0	$ 0	0	0
Balance at beginning period, Shares at Feb. 28, 2021												0	0
Net loss									(3,857,088)			$ 0	$ 0	0	(3,857,088)
Issuance of Class B common stock to Sponsor									25,000			$ 0	$ 575	24,425	0
Issuance of Class B common stock to Sponsor, Shares												0	5,750,000
Sale of 715,500 shares of Class A common stock in private placement to Sponsor, net of offering costs, Shares												715,500	0
Sale of 715,500 shares of Class A common stock in private placement to Sponsor, net of offering costs									7,138,437			$ 72	$ 0	7,138,365	0
Remeasurement of redeemable Class A common stock to redemption amount, Shares												0	0
Remeasurement of redeemable Class A common stock to redemption amount									(13,181,867)			$ 0	$ 0	(7,162,790)	(6,019,077)
Waiver of deferred underwriting commissions by underwriter, Shares												0	0
Waiver of deferred underwriting commissions by underwriter									1,000,000			$ 0	$ 0	0	1,000,000
Balance at end of period, Shares at Dec. 31, 2021			15,189,091									715,500	5,750,000
Balance at end of period at Dec. 31, 2021		$ (111,457,000)	$ 1,000			3,618,000	(115,076,000)	$ 0	(8,875,518)			$ 72	$ 575	0	(8,876,165)
Balance at end of period, Temporary equity at Dec. 31, 2021				$ 171,833,000					230,000,000
Balance at end of period, Shares, Temporary equity at Dec. 31, 2021		99,734,543		99,734,543						23,000,000	5,750,000
Stock-based compensation		$ 661,000				661,000
Issuance of common stock, Shares		(881,993)	881,993
Issuance of common stock		$ 422,000				422,000
Vesting of early exercise of common stock options, Shares			733,392
Vesting of early exercise of common stock options		375,000				375,000
Net loss		(11,808,000)					(11,808,000)		(1,309,849)			$ 0	$ 0	0	(1,309,849)
Balance at end of period, Shares at Mar. 31, 2022			16,804,476									715,500	5,750,000
Balance at end of period at Mar. 31, 2022		$ (121,807,000)	$ 1,000			$ 5,076,000	$ (126,884,000)		(10,185,367)			$ 72	$ 575	$ 0	$ (10,186,014)
Balance at end of period, Temporary equity at Mar. 31, 2022				$ 171,833,000					$ 230,000,000
Balance at end of period, Shares, Temporary equity at Mar. 31, 2022		99,734,543		99,734,543						23,000,000
[1]The period from March 1, 2021 (inception) through March 31, 2021 includes up to 750,000 shares of Class B common stock which were subject to forfeiture if the over-allotment option was not exercised in full or in part by the underwriter. The over-allotment option was exercised in full on May 28, 2021; thus, these shares are no longer subject to forfeiture (see Notes 5 and 7).

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Series B Redeemable Convertible Preferred Stock [Member]
Adjustment for preferred stock tranche liability incurred	$ 33		$ 5,400
Adjustments To Additional Paid In Capital Stock Issued Issuance Costs	$ 6		300
Series B Redeemable Convertible Preferred Stock [Member] | Conversion Of Convertible Debt Into Redeemable Convertible Preferred Stock [Member]
Adjustment for preferred stock tranche liability incurred			$ 800
Series B Redeemable Convertible Preferred Stock [Member] | Issuance Of Redeemable Convertible Preferred Stock Including Extinguishment Of Preferred Stock Tranche Liability [Member]
Adjustments To Additional Paid In Capital Stock Issued Issuance Costs		$ 6
Adjustment for extinguishment of preferred stock tranche liability		$ 15,200

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows - USD ($)	1 Months Ended	3 Months Ended		10 Months Ended	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Cash Flows from Operating Activities:
Net loss		$ (11,808,000)	$ (21,002,000)		$ (55,319,000)	$ (19,862,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation		240,000	165,000		769,000	564,000
Amortization of operating lease right-of-use assets		770,000	375,000		2,241,000	1,421,000
Accretion of discount on short-term investments					0	(3,000)
Change in fair value of convertible notes					0	720,000
Change in preferred stock tranche liability		0	11,824,000		14,742,000	(5,748,000)
Stock-based compensation expense		661,000	372,000		2,295,000	272,000
Loss on impairment of fixed assets		0	0		22,000	238,000
Loss on write-off of fixed assets		12,000	0
Changes in operating assets and liabilities:
Accrued expenses and other current liabilities		(1,413,000)	(98,000)		2,574,000	(37,000)
Accounts payable		(164,000)	723,000		(617,000)	(324,000)
Accounts receivable		53,000	60,000		(395,000)	(10,000)
Prepaid expenses and other assets		(381,000)	(431,000)		(1,642,000)	(231,000)
Deferred revenue		(453,000)	0		1,832,000	165,000
Operating lease liabilities		2,424,000	(353,000)		(1,137,000)	(1,338,000)
Net cash from operating activities		(10,059,000)	(8,365,000)		(34,635,000)	(24,173,000)
Cash Flows from Investing Activities:
Purchase of short-term investments					0	(446,000)
Maturity of short-term investments					0	12,965,000
Purchases of property and equipment		(7,380,000)	(206,000)		(5,543,000)	(1,161,000)
Net cash from investing activities		(7,380,000)	(206,000)		(5,543,000)	11,358,000
Cash Flows from Financing Activities:
Payment of issuance costs related to Series B redeemable convertible preferred stock		0	(42,000)
Proceeds from issuance of common stock upon exercise of stock options		140,000	1,432,000		1,500,000	333,000
Proceeds from issuance of notes converted to Series B redeemable convertible preferred stock					0	8,000,000
Proceeds from issuance of Series B redeemable convertible preferred stock		0	2,333,000		67,000,000	30,000,000
Payment of redeemable convertible preferred stock issuance costs					(48,000)	(282,000)
Payment of deferred offering costs		0	(165,000)
Payment of deferred transaction costs related to pending business combination		(595,000)	0
Net cash provided by financing activities		(455,000)	3,558,000		68,435,000	38,051,000
Net change in cash and cash equivalents		(17,894,000)	(5,013,000)		28,257,000	25,236,000
Cash, cash equivalents, and restricted cash, beginning of the year		59,291,000	31,034,000		31,034,000	5,798,000
Cash, cash equivalents, and restricted cash, end of the year	$ 26,021,000	41,397,000	26,021,000	$ 59,291,000	59,291,000	31,034,000
Reconciliation of cash, cash equivalents and restricted cash [Abstract]
Cash and cash equivalents	25,524,000	38,140,000	25,524,000	56,034,000	56,034,000	30,537,000
Restricted Cash	497,000	3,257,000	497,000
Total cash, cash equivalents and restricted cash	26,021,000	41,397,000	26,021,000	59,291,000	59,291,000	31,034,000
Supplemental disclosures of non-cash investing and financing activities:
Purchase of property and equipment in accounts payable and accrued expenses		8,920,000	115,000		4,439,000	39,000
Conversion of convertible notes to Series B redeemable convertible preferred stock and Series B preferred stock tranche liability					0	8,720,000
Recognition of Series B preferred stock tranche liability		0	33,000		33,000	6,183,000
Extinguishment of Series B preferred stock tranche liability					15,210,000	0
Deferred transaction costs related to pending business combination in accounts payable and accrued expenses		2,462,000	94,000		1,429,000	0
Receivables in transit from issuance of common stock upon exercise of stock options		306,000	0		25,000	$ 0
Preferred stock issuance costs included in accounts payable and accrued expenses		0	5,000
DYNAMICS SPECIAL PURPOSE [Member]
Cash Flows from Operating Activities:
Net loss	(1,178)	(1,309,849)		(3,857,088)
Adjustments to reconcile net loss to net cash used in operating activities:
Interest and dividend income on investments held in Trust Account	0	(23,162)		(8,784)
Payment of operating and formation costs by related party	150	0
Changes in operating assets and liabilities:
Prepaid expenses				(558,556)
Prepaid expenses and other current assets	0	71,333
Accounts payable and other current liabilities	1,028	(6,659)		39,520
Accrued expenses and other current liabilities	0	889,502		3,078,822
Franchise tax payable	0	(113,795)		163,839
Net cash from operating activities	0	(492,630)		(1,142,247)
Cash Flows from Investing Activities:
Cash deposited into Trust Account				(230,000,000)
Net cash from investing activities				(230,000,000)
Cash Flows from Financing Activities:
Proceeds from promissory note—related party				250,000
Repayment of promissory note—related party				(250,000)
Proceeds from initial public offering, net of underwriting discount paid				225,400,000
Proceeds from sale of private placement shares				7,155,000
Payment of issuance costs related to Series B redeemable convertible preferred stock				(523,430)
Net cash provided by financing activities				232,031,570
Net change in cash and cash equivalents	0	(492,630)		889,323
Cash, cash equivalents, and restricted cash, beginning of the year	0	889,323		0
Cash, cash equivalents, and restricted cash, end of the year	0	396,693	0	889,323	889,323
Reconciliation of cash, cash equivalents and restricted cash [Abstract]
Cash and cash equivalents		396,693		889,323	889,323
Total cash, cash equivalents and restricted cash	0	396,693	$ 0	889,323	$ 889,323
Supplemental disclosures of non-cash investing and financing activities:
Deferred offering costs included in accrued offering costs	337,157	0
Deferred offering costs included in due to related party	11,500	0
Remeasurement of Class A common stock subject to redemption to redemption value				13,181,867
Deferred underwriting fee payable				8,050,000
Offering costs paid in exchange for issuance of Class B common stock to Sponsor	$ 25,000	$ 0		25,000
Waiver of deferred underwriting commissions by underwriter				$ 1,000,000

Organization and Description of

Organization and Description of Business and Basis of Presentation	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Description of Business and Basis of Presentation	1. Organization and Description of Business and Basis of Presentation Senti Biosciences, Inc. or (the “Company”), was incorporated under the laws of the State of Delaware in June 2016, and is a biotechnology company that programs next-generation cell and gene therapies with what we refer to as “gene circuits.” The Company is headquartered in South San Francisco, California. Basis of Presentation The accompanying condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and as amended by Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”). The condensed consolidated financial statements include the accounts of Senti Biosciences, Inc., and its wholly-owned subsidiary. All intercompany balances and transactions have been eliminated in consolidation. We have one business activity and operate in one reportable segment. Reclassification Certain prior period amounts in Note 4, Other Financial Statement Information Liquidity and Going Concern The Company has devoted substantially all of its efforts to organizing and staffing, business planning, raising capital, and conducting preclinical studies and has not realized substantial revenues from its planned principal operations. In addition, the Company has a limited operating history, has incurred recurring operating losses and negative cash flows from operations since inception, has an accumulated deficit, has funded its operations primarily with proceeds from sale of redeemable convertible preferred stock and the issuance of convertible notes, and expects that it will continue to incur net losses and negative cash flows from operations into the foreseeable future, particularly as the Company advances its preclinical activities and clinical trials for its product candidates in development. The Company’s continued existence is dependent upon management’s ability to develop profitable operations. Management is devoting substantially all of its efforts to developing its business and raising capital and there can be no assurance that the Company’s efforts will be successful. No assurance can be given that management’s actions will result in profitable operations or the meeting of ongoing liquidity needs. The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. In 2021 and 2020, the Company received aggregate proceeds of $67.0 million and $30.0 million, respectively, from the issuance of its Series B redeemable convertible preferred stock. Additionally, in 2020, the Company received $8.0 million from the issuance of promissory notes. As of March 31, 2022, the Company had an accumulated deficit of $126.9 million, and cash, cash equivalents and restricted cash of $41.4 million. As of December 31, 2021, the Company had an accumulated deficit of $115.1 million, and cash, cash equivalents and restricted cash of $59.3 million. As of May 20, 2022, the issuance date of the condensed consolidated financial statements as of and for the three months ended March 31, 2022, the Company expects that its cash and cash equivalents will not be sufficient to fund its operating expenses and capital expenditure requirements for at least one year from the issuance date of the condensed consolidated financial statements and therefore the Company concluded that substantial doubt existed about the Company’s ability to continue as a going concern. The Company is seeking to complete a liquidity event via a special purpose acquisition company (“SPAC”) (see pending merger with Dynamics Special Purpose Corp. Pending Merger with Dynamics Special Purpose Corp. On December 19, 2021, the Company entered into a Business Combination Agreement with Dynamics Special Purpose Corp. (“DYNS”), a publicly-traded SPAC. Under the terms of the proposed transaction, DYNS will merge with the Company at an estimated combined enterprise value of approximately $276.0 million. The cash components of the transaction will be funded by DYNS’ cash in trust of $230.0 million (assuming no redemptions) as well as a $66.8 million private placement of common stock at $10.00 per share from various accredited investors.	1. Organization and Description of Business Senti Biosciences, Inc. or (the “Company”), was incorporated under the laws of the State of Delaware in June 2016, and is a biotechnology company that programs next-generation cell and gene therapies with what we refer to as “gene circuits.” The Company is headquartered in South San Francisco, California. Liquidity and Going Concern The Company has devoted substantially all of its efforts to organizing and staffing, business planning, raising capital, and conducting preclinical studies and has not realized substantial revenues from its planned principal operations. In addition, the Company has a limited operating history, has incurred recurring operating losses and negative cash flows from operations since inception, has an accumulated deficit, has funded its operations primarily with proceeds from sale of redeemable convertible preferred stock and the issuance of convertible notes, and expects that it will continue to incur net losses and negative cash flows from operations into the foreseeable future, particularly as the Company advances its preclinical activities and clinical trials for its product candidates in development. The Company’s continued existence is dependent upon management’s ability to develop profitable operations. Management is devoting substantially all of its efforts to developing its business and raising capital and there can be no assurance that the Company’s efforts will be successful. No assurance can be given that management’s actions will result in profitable operations or the meeting of ongoing liquidity needs. The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. In 2021 and 2020, the Company received aggregate proceeds of $67.0 million and $30.0 million, respectively, (Note 6) from the issuance of its Series B redeemable convertible preferred stock. Additionally, in 2020, the Company received $8.0 million from the issuance of promissory notes (Note 5). As of December 31, 2021, the Company had an accumulated deficit of $115.1 million, and cash, cash equivalents and restricted cash of $59.3 million. As of December 31, 2020, the Company had an accumulated deficit of $59.8 million, and cash, cash equivalents and restricted cash of $31.0 million. As of April 1, 2022, the issuance date of the consolidated financial statements as of and for the year ended December 31, 2021, the Company expects that its cash and cash equivalents will not be sufficient to fund its operating expenses and capital expenditure requirements for at least one year from the issuance date of the consolidated financial statements and therefore the Company concluded that substantial doubt existed about the Company’s ability to continue as a going concern. The Company is seeking to complete a liquidity event via a special purpose acquisition company (“SPAC”) (see pending merger with Dynamics Special Purpose Corp. Pending Merger with Dynamics Special Purpose Corp. On December 19, 2021, the Company entered into a Business Combination Agreement with Dynamics Special Purpose Corp. (“DYNS”), a publicly traded SPAC. Under the terms of the proposed transaction, DYNS will merge with the Company at an estimated combined enterprise value of approximately $276.0 million. The cash components of the transaction will be funded by DYNS’ cash in trust of $230.0 million (assuming no redemptions) as well as a $66.8 million private placement of common stock at $10.00 per share from various accredited investors.

Description of Organization, Bu

Description of Organization, Business Operations, and Going Concern	3 Months Ended	10 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
DYNAMICS SPECIAL PURPOSE [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Description of Organization, Business Operations, and Going Concern	NOTE 1. DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS, AND GOING CONCERN Dynamics As of March 31, 2022, the Company had not commenced any operations. All activity for the period from March 1, 2021 (inception) through March 31, 2022 related to the Company’s formation, its initial public offering (“Initial Public Offering”), which is described below, and identifying a target company for a Business Combination and negotiating and entering into binding agreements in respect of such Business Combination. The Company will not generate any operating revenues until after the completion of a Business Combination, at the earliest. The Company generates non-operating The registration statement for the Initial Public Offering was declared effective on May 25, 2021. On May 28, 2021, the Company consummated the Initial Public Offering of 23,000,000 shares of Class A common stock (the “Public Shares”), including 3,000,000 shares of Class A common stock that were issued pursuant to the underwriter’s exercise of its over-allotment option in full, at $10.00 per Public Share, generating gross proceeds of $230,000,000, which is discussed in Note 3. Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of 715,500 shares of Class A common stock (the “Private Placement Shares”) at a price of $10.00 per Private Placement Share in a private placement to Dynamics Sponsor LLC (the “Sponsor”), generating gross proceeds of $7,155,000, which is described in Note 4. Transaction costs amounted to $13,198,430 consisting of $4,600,000 of underwriting fees, $8,050,000 of deferred underwriting fees, and $548,430 of other offering costs. Subsequent to the Initial Public Offering, the underwriter agreed on December 17, 2021 to waive $1,000,000 of its deferred underwriting fees of $8,050,000, thereby reducing those fees to $7,050,000; thus, the transaction costs related to the Company’s Initial Public Offering amounted to $12,198,430. Following the closing of the Initial Public Offering on May 28, 2021, an amount of $230,000,000 ($10.00 per Public Share) from the net proceeds of the sale of the Public Shares in the Initial Public Offering and the sale of the Private Placement Shares was placed in a trust account (the “Trust Account”), and is invested only in U.S. government securities with maturities of 185 days or less, or in money market funds meeting certain conditions under Rule 2a-7 below. The Company’s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of the Private Placement Shares, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. There is no assurance that the Company will be able to complete a Business Combination, including the proposed Business Combination with Senti (as defined and discussed below) successfully. The Company must complete a Business Combination with The Company will provide its stockholders with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a stockholder meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion, subject to applicable law and stock exchange listing requirements. The stockholders will be entitled to redeem their Public Shares for a pro rata portion of the amount held in the Trust Account, calculated as of two business days prior to the completion of a Business Combination, including any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations. The Company will proceed with a Business Combination if the Company has net tangible assets of at least $5,000,001 upon consummation of such Business Combination and a majority of the shares voted are voted in favor of the Business Combination. If a stockholder vote is not required under applicable law or stock exchange listing requirements and the Company does not decide to hold a stockholder vote for business or other reasons, the Company will, pursuant to its amended and restated certificate of incorporation (the “Amended and Restated Certificate of Incorporation”), conduct the redemptions pursuant to the tender offer rules of the Securities and Exchange Commission (“SEC”), and file tender offer documents with the SEC prior to completing a Business Combination. If the Company seeks stockholder approval in connection with a Business Combination, the holders of the Founder Shares (as defined in Note 5) have agreed to vote their Founder Shares, Private Placement Shares and any Public Shares purchased in or after the Initial Public Offering in favor of approving a Business Combination and to waive their redemption rights with respect to any such shares in connection with a stockholder vote to approve a Business Combination. Additionally, each public stockholder may elect to redeem their Public Shares without voting, and if they do vote, irrespective of whether they vote for or against the proposed Business Combination. Notwithstanding the foregoing, if the Company seeks stockholder approval of a Business Combination and it does not conduct redemptions pursuant to the tender offer rules, the Company’s Amended and Restated Certificate of Incorporation provides that a public stockholder, together with any affiliate of such stockholder or any other person with whom such stockholder is acting in concert or as a “group” (as defined under Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), will be restricted from redeeming its shares with respect to more than an aggregate of 15% of the Public Shares without the Company’s prior written consent. The initial stockholders have agreed to waive (a) their redemption rights with respect to any Founder Shares, Private Placement Shares and Public Shares they hold in connection with the completion of an initial Business Combination, (b) their redemption rights with respect to any Founder Shares, Private Placement Shares and Public Shares they hold in connection with a stockholder vote to approve an amendment to the Amended and Restated Certificate of Incorporation to modify the substance or timing of the Company’s obligation to allow redemption in connection with an initial Business Combination or to redeem 100% of the Public Shares if the Company has not consummated an initial Business Combination within 24 months from the closing of the Initial Public Offering or with respect to any material provision relating to the rights of holders of Public Shares, and (c) their rights to liquidating distributions from the Trust Account with respect to any Founder Shares and Private Placement Shares they hold if the Company fails to complete an initial Business Combination within 24 months from the closing of the Initial Public Offering. However, if the initial stockholders acquired Public Shares in or after the Initial Public Offering, such Public Shares would be entitled to liquidating distributions from the Trust Account if the Company failed to complete a Business Combination within the Combination Period (as defined below). The Company will have until May 28, 2023 to complete a Business Combination (the “Combination Period”). If the Company is unable to complete a Business Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but no more than ten business days thereafter, subject to lawfully available funds therefor, redeem the Public Shares at a per-share The underwriter has agreed to waive its rights to its deferred underwriting fees (see Note 6) held in the Trust Account in the event the Company does not complete a Business Combination within in the Combination Period and, in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution will be less than the Initial Public Offering price per Public Share ($10.00). In order to protect the amounts in the Trust Account, the Sponsor has agreed that it will be liable to the Company if and to the extent any claims by a third party for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account to below (i) $10.00 per Public Share, or (ii) the actual amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account, if less than $10.00 per Public Share due to reductions in the value of the Trust Account assets, less taxes payable, provided that such liability will not apply to any claims by a third party or prospective target business who executed a waiver of any and all rights to the monies held in the Trust Account (whether or not such waiver is enforceable), nor will it apply to any claims under the Company’s indemnity of the underwriter of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (other than the Company’s independent registered accounting firm), prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account. Business Combination Agreement On December 19, 2021, we entered into a business combination agreement (as amended from time to time, the “Business Combination Agreement”) with Merger Sub and Senti Biosciences, Inc., a Delaware corporation (“Senti”). The Business Combination Agreement provides, among other things, that on the terms and subject to the conditions set forth therein, Merger Sub will merge with and into Senti, with Senti surviving as a wholly- owned subsidiary of the Company (the “Merger”). Upon the closing of the Merger (the “Closing”), the Company will change its name to “Senti Biosciences, Inc.” The date on which the Closing actually occurs is hereinafter referred to as the “Closing Date.” The Business Combination Agreement and the transactions contemplated thereby (and contemplated in the Ancillary Documents, as defined in the Business Combination Agreement) are referred to in these Notes to unaudited condensed consolidated financial statements as the “Senti Business Combination.” The Senti Business Combination was approved by the boards of directors of each of the Company and Senti. Under the Business Combination Agreement, the Company will acquire all of the outstanding equity interests of Senti in exchange for shares of the Company’s Class A common stock, par value $0.0001 per share (the “Class A Common Stock”), based on an implied Senti equity value of $240,000,000, to be paid to Senti stockholders at the effective time of the Merger (the “Effective Time”). In addition, Senti stockholders will have the right to receive (i) an aggregate of 1,000,000 shares of Class A Common Stock if, after Closing, the volume weighted average price of the Class A Common Stock on the Nasdaq Capital Market (“Nasdaq”), or any other national securities exchange on which the shares of Class A Common Stock are then traded (“VWAP”), is greater than or equal to $15.00 over any 20 trading days within any consecutive 30 trading day period, in the period that ends on the second anniversary of the Closing Date, and (ii) an additional 1,000,000 shares of Class A Common Stock in the aggregate if, after Closing, the VWAP of Class A Common Stock is greater than or equal to $20.00 over any 20 trading days within any consecutive 30 trading day period, in the period that ends on the third anniversary of the Closing Date. Pursuant to the Business Combination Agreement, at or prior to the Effective Time, each option exercisable for Senti equity that is outstanding immediately prior to the Effective Time shall be converted into an option to purchase a number of shares of Class A Common Stock equal to the number of shares of Senti common stock subject to such option immediately prior to the Effective time multiplied by the exchange ratio derived under the Business Combination Agreement. The parties to the Business Combination Agreement have agreed to customary representations and warranties for transactions of this type. In addition, the parties to the Business Combination Agreement agreed to be bound by certain customary covenants for transactions of this type, including, among others, covenants with respect to the conduct of Senti, the Company and their respective subsidiaries during the period between execution of the Business Combination Agreement and Closing. The representations, warranties, agreements and covenants of the parties set forth in the Business Combination Agreement will terminate at Closing, except for a limited number of representations and warranties and those covenants and agreements that, by their terms, contemplate performance after Closing. Each of the parties to the Business Combination Agreement has agreed to use its reasonable best efforts to take or cause to be taken all actions, and to do or cause to be done all things, reasonably necessary to consummate and expeditiously implement the Merger. Under the Business Combination Agreement, the obligations of the parties to consummate the Merger are subject to the satisfaction or waiver of certain customary closing conditions of the respective parties, including, without limitation: (i) the approval and adoption of the Business Combination Agreement and transactions contemplated thereby by requisite vote of the Company’s stockholders (the “Company Stockholder Approval”) and Senti’s stockholders (the “Senti Stockholder Approval”); (ii) the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended; (iii) the absence of a Company Material Adverse Effect or DYNS Material Adverse Effect (each, as defined in the Business Combination Agreement) since the date of the Business Combination Agreement that is continuing; (iv) after giving effect to the transactions contemplated by the Business Combination Agreement, the Company has net tangible assets of at least $5,000,001 upon consummation of the Merger; (v) the Company’s initial listing application with Nasdaq in connection with the Merger has been approved and, immediately following the Effective Time, the Company has satisfied any applicable initial and continuing listing requirements of Nasdaq and the shares of the Company’s Class A Common Stock have been approved for listing on Nasdaq, subject only to official notice of the issuance thereof; and (vi) the registration statement filed with the SEC on Form S-4 On February 12, 2022, the Business Combination Agreement was amended by the parties thereto to reflect, among other things, (i) corrections to certain aspects section 5.7 of the Business Combination Agreement, and (ii) changes to certain terms of the options Senti granted to certain persons at the time the Business Combination Agreement was signed. Other Agreements The Business Combination Agreement contemplates the execution of various additional agreements and instruments, on or before the Closing, including, among others, the following: Sponsor Support Agreement In connection with the execution of the Business Combination Agreement, the Sponsor, as the sole holder of the Company’s Class B common stock, par value $0.0001 per share (the “Class B Common Stock”, and also referred to herein as the Founder Shares (as defined in Note 5)) and other persons party thereto (“Other Company Insiders,” and together with the Sponsor, collectively, the “Company Insiders”), entered into a support agreement with the Company and Senti (the “Sponsor Support Agreement”). Under the Sponsor Support Agreement, the Sponsor agreed to vote, at any meeting of the stockholders of the Company and in any action by written consent of the stockholders of the Company, all of such Sponsor’s Class A Common Stock and Class B Common Stock (i) in favor of (a) the Business Combination Agreement and the transactions contemplated thereby, and (b) the other proposals that the Company and Senti agreed in the Business Combination Agreement shall be submitted at such meeting for approval by the Company’s stockholders together with the proposal to obtain the Company Stockholder Approval (together with the Company Stockholder Approval, these proposals are the Required Transaction Proposals (as defined in the Business Combination Agreement)), and (ii) against any proposal that conflicts with, or materially impedes or interferes with, any such proposal or that would adversely affect or delay the Merger. The Sponsor Support Agreement also prohibits the Sponsor from, among other things and subject to certain exceptions, selling, assigning or transferring any Class A Common Stock or Class B Common Stock held by the Sponsor prior to the Closing or taking any action that would have the effect of preventing or materially delaying the Sponsor from performing its obligations under the Sponsor Support Agreement. In addition, in the Sponsor Support Agreement, the Sponsor agreed to waive, and not to assert or perfect, among other things, any rights to adjustment or other anti-dilution protections with respect to the rate at which the shares of Class B Common Stock held by the Sponsor convert into shares of Class A Common Stock in connection with the transactions contemplated by the Business Combination Agreement. The Sponsor Support Agreement also includes a lock-up in respect of the Sponsor’s equity interests in the Company. Pursuant to the Sponsor Support Agreement, the Sponsor agreed that, subject to limited exceptions, it would not sell, assign or transfer any Class A Common Stock or Class B Common Stock until the earlier of (i) the anniversary of the Closing, and (ii) subsequent to the Closing, (x) if the last reported sale price of the Class A Common Stock equals or exceeds $ per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any trading days within any consecutive trading day period commencing at least days after the Closing, or (y) the date upon completion of a liquidation, merger, stock exchange, reorganization or other similar transaction that results in all of the public stockholders having the right to exchange their common stock for cash, securities or other property. Senti Support Agreement In connection with the execution of the Business Combination Agreement, certain Senti stockholders (the “Senti Supporting Stockholders”) entered into support agreements with the Company (the “Senti Support Agreements”). Under the Senti Support Agreements, each Senti Supporting Stockholder agreed, within forty-eight hours The Senti Support Agreements also prohibit the Senti Supporting Stockholders from, among other things, (i) transferring any of the Subject Senti Shares prior to the Closing, (ii) entering into (a) any option, commitment or other arrangement that would require the Senti Supporting Stockholders to transfer the Subject Senti Shares, or (b) any voting trust, proxy or other contract with respect to the voting of the Subject Senti Shares, or (iii) taking any action in furtherance of the foregoing. In addition, under the Senti Support Agreement, each Senti Supporting Stockholder agreed (i) not to exercise any rights of appraisal or dissenter’s rights relating to the Business Combination Agreement and the transactions contemplated thereby, and (ii) not to commence or participate in any claim or action against Senti, the Company or any of their affiliates relating to the negotiation, execution or delivery of the Senti Support Agreement or the Business Combination Agreement or the consummation of the Merger. Additionally, (i) certain Senti Support Agreements prohibit the applicable Senti Supporting Stockholders from transferring the shares of Class A Common Stock which they will receive in the Merger for, subject to certain permitted transfers, up to 18 months following the Closing, which may be reduced to 12 months upon the meeting of certain criteria (such period, the “Extended Lock-Up”), Lock-Up”); Lock-Up, Lock-Up lock-up, Lock-Up, Lock-Up lock-up. On February 12, 2022, the Company entered into amendments to certain Senti Support Agreements to amend those agreements such that, among other things, the shares of Class A Common Stock of the relevant Senti Supporting Stockholders may not be transferred, subject to certain permitted transfers, for three years following the Closing (such period, “the Three Year Lock-Up”). Lock-Up Lock-Up Lock-Up PIPE Subscription Agreements In connection with the execution of the Business Combination Agreement, the Company entered into subscription agreements with certain private investors (the “Subscription Agreements”), pursuant to which, among other things, such investors have subscribed to purchase an aggregate of 6,680,000 shares of Class A Common Stock (together, the “Subscriptions”) for a purchase price of $10.00 per share, or an aggregate purchase price of $66,800,000, which shares are to be issued at the Closing; provided that the Subscription Agreements permit the Company to accept additional subscriptions for a purchase price of $10.00 per share to be issued at the Closing, following the execution of the Business Combination Agreement. The obligations of each party to consummate the Subscriptions are conditioned upon, among other things, customary closing conditions and the consummation of the transactions contemplated by the Business Combination Agreement. Non-Redemption In connection with the execution of the Business Combination Agreement, the Sponsor, as the holder of 5,750,000 shares of Class B Common Stock (the Founder Shares (as defined in Note 5)), the Company and each of certain funds and accounts managed by Morgan Stanley Investment Management Inc., T. Rowe Price Group, Inc., The Invus Group, LLC and ARK Investment Management LLC and/or their respective investment funds (each, an “Investor”, and collectively, the “Investors”) entered into non-redemption “Non-Redemption Pursuant to the Non-Redemption Non-Redemption non-discretionary shares of its Class B Common Stock and the Company agreed to cancel such shares and concurrently issue to the Investors an equivalent number of shares of Class A Common Stock, in each case, at or promptly following the consummation of the Merger. The shares of Class A Common Stock to which the Investors were entitled as at the date the Non-Redemption Agreements were signed represented approximately 11.111% of the Investors’ aggregate holdings of Public Shares as at such date. On May 9, 2022, the Company, the Sponsor and the Investors agreed to amend the Non-Redemption Agreements such that the number of shares of Class A Common Stock to which each Investor may be entitled equals 11.111% of the number of Public Shares held by the Investor at the time the Merger is consummated (as opposed to when the Non-Redemption Agreement was signed). As at April 29, 2022, 7,968,483 shares of Class A Common Stock, in the aggregate, were subject to Non-Redemption and an equivalent number of shares of Class B Common Stock will be forfeited by the Sponsor and canceled by the Company (as opposed to 965,728 shares, as was the case prior to such amendments to the Non-Redemption Agreements). Investor Rights Agreement In connection with the Closing, the Company, certain stockholders of the Company (including the Sponsor) and certain stockholders of Senti will enter into an investor rights and lock-up The Investor Rights Agreement will also restrict the ability of each stockholder who is a party thereto (other than the Company) to transfer its shares of Class A Common Stock (or any securities convertible into or exercisable or exchangeable for shares of Class A Common Stock) for, subject to certain permitted transfers and depending on the stockholder, a period of one year following the Closing Date (the “12 Month Lock-Up”) Lock-Up”); Lock-Up, Lock-Up lock-up; Lock-Up, Lock-Up lock-up. Going Concern As of March 31, 2022, the Company had $396,693 in cash held outside of the Trust Account and a working capital deficit of $3,224,077. The Company has incurred and expects to continue to incur significant costs in pursuit of its acquisition plans (including in respect of the Senti Business Combination). These conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of time within one year after the date that the unaudited condensed consolidated financial statements are issued. Management plans to address this uncertainty through the Senti Business Combination, as discussed above. There is no assurance that the Company’s plans to consummate the Senti Business Combination (or any other Business Combination) will be successful or successful within the Combination Period. The unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Risks and Uncertainties Management continues to evaluate the impact of the COVID-19 Additionally, as a result of the military action commenced in February 2022 by the Russian Federation and Belarus in the country of Ukraine and related economic sanctions, the Company’s ability to consummate a Business Combination, or the operations of a target business with which the Company ultimately consummates a Business Combination, may be materially and adversely affected. In addition, the Company’s ability to consummate a transaction may be dependent on the ability to raise equity and debt financing which may be impacted by these events, including as a result of increased market volatility, or decreased market liquidity in third-party financing being unavailable on terms acceptable to the Company or at all. The impact of this action and related sanctions on the world economy and the specific impact on the Company’s financial position, results of operations and/or ability to consummate a Business Combination are not yet determinable. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.​​​​​​​	NOTE 1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS Dynamics Special Purpose Corp. (the “Company”) is a blank check company incorporated in Delaware on March 1, 2021. As used herein, “the Company” refers to Dynamics Special Purpose Corp. and its wholly- owned and As of December 31, 2021, the Company had not commenced any operations. All activity for the period from March 1, 2021 (inception) through December 31, 2021 relates to the Company’s formation, the initial public offering (“Initial Public Offering”), which is described below, and identifying a target company for a Business Combination and negotiating and entering into binding agreements in respect of such Business Combination. The Company will not generate any operating revenues until after the completion of a Business Combination, at the earliest. The Company will generatenon-operatingincome in the form of interest income on the proceeds derived from the Initial Public Offering. The Company has selected December 31 as its fiscal year end. The registration statement for the Initial Public Offering was declared effective on May 25, 2021. On May 28, 2021, the Company consummated the Initial Public Offering of 23,000,000 shares of Class A common stock (the “Public Shares”), including 3,000,000 shares of Class A common stock that were issued pursuant to the underwriter’s exercise of its Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of 715,500 shares of Class A common stock (the “Private Placement Shares”) at a price of $10.00 per Private Placement Share in a private placement to Dynamics Sponsor LLC (the “Sponsor”), generating gross proceeds of $7,155,000, which is described in Note 4. Transaction costs for the Initial Public Offering amounted to $13,198,430 consisting of $4,600,000 of underwriting fees, $8,050,000 of deferred underwriting fees, and $548,430 of other offering costs. Subsequent to the Initial Public Offering, the underwriter agreed on December 17, 2021 to waive $1,000,000 of its deferred underwriting fees of $8,050,000, thereby reducing those fees to $7,050,000; thus, the transaction costs related to our Initial Public Offering amounted to $12,198,430. Following the closing of the Initial Public Offering on May 28, 2021, an amount of $230,000,000 ($10.00 per Public Share) from the net proceeds of the sale of the Public Shares in the Initial Public Offering and the sale of the Private Placement Shares was placed in a trust account (the “Trust Account”), and will be invested only in U.S. government securities with maturities of 185 days or less , 2a-7 , The Company’s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of the Private Placement Shares, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. There is no assurance that the Company will be able to complete a Business Combination successfully. The Company must complete a Business Combination with one or more target businesses that together have an aggregate fair market value of at least 80% of the value of the Trust Account (excluding the deferred underwriting fees The Company will provide its stockholders with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a stockholder meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion, subject to applicable law and stock exchange listing requirements. The stockholders will be entitled to redeem their Public Shares for a pro rata portion of the amount held in the Trust Account (initially anticipated to be $10.00 per share), calculated as of two business days prior to the completion of a Business Combination, including any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations. The Company will proceed with a Business Combination if the Company has net tangible assets of at least $ upon consummation of such Business Combination and a majority of the shares voted are voted in favor of the Business Combination. If a stockholder vote is not required under applicable law or stock exchange listing requirements and the Company does not decide to hold a stockholder vote for business or other reasons, the Company will, pursuant to its amended and restated certificate of incorporation (the “Amended and Restated Certificate of Incorporation”), conduct the redemptions pursuant to the tender offer rules of the Securities and Exchange Commission (“SEC”), and file tender offer documents with the SEC prior to completing a Business Combination. If the Company seeks stockholder approval in connection with a Business Combination, the holders of the Founder Shares (as defined in Note 5) have agreed to vote their Founder Shares, Private Placement Shares and any Public Shares purchased in or after the Initial Public Offering in favor of approving a Business Combination and to waive their redemption rights with respect to any such shares in connection with a stockholder vote to approve a Business Combination. Additionally, each public stockholder may elect to redeem their Public Shares without voting, and if they do vote, irrespective of whether they vote for or against the proposed Business Combination. Notwithstanding the foregoing, if the Company seeks stockholder approval of a Business Combination and it does not conduct redemptions pursuant to the tender offer rules, the Company’s Amended and Restated Certificate of Incorporation provides that a public stockholder, together with any affiliate of such stockholder or any other person with whom such stockholder is acting in concert or as a “group” (as defined under Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), will be restricted from redeeming its shares with respect to more than an aggregate of 15% of the Public Shares without the Company’s prior written consent. The initial stockholders have agreed to waive (a) their redemption rights with respect to any Founder Shares, Private Placement Shares and Public Shares they hold in connection with the completion of an initial Business Combination, (b) their redemption rights with respect to any Founder Shares, Private Placement Shares and Public Shares they hold in connection with a stockholder vote to approve an amendment to the Amended and Restated Certificate of Incorporation to modify the substance or timing of the Company’s obligation to allow redemption in connection with an initial Business Combination or to redeem of the Public Shares if the Company has not consummated an initial Business Combination within from the closing of the Initial Public Offering or with respect to any material provision relating to the rights of holders of Public Shares, and (c) their rights to liquidating distributions from the Trust Account with respect to any Founder Shares and Private Placement Shares they hold if the Company fails to complete an initial Business Combination within 24 months from the closing of the Initial Public Offering. However, if the initial stockholders acquire Public Shares in or after the Initial Public Offering, such Public Shares will be entitled to liquidating distributions from the Trust Account if the Company fails to complete a Business Combination within the Combination Period (as defined below). The Company will have until May 28, 2023 to complete a Business Combination (the “Combination Period”). If the Company is unable to complete a Business Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but no more than ten business days thereafter, subject to lawfully available funds therefor, redeem the Public Shares at aper-shareprice, payable in cash, equal to the aggregate amount then on deposit in the Trust Account , interest to pay dissolution expenses), divided by the number of then-outstanding Public Shares, which redemption will completely extinguish public stockholders’ rights as stockholders (including the right to receive further liquidating distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining stockholders and board of directors, dissolve and liquidate, subject in each case to the Company’s obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law. The underwriter has agreed to waive its rights to its deferred underwriting commission (see Note 6) held in the Trust Account in the event the Company does not complete a Business Combination within in the Combination Period and, in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution will be less than the Initial Public Offering price per Public Share ($10.00). In order to protect the amounts in the Trust Account, the Sponsor has agreed that it will be liable to the Company if and to the extent any claims by a third party for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account to below (i) $10.00 per Public Share, or (ii) the actual amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account, if less than $10.00per Public Share due to reductions in the value of the Trust Account assets, less taxes payable, provided that such liability will not apply to any claims by a third party or prospective target business who executed a waiver of any and all rights to the monies held in the Trust Account (whether or not such waiver is enforceable), nor will it apply to any claims under the Company’s indemnity of the underwriter of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (other than the Company’s independent registered accounting firm), prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account. Business Combination Agreement On December 19, 2021, the Company entered into a business combination agreement (the “Business Combination Agreement”) by and among the Company, Merger Sub and Senti Biosciences, Inc., a Delaware corporation (“Senti”). The Business Combination Agreement provides, among other things, that on the terms and subject to the conditions set forth therein, Merger Sub will merge with and into Senti, with Senti surviving as a wholly-owned subsidiary of the Company (the “Merger”). Upon the closing of the Merger (the “Closing”), the Company will change its name to “Senti Biosciences, Inc.” The date on which the Closing actually occurs is hereinafter referred to as the “Closing Date.” The Business Combination Agreement and the transactions contemplated thereby are referred to in these Notes to Consolidated Financial Statements Under the Business Combination Agreement, the Company will acquire all of the outstanding equity interests of Senti in exchange for shares of the Company’s Class A common stock, par value $0.0001 per share (the “Class A Common Stock”), based on an implied Senti equity value of $240,000,000, to be paid to Senti stockholders at the effective time of the Merger (the “Effective Time”). In addition, Senti stockholders will have the right to receive (i) an aggregate of 1,000,000 shares of Class A Common Stock if, after Closing, the volume weighted average price of the Class A Common Stock or equal to $15.00 over any 20 trading days within any consecutive 30 trading day period, in the period that ends on the second third Pursuant to the Business Combination Agreement, at or prior to the Effective Time, each option exercisable for Senti equity that is outstanding immediately prior to the Effective Time shall be assumed by the Company and continue in full force and effect on the same terms and conditions as are currently applicable to such options, subject to adjustments to exercise price and number of shares of Class A Common Stock issued upon exercise. The parties to the Business Combination Agreement have agreed to customary representations and warranties for transactions of this type. In addition, the parties to the Business Combination Agreement agreed to be bound by certain customary covenants for transactions of this type, including, among others, covenants with respect to the conduct of Senti, the Company and their respective subsidiaries during the period between execution of the Business Combination Agreement and Closing. The representations, warranties, agreements and covenants of the parties set forth in the Business Combination Agreement will terminate at Closing, except for those covenants and agreements that, by their terms, contemplate performance after Closing. Each of the parties to the Business Combination Agreement has agreed to use its reasonable best efforts to take or cause to be taken all actions, and to do or cause to be done all things, reasonably necessary to consummate and expeditiously implement the Merger. Under the Business Combination Agreement, the obligations of the parties to consummate the Merger are subject to the satisfaction or waiver of certain customary closing conditions of the respective parties, including, without limitation: (i) the approval and adoption of the Business Combination Agreement and transactions contemplated thereby by requisite vote of the Company’s stockholders (the “Company Stockholder Approval”) and Senti’s stockholders (the “Senti Stockholder Approval”); (ii) the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended; (iii) the absence of a Company Material Adverse Effect or DYNS Material Adverse Effect (each, as defined in the Business Combination Agreement) since the date of the Business Combination Agreement that is continuing; (iv) after giving effect to the transactions contemplated by the Business Combination Agreement, the Company has net tangible assets of at least upon consummation of the Merger; (v) the Company’s initial listing application with Nasdaq in connection with the Merger has been approved and, immediately following the Effective Time, the Company has satisfied any applicable initial and continuing listing requirements of Nasdaq and the shares of the Company’s Class A Common Stock have been approved for listing on Nasdaq, subject only to official notice of the issuance thereof; and (vi) the registration statement filed with the SEC on Form S-4 (after reduction for the aggregate amount of payments made or required to be made in connection with the DYNS Stockholder Redemption (as defined in the Business Combination Agreement)) and the amount of funds available pursuant to the PIPE Financing (as defined in the Business Combination Agreement). On February 12, 2022, following the period to which these consolidated financial statements relate, the Business Combination Agreement was amended by the parties thereto to reflect, among other things, (i) a correction to section 5.7 of the Business Combination Agreement, and (ii) changes to the options Senti granted to certain persons at the time the Business Combination Agreement was signed. Other Agreements The Business Combination Agreement contemplates the execution of various additional agreements and instruments, on or before the Closing, including, among others, the following: Sponsor Support Agreement In connection with the execution of the Business Combination Agreement, the Sponsor, as the sole holder of the Company’s Class B common stock, par value $0.0001per share (the “Class B Common Stock”, and also referred to herein as the Founder Shares (as defined in Note 5)) and other persons party thereto (“Other Company Insiders,” and together with the Sponsor, collectively, the “Company Insiders”), entered into a support agreement with the Company and Senti (the “Sponsor Support Agreement”). Under the Sponsor Support Agreement, the Sponsor agreed to vote, at any meeting of the stockholders of the Company and in any action by written consent of the stockholders of the Company, all of such Sponsor’s Class A Common Stock and Class B Common Stock (i) in favor of (a) the Business Combination Agreement and the transactions contemplated thereby, and (b) the other proposals that the Company and Senti agreed in the Business Combination Agreement shall be submitted at such meeting for approval by the Company’s stockholders together with the proposal to obtain the Company Stockholder Approval (together with the Company Stockholder Approval, these proposals are the Required Transaction Proposals (as defined in the Business Combination Agreement)), and (ii) against any proposal that conflicts with, or materially impedes or interferes with, any such proposal or that would adversely affect or delay the Merger. The Sponsor Support Agreement also prohibits the Sponsor from, among other things and subject to certain exceptions, selling, assigning or transferring any Class A Common Stock or Class B Common Stock held by the Sponsor prior to the Closing or taking any action that would have the effect of preventing or materially delaying the Sponsor from performing its obligations under the Sponsor Support Agreement. In addition, in the Sponsor Support Agreement, the Sponsor agreed to waive, and not to assert or perfect, among other things, any rights to adjustment or other anti-dilution protections with respect to the rate at which the shares of Class B Common Stock held by the Sponsor convert into shares of Class A Common Stock in connection with the transactions contemplated by the Business Combination Agreement. The Sponsor Support Agreement also includes a lock-up in respect of the Sponsor’s equity interests in the Company. Pursuant to the Sponsor Support Agreement, the Sponsor agreed that, subject to limited exceptions, it would not sell, assign or transfer any Class A Common Stock or Class B Common Stock until the earlier of (i) the one year anniversary of the Closing, and (ii) subsequent to the Closing, (x) if the last reported sale price of the Class A Common Stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30 consecutive trading day period commencing at least 150 days after the Closing, or (y) the date upon completion of a liquidation, merger, stock exchange, reorganization or other similar transaction that results in all of the public stockholders having the right to exchange their common stock for cash, securities or other property. Senti Support Agreement In connection with the execution of the Business Combination Agreement, certain Senti stockholders (the “Senti Supporting Stockholders”) entered into support agreements with the Company (the “Senti Support Agreements”). Under the Senti Support Agreements, each Senti Supporting Stockholder agreed, within forty-eight hours following the effectiveness of the Registration Statement, to execute and deliver a written consent with respect to all outstanding shares of Senti common stock and preferred stock held by such Senti Supporting Stockholder (the “Subject Senti Shares”) approving the Business Combination Agreement and the transactions contemplated thereby. In addition to the foregoing, each Senti Supporting Stockholder agreed that, at any meeting of the holders of Senti capital stock, each such Senti Supporting Stockholder will appear at the meeting, in person or by proxy, and cause its Subject Senti Shares to be voted (i) to approve and adopt the Business Combination Agreement, the transactions contemplated thereby, and any other matters necessary or reasonably requested by Senti for consummation of the Merger, and (ii) against any proposal that conflicts or materially impedes or interferes with, or would adversely affect or delay, the consummation of the transactions contemplated by the Business Combination Agreement. The Senti Support Agreement also prohibits the Senti Supporting Stockholders from, among other things, (i) transferring any of the Subject Senti Shares prior to the Closing, (ii) entering into (a) any option, commitment or other arrangement that would require the Senti Supporting Stockholders to transfer the Subject Senti Shares, or (b) any voting trust, proxy or other contract with respect to the voting of the Subject Senti Shares, or (iii) taking any action in furtherance of the foregoing. In addition, under the Senti Support Agreement, each Senti Supporting Stockholder agreed (i) not to exercise any rights of appraisal or dissenter’s rights relating to the Business Combination Agreement and the transactions contemplated thereby, and (ii) not to commence or participate in any claim or action against Senti, the Company or any of their affiliates relating to the negotiation, execution or delivery of the Senti Support Agreement or the Business Combination Agreement or the consummation of the Merger. Additionally, (i) certain Senti Support Agreements prohibit the applicable Senti Supporting Stockholders from transferring the shares of Class A following the Closing, which may be upon the meeting of certain criteria (such period, the “Extended Lock-Up”), following the Closing (such period, the “General Lock-Up”); lock-up, and (b) with respect to the GeneralLock-Up,if lock-up. On February 12, 2022, following the period to which these consolidated financial statements relate, the Company entered into amendments to certain Senti Support Agreements to amend those agreements such that, among other things, the shares of Class A Common Stock of the relevant Senti Supporting Stockholders may not be transferred, subject to certain permitted transfers, for three years following the Closing (such period, “the Three Year Lock-Up”). Unlike the Extended Lock-Up and the General Lock-Up described above, the Three Year Lock-Up does not terminate early based on the share price performance of Class A Common Stock. PIPE Subscription Agreements In connection with the execution of the Business Combination Agreement, the Company entered into subscription agreements with certain private aggregate of6,680,000shares of Class A Common Stock (together, the “Subscriptions”) for a purchase price of $10.00per share, or an aggregate purchase price of which shares are to be issued at the Closing; provided that the Subscription Agreements permit the Company to accept additional price of $10.00per share to be issued at the Closing, following the execution of the Business Combination Agreement. The Non-Redemption In connection with the execution of the Business Combination Agreement, the Sponsor, as the holder of shares of Class B Common Stock (the Founder Shares (as defined in Note 5)), the Company and each of Morgan Stanley Investment Management Inc., T. Rowe Price Group, Inc., The Invus Group, LLC and ARK Investment Management LLC and/or their respective investment funds (each, an “Investor”, and collectively, the “Investors”) entered into non-redemption “Non-Redemption Pursuant to the Non-Redemption Non-Redemption shares of Class A Common Stock, in the aggregate (the “Investor Shares”), and (b) to not, among other things, sell, encumber or otherwise transfer the Investor Shares other than in connection with non-discretionary shares of its Class B Common Stock and the Company has agreed to cancel such shares and concurrently issue to the Investors an equivalent number of shares of Class A Common Stock, in each case, at or promptly following the consummation of the Merger. Investor Rights Agreement In connection with the Closing, the Company, certain stockholders of the Company (including the Sponsor) and certain stockholders of Senti will enter into an investor rights and lock-up The Investor Rights Agreement will also restrict the ability of each stockholder who is a party thereto (other than the Company) to transfer its shares of Class A Common Stock (or any securities convertible into or exercisable or exchangeable for shares of Class A Common Stock) for, subject to certain permitted transfers and depending on the stockholder, a period of following the Closing Date (the “12 Month Lock-Up”) 18 Month Lock-Up”); provided that (i) the foregoing restrictions shall not apply to any shares of Class A Common Stock purchased pursuant to the Subscription Agreements and (ii)(A) in respect of the 12 Month Lock-Up, if lock-up; Lock-Up, trading day period commencing at least days after the Closing Date, then the 18 Lock-Up . Going Concern As of December 31, 2021, the Company had $889,323 in cash held outside of the Trust Account and a working capital deficit of $1,984,816. The Company has incurred and expects to continue to incur significant costs in pursuit of its acquisition plans (including in respect of the Senti Business Combination). These conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of time within one year after the date that the consolidated financial statements are issued. Management plans to address this uncertainty through the Senti Business Combination, as discussed above. There is no assurance that the Company’s plans to consummate the Senti Business Combination (or any other Business Combination) will be successful or successful within the Combination Period. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Risks and Uncertainties Management continues to evaluate the impact of the COVID-19

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended	10 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2021
Accounting Policies [Line Items]
Summary of Significant Accounting Policies and Basis of Presentation	2. Summary of Significant Accounting Policies and Basis of Presentation There have been no material changes to the Company’s significant accounting policies as of and for the three months ended March 31, 2022, as compared to the significant accounting policies described in the Company’s audited annual consolidated financial statements as of and for the year ended December 31, 2021, except as discussed below. Recently Adopted Accounting Pronouncements In November 2021, the FASB issued Accounting Standards Update (ASU) No. 2021-10, In May 2021, the FASB issued ASU 2021-04 Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 370-50), 815-40); Task Force) In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) 815-40): In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes		2. Summary of Significant Accounting Policies and Basis of Presentation Basis of Presentation The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and as amended by Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”). The consolidated financial statements include the accounts of Senti Biosciences, Inc., and its wholly-owned subsidiary. All intercompany balances and transactions have been eliminated in consolidation. We have one business activity and operate in one reportable segment. Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates, judgments, and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual for research and development expenses, the valuation of stock-based awards, the valuation of convertible notes, the valuation of common and redeemable convertible preferred stock, the valuation of preferred stock tranche liability, standalone selling price (“SSP”) and the determination of the incremental borrowing rate. Actual results could differ from those estimates, and such differences could be material to the financial position and consolidated statements of operations and comprehensive loss. Impact of the COVID-19 During 2021, widespread availability of COVID-19 re-open COVID-19 COVID-19 pre-pandemic Concentration of Credit Risk Financial instruments that potentially subject the Company to a significant concentration of credit risk consist of cash, cash equivalents, and short-term investments that are maintained in checking and money market accounts at one financial institution, which at times, may exceed federally insured limits. The Company’s short-term investments, if any, are limited to certain types of debt securities issued by the U.S. government, its agencies, and institutions with investment-grade credit ratings, and places restrictions on maturities and concentration by type and issuer. The Company believes that it is not exposed to significant credit risk due to the financial position of the institutions in which those deposits and short-term investments are held. As of December 31, 2021 and 2020, the Company has not experienced any credit losses in such accounts or investments. Cash, Cash Equivalents, and Restricted Cash Cash equivalents consist of amounts deposited in money market funds and securities with original maturity dates of three months or less, which are stated at fair value. The Company’s restricted cash consists of cash deposited with a financial institution as collateral for a letter of credit required under the Company’s headquarters and research facility leases. The restricted cash is presented separately from cash and cash equivalents and classified as non-current The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that total to the amounts shown in the consolidated statements of cash flows for the Company: December 31, 2021 2020 Cash and cash equivalents 56,034 30,537 Restricted cash 3,257 497 Total $ 59,291 $ 31,034 Short-term Investments Investments in marketable securities with original maturities less than 12 months from the balance sheet date, if any, are classified as short-term investments. Investments with original maturities of greater than 12 months from the balance sheet date, if any, are classified as long-term. The Company classifies all of its investments as available-for-sale available-for-sale Fair Value Measurements Certain assets and liabilities of the Company are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows: • Level 1 – Quoted prices in active markets for identical assets or liabilities. • Level 2 – Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. • Level 3 – Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies, and similar techniques. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The estimated fair values of the Company’s cash and cash equivalents, restricted cash, trade, and other receivables and accounts payable approximate their carrying values given their short-term nature. The Company’s convertible notes and preferred stock tranche liability were carried at fair value from the date of issuance through their respective extinguishment in October 2020 and May 2021, and were determined using Level 3 inputs in the fair value hierarchy described above. Property and Equipment, Net Property and equipment, net is stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, which are as follows: Small equipment 2 years Computer equipment and software 3 years Laboratory equipment 5-7 Furniture and fixtures 5-7 Leasehold improvements Shorter of the lease term and the useful life The Company capitalizes certain costs incurred during the construction phase of a project or asset into construction-in-progress. When assets are retired or disposed of, any resulting gain or loss is included in net loss. Expenditures for maintenance and repairs are expensed as incurred. Impairment of Long-Lived Assets The Company evaluates its long-lived assets, such as property and equipment, net, for impairment whenever events or changes in circumstances indicate that the carrying value of assets may not be recoverable. Recoverability of these assets is measured by comparing their carrying value to the future net undiscounted cash flows the assets are expected to generate over their remaining economic life. If such assets are considered to be impaired, the amount of any impairment is measured as the difference between their carrying value and their fair value. If the useful life is shorter than originally estimated, the Company amortizes the remaining carrying value over the revised shorter useful life. Leases The Company determines if an arrangement is or contains a lease at inception. Operating leases are recorded on the consolidated balance sheets with right-of-use The Company has elected to not separate lease and non-lease non-lease Revenue Recognition Contract Revenue Revenue is recognized when a customer obtains control of promised goods or services. The Company applies the following five steps to recognize revenue: (i) identify the contract with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to performance obligations in the contract; and (v) recognize revenue when (or as) the performance obligations are satisfied. A performance obligation is defined as a promise to transfer a product or a service to a customer that is distinct. A product or a service is distinct if both (i) the customer can benefit from the product or the service either on its own or together with other resources that are readily available to the customer and (ii) the Company’s promise to transfer the product or the service to the customer is separately identifiable from other promises in the contract. Each distinct promise to transfer a product or a service is a unit of accounting for revenue recognition. If a promise to transfer a product or a service is not distinct from other promises in the contract, such promises should be combined into a single performance obligation. The assessment of each of these elements may require significant judgments. Arrangements that include rights to additional goods or services that are exercisable at a customer’s discretion are generally considered options. If these options provide a material right to the customer, they are considered performance obligations. The identification of material rights requires judgments related to the determination of the value of the underlying license relative to the option exercise price, including assumptions about technical feasibility and the probability of developing a candidate that would be subject to the option rights. The transaction price is the amount of consideration the Company is entitled to receive in exchange for the transfer of control of a product or a service to a customer. The Company’s agreements may include both fixed and variable consideration. Fixed payments are included in the transaction price, while variable consideration, such as milestone payments and fees for research services, are estimated and constrained (if required) at the inception of the contract and evaluated on a periodic basis thereafter. If a contract has multiple performance obligations, the Company allocates the transaction price to each distinct performance obligation based on the relative stand-alone selling price (“SSP”) of the performance obligation. The Company determines SSP at contract inception and at contract modification. Determining the SSP for performance obligations requires significant judgment. Changes in the key assumptions used to determine the SSP could have a significant effect on the allocation of arrangement consideration between multiple performance obligations. For each distinct performance obligation, revenue is recognized as the Company transfers control of the product or the service applicable to such performance obligations. In instances where the Company first receives consideration in advance of satisfying its performance obligation, the Company classifies such consideration as deferred revenue until the Company satisfies such performance obligations. In instances where the Company first satisfies its performance obligation prior to its receipt of consideration, the consideration is a contract asset recorded in prepaid expenses and other current assets on the consolidated balance sheets. Grant Income The Company receives government grants that reimburse the Company for certain allowable costs for funded projects. Grant income is recognized on a systematic basis over the period in which the Company recognizes qualified research and development costs that grant is intended to compensate and there is reasonable assurance that the Company will meet the terms and conditions of the grant. This income is recorded as grant income in the consolidated statements of operations and comprehensive loss. Grant payments received in excess of grant revenue earned are recognized as deferred revenue on the balance sheets, and grant income earned in excess of grant payments received is recognized as trade and other receivables on the consolidated balance sheets. Research and Development Expenses Research and development costs are expensed as incurred. Research and development costs consist of salaries and other personnel-related expenses, including associated stock-based compensation, lab supplies and services, in-license Nonrefundable advance payments for goods and services that will be used or received in future research and development activities are deferred and recognized as an expense in the period in which the related goods are delivered, or services are performed. The Company has acquired and may continue to acquire the rights to gene circuit or other technologies from third parties. The upfront payments to acquire a license, product, or rights, as well as any annual maintenance charges and future milestone payments, are immediately recognized as research and development expense provided that there is no alternative future use of the rights in other research and development projects.​​​​​​​ Deferred Offering Costs Deferred offering costs consists of incremental legal, accounting and other fees directly attributable to equity offerings. Deferred offering costs are capitalized within prepaid and other current assets on the consolidated balance sheets and are offset against proceeds of the offering in the consolidated statements of redeemable convertible preferred stock and stockholders’ deficit as a reduction of additional paid-in Commitments and Contingencies The Company recognizes a liability with regard to loss contingencies when it believes it is probable a liability has occurred and the amount can be reasonably estimated. If some amount within a range of loss appears at the time to be a better estimate than any other amount within the range, the Company accrues that amount. When no amount within the range is a better estimate than any other amount, the Company accrues the minimum amount in the range. The Company has not recorded any such liabilities as of December 31, 2021 and 2020. Fair Value Option for Convertible Notes The Company elected to account for its convertible notes at fair value as of the issuance date in order to measure those liabilities at amounts that more accurately reflect the current economic environment in which the Company operates. Accordingly, the Company recorded these convertible notes issued in August 2020 at fair value with changes in fair value recognized in change in fair value of convertible notes in the consolidated statements of operations and comprehensive loss. As a result of applying the fair value option, direct costs and fees related to the convertible notes were expensed in the period incurred. Accretion and Classification of Redeemable Convertible Preferred Stock The Company’s redeemable convertible preferred stock is recorded based on proceeds received, net of the related preferred stock tranche liability and issuance costs, and is classified outside of stockholders’ deficit on the consolidated balance sheets because the holders of such shares have liquidation rights in the event of a deemed liquidation that, in certain situations, are not solely within the control of the Company and would require the redemption of the then-outstanding redeemable convertible preferred stock. The Company’s Series A and Series B redeemable convertible preferred stock are subject to liquidation, dissolution, or winding up of the Company, either voluntary or involuntary (Note 6). Because the occurrence of a deemed liquidation event is not currently probable as of December 31, 2021, the carrying values of the redeemable convertible preferred stock are not being accreted to their redemption values. Subsequent adjustments to accrete the carrying values of the redeemable convertible preferred stock to its redemption price would be made only when a deemed liquidation event becomes probable. Preferred Stock Tranche Liability The Company’s Series B redeemable convertible preferred stock included an obligation whereby the investors agreed to buy, and the Company agreed to sell additional shares at a fixed price in the event that certain agreed-upon milestones were achieved or at the election of investors. This obligation was determined to be a freestanding financial instrument that should be accounted for as a liability at fair value (Notes 3 and 6). This preferred stock tranche liability was revalued at each reporting period through settlement with changes in the fair value recorded as a change in preferred stock tranche liability in the consolidated statements of operations and comprehensive loss. The fair value at settlement was reclassified to redeemable convertible preferred stock at such time. Stock-Based Compensation The Company recognizes stock-based compensation expense related to employees and non-employees The Company has allowed specified option holders to exercise unvested options. The options that are exercised prior to vesting continue to vest according to the respective option agreement, and such unvested shares are subject to repurchase by the Company at the option holder’s original exercise price in the event the option holder’s service with the Company voluntarily or involuntarily terminates. The Company records proceeds from the early exercise of options as a current and long-term liability in the consolidated balance sheet, and reclassifies this liability to additional paid-in Net Loss Per Share The Company follows the two-class two-class two-class Basic net loss per share attributable to common stockholders is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period. Diluted net loss per share attributable to common stockholders is computed by adjusting net loss attributable to common stockholders for an allocation of the undistributed earnings and dividing it by the weighted-average number of common shares outstanding for the period, including potential dilutive common shares. For purposes of this calculation, the Company’s outstanding stock options, redeemable convertible preferred stock, and potential issuance of redeemable convertible preferred stock under existing preferred stock tranches, are considered potential dilutive common shares. The Company’s participating securities contractually entitle the holders of such securities to participate in dividends but do not contractually require the holders of such securities to participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss, such losses are not allocated to such participating securities. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. Income Taxes The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the consolidated statement of operations in the period that includes the enactment date. The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning The Company records uncertain tax positions on the basis of a two-step more-likely-than-not Recently Adopted Accounting Pronouncements In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326) In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820) In November 2018, the FASB issued ASU No. 2018-18, Collaborative Arrangements collaborative arrangement participant is a customer in the context of a unit of account and precludes recognizing as revenue consideration received from a collaborative arrangement participant if the participant is not a customer. The Company adopted this standard as of January 1, 2021 which did not have a material impact on its consolidated financial statements.​​​​​​​ Accounting Pronouncements Not Yet Adopted In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes In March 2020, the Financial Accounting Standards Board issued ASU No. 2020-03, Codification Improvements to Financial Instruments In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) 815-40): In October 2020, the FASB issued ASU No. 2020-10, Codification Improvements In November 2021, the FASB issued ASU 2021-10, Government Assistance (Topic 832) - Disclosures by Business Entities about Government Assistance, 2021-10 In May 2021, the FASB issued ASU 2021-04 Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 370-50), Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40);
DYNAMICS SPECIAL PURPOSE [Member]
Accounting Policies [Line Items]
Summary of Significant Accounting Policies and Basis of Presentation	NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Principles of Consolidation and Financial Statement Presentation The accompanying unaudited condensed consolidated financial statements of the Company are presented in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and pursuant to the rules and regulations of the SEC. The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned and controlled subsidiary, Merger Sub, after elimination of any intercompany transactions and balances as of March 31, 2022 and December 31, 2021. Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a comprehensive presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company’s annual report on Form 10-K Emerging Growth Company The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging Use of Estimates The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the unaudited condensed consolidated financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ from those estimates. Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Investments Held in Trust Account As of March 31, 2022 and December 31, 2021, the assets held in the Trust Account were comprised of U.S. government securities, within the meaning set forth in Section 2(a) (16) of the Investment Company Act, with maturities of 185 days or less, or investments in money market funds that invest in U.S. government securities and generally have a readily determinable fair value, or a combination thereof. When the Company’s investments held in the Trust Account are comprised of U.S. government securities, the investments are classified as trading securities. When the Company’s investments held in the Trust Account are comprised of money market funds, the investments are recognized at fair value. Trading securities and investments in money market funds are presented on the unaudited condensed consolidated balance sheet at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of these securities are reported in the statements of operations. The estimated fair values of investments held in the Trust Account are determined using available market information. Class A Common Stock Subject to Possible Redemption The Public Shares sold in the Initial Public Offering contain a redemption feature which allows for the redemption of such Public Shares in connection with the Company’s liquidation, if there is a stockholder vote or tender offer in connection with the Business Combination and in connection with certain amendments to the Company’s Amended and Restated Certificate of Incorporation. In accordance with SEC and its staff’s guidance on redeemable equity instruments, which has been codified in Accounting Standards Codification (“ASC”) Topic 480, Distinguishing Liabilities from Equity, redemption provisions not solely within the control of the Company require common stock subject to redemption to be classified outside of permanent equity. Therefore, all Class A Common Stock has been classified outside of permanent equity. The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable common stock to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying amount of redeemable common stock are affected by charges against additional paid in capital and accumulated deficit. As of March 31, 2022 and December 31, 2021, the Investor Shares (see Note 1) are classified as temporary equity within Class A Common Stock subject to redemption in the Company’s unaudited condensed consolidated balance sheet. The Non-Redemption Non-Redemption Non-Redemption Company Non-Redemption As of March 31, 2022 and December 31, 2021, the Class A common stock subject to redemption reflected in the balance sheet are reconciled in the following table: Gross proceeds $ 230,000,000 Less: Issuance costs allocated to Class A common stock (13,181,867 ) Plus: Accretion of carrying value to redemption value 13,181,867 Class A common stock subject to possible redemption $ 230,000,000 Offering Costs Associated with the Initial Public Offering The Company complies with the requirements of ASC 340-10-S99-1 5A - Expenses As noted in Note 1, subsequent to the Initial Public Offering, the underwriter agreed on December 17, 2021 to waive $1,000,000 of its deferred underwriting fees of $8,050,000, thereby reducing those fees to $7,050,000; thus, the offering costs related to the Company’s Initial Public Offering amounted to $12,198,430. Income Taxes The Company follows the asset and liability method of accounting for income taxes under ASC Topic 740, Income Taxes tion. Net Loss Per Share of Common Stock Net loss per common share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. As the Public Shares are considered to be redeemable at fair value, and a redemption at fair value does not amount to a distribution different than other stockholders, Class A and Class B common stock are presented as one class of stock in calculating net loss per share. As a result, the calculated net loss per share is the same for Class A and Class B shares of common stock. As of March 31, 2022 and December 31, 2021, the Company did not have any dilutive securities and other contracts that could, potentially, be exercised or converted into shares of common stock and then share in the earnings of the Company. As a result, diluted loss per share is the same as basic loss per share for the periods presented. The following table reflects the calculation of basic and diluted net loss per common share (in dollars, except per share amounts): For the three months ended For the period from March 1, Class A Class B Class A Class B Basic and diluted net income (loss) per share: Numerator: Net loss $ (1,054,241 ) $ (255,608 ) $ — $ (1,178 ) Denominator: Basic and diluted weighted average shares 23,715,500 5,750,000 — 5,000,000 Basic and diluted net loss per share $ (0.04 ) $ (0.04 ) $ — $ (0.00 ) Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account. Fair Value of Financial Instruments The Company applies ASC Topic 820, Fair Value Measurement measurement date. The fair value hierarchy established in ASC 820 generally requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs reflect the assumptions that market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the reporting entity. Unobservable inputs reflect the entity’s own assumptions based on market data and the entity’s judgments about the assumptions that market participants would use in pricing the asset or liability and are to be developed based on the best information available in the circumstances. The carrying amounts reflected in the unaudited condensed consolidated balance sheet for current assets and current liabilities approximate fair value due to their short-term nature. Level 1 — Assets and liabilities with unadjusted, quoted prices listed on active market exchanges. Inputs to the fair value measurement are observable inputs, such as quoted prices in active markets for identical assets or liabilities. Level 2 — Inputs to the fair value measurement are determined using prices for recently traded assets and liabilities with similar underlying terms, as well as direct or indirect observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals. Level 3 — Inputs to the fair value measurement are unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no market data exists for the assets or liabilities. See Note 8 for additional information on assets and liabilities measured at fair value. Recent Accounting Standards Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company’s financial statements.	NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Principles of Consolidation and Financial Statement Presentation The accompanying consolidated financial statements of the Company are presented in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and pursuant to the rules and regulations of the SEC. The consolidated financial statements include the accounts of the Company and its wholly-owned and controlled subsidiary, Merger Sub, after elimination of any intercompany transactions and balances as of December 31, 2021. Emerging Growth Company The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the consolidated financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ from those estimates. Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of December 31, 2021. As of December 31, 2021, we had operating cash (i.e. cash held outside the Trust Account) of $889,323. Investments Held in Trust Account As of December 31, 2021, the assets held in the Trust Account were comprised of U.S. government securities, within the meaning set forth in Section 2(a) (16) of the Investment Company Act, with maturities of 185 days or less, or investments in money market funds that invest in U.S. government securities and generally have a readily determinable fair value, or a combination thereof. When the Company’s investments held in the Trust Account are comprised of U.S. government securities, the investments are classified as trading securities. When the Company’s investments held in the Trust Account are comprised of money market funds, the investments are recognized at fair value. Trading securities and investments in money market funds are presented on the consolidated balance sheet at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of these securities are reported in the statements of operations. The estimated fair values of investments held in the Trust Account are determined using available market information. Class A Common Stock Subject to Possible Redemption The Public Shares sold in the Initial Public Offering contain a redemption feature which allows for the redemption of such Public Shares in connection with the Company’s liquidation, if there is a stockholder vote or tender offer in connection with the Business Combination and in connection with certain amendments to the Company’s Amended and Restated Certificate of Incorporation. In accordance with SEC and its staff’s guidance on redeemable equity instruments, which has been codified in Accounting Standards Codification (“ASC”) Topic 480, Distinguishing Liabilities from Equit Therefore, all Class A Common Stock has been classified outside of permanent equity. The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable common stock to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying amount of redeemable common stock are affected by charges against additional paid in capital and accumulated deficit. As of December 31, 2021, the Investor Shares (see Note 1) are classified as temporary equity within Class A Common Stock subject to redemption in the Company’s consolidated balance sheet. The Non-Redemption Non-Redemption Non-Redemption Non-Redemption As of December 31, 2021, the Class A Common Stock subject to redemption reflected in the consolidated balance sheet is reconciled in the following table: Gross proceeds $ 230,000,000 Less: Issuance costs allocated to Class A Common Stock (13,181,867 ) Plus: Remeasurement of carrying value to redemption value 13,181,867 Class A Common Stock subject to possible redemption $ 230,000,000 Offering Costs Associated with the Initial Public Offering The Company complies with the requirements of ASC 340-10-S99-1 incurred related to the Initial Public Offering. Offering costs directly attributable to the issuance of an equity contract to be classified in equity are recorded as a reduction in equity. Offering costs for equity contracts that are classified as assets and liabilities are expensed immediately. The Company incurred offering costs amounting to $13,198,430 as a result of the Initial Public Offering (consisting of a $4,600,000 underwriting fee, $8,050,000 of deferred underwriting fees, and $548,430 of other offering costs). The Company recorded $13,181,867 of offering costs as a reduction of temporary equity in connection with the issuance of the Public Shares. The Company recorded $16,563 of offering costs as a reduction of permanent equity in connection with the issuance of the Private Placement Shares. Income Taxes The Company follows the asset and liability method of accounting for income taxes under ASC Topic 740, Income Taxes ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of December 31, 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception. Net Loss Per Share of Common Stock Net loss per common share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. As the Public Shares are considered to be redeemable at fair value, and a redemption at fair value does not amount to a distribution different than other stockholders, Class A Common Stock and Class B Common Stock are presented as one class of stock in calculating net loss per share. As a result, the calculated net loss per share is the same for Class A Common Stock and Class B Common Stock. As of December 31, 2021, the Company did not have any dilutive securities and other contracts that could, potentially, be exercised or converted into shares of common stock and then share in the earnings of the Company. As a result, diluted loss per share is the same as basic loss per share for the periods presented. The following table reflects the calculation of basic and diluted net loss per common share (in dollars, except per share amounts): For the Period from March 1, 2021 Class A Class B Basic and diluted net loss per share: Numerator: Net loss $ (2,919,481 ) $ (937,607 ) Denominator: Basic and diluted weighted average shares outstanding 16,872,995 5,418,853 Basic and diluted net loss per share $ (0.17 ) $ (0.17 ) Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account. Fair Value of Financial Instruments The Company applies ASC Topic 820, Fair Value Measurement The carrying amounts reflected in the consolidated balance sheet for current assets and current liabilities approximate fair value due to their short-term nature. Level 1 — Assets and liabilities with unadjusted, quoted prices listed on active market exchanges. Inputs to the fair value measurement are observable inputs, such as quoted prices in active markets for identical assets or liabilities. Level 2 — Inputs to the fair value measurement are determined using prices for recently traded assets and liabilities with similar underlying terms, as well as direct or indirect observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals. Level 3 — Inputs to the fair value measurement are unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no market data exists for the assets or liabilities. See Note 9 for additional information on assets and liabilities measured at fair value. Recent Accounting Standards In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-06, Debt — Debt with Conversion and Other Options (Subtopic 470-20) 815-40) 2020-06”) 2020-06 2020-06 if-converted 2020-06 2020-06 2020-06 Management does not believe that any other recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company’s consolidated financial statements.

Initial Public Offering

Initial Public Offering	3 Months Ended	10 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Dynamics Special Purpose
Initial Public Offering	NOTE 3. INITIAL PUBLIC OFFERING The registration statement for the Company’s Initial Public Offering was declared effective on May 25, 2021. On May 28, 2021, the Company completed its Initial Public Offering of 23,000,000 shares of Class A common stock, including 3,000,000 shares of Class A common stock that were issued pursuant to the underwriter’s exercise of its over-allotment option in full, at $10.00 per Public Share, generating gross proceeds of $230,000,000.	NOTE 3. INITIAL PUBLIC OFFERING The registration statement for the Company’s Initial Public Offering was declared effective on May 25, 2021. On May 28, 2021, the Company completed its Initial Public Offering of 23,000,000 shares of Class A Common Stock , including 3,000,000 shares of Class A Common Stock that were issued pursuant to the underwriter’s exercise of its over-allotment option in full, at $10.00 per Public Share, generating gross proceeds of $230,000,000.

Private Placement

Private Placement	3 Months Ended	10 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Dynamics Special Purpose
Private Placement	NOTE 4. PRIVATE PLACEMENT Simultaneously with the closing of the Initial Public Offering, the Sponsor purchased an aggregate of 715,500 Private Placement Shares at a price of $10.00 per Private Placement Share, generating gross proceeds of $7,155,000. A portion of the proceeds from the sale of the Private Placement Shares was added to the net proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Placement Shares held in the Trust Account will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law).	NOTE 4. PRIVATE PLACEMENT Simultaneously with the closing of the Initial Public Offering, the Sponsor purchased an aggregate of 715,500 Private Placement Shares at a price of $10.00 per Private Placement Share, generating gross proceeds of $7,155,000. A portion of the proceeds from the sale of the Private Placement Shares was added to the net proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Placement Shares held in the Trust Account will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law).

Other Financial Statement infor

Other Financial Statement information	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Other Financial Statement Information [Abstract]
Other Financial Statement information	4. Other Financial Statement information Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consisted of the following (in thousands): March 31, December 31, Deposits $ 1,324 $ 1,157 SPAC deferred offering costs 3,073 1,446 Prepaid expenses (including prepaid rent) 1,003 798 Other 648 275 Total prepaid expenses and other current assets $ 6,048 $ 3,676 Property and Equipment, Net Property and equipment, net consisted of the following (in thousands): March 31, December 31, Lab equipment $ 5,301 $ 4,988 Leasehold improvements 431 431 Computer equipment and software 309 262 Furniture and fixtures 294 294 Construction in progress 19,599 8,048 Property and equipment at cost 25,934 14,023 Less: accumulated depreciation (1,867 ) (1,655 ) Property and equipment, net $ 24,067 $ 12,368 Depreciation expense for the three months ended March 31, 2022 and 2021 was $0.2 million and $0.2 million, respectively. For the three months ended March 31, 2022 and 2021, the Company impaired fixed assets and recorded impairment losses of zero. Accrued Expenses and Other Liabilities Accrued expenses and other liabilities consisted of the following (in thousands): March 31, December 31, Accrued professional and service fees $ 7,680 $ 2,555 Accrued employee-related expenses 1,247 2,665 Other accrued expenses 52 111 Total accrued expenses and other current liabilities $ 8,979 $ 5,331	4. Other Financial Statement information Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consisted of the following (in thousands): December 31, 2021 2020 Deposits $ 1,157 $ 25 SPAC deferred offering costs 1,446 — Unbilled contract — 229 Other 1,073 830 Total prepaid expenses and other current assets $ 3,676 $ 1,084 Property and Equipment, Net Property and equipment, net consisted of the following (in thousands): December 31, 2021 2020 Lab equipment $ 4,988 $ 3,459 Leasehold improvements 431 158 Computer equipment and software 262 214 Furniture and fixtures 294 232 Construction in progress 8,048 231 Property and equipment at cost 14,023 4,294 Less: accumulated depreciation (1,655 ) (982 ) Property and equipment, net $ 12,368 $ 3,312 Depreciation expense for the years ended December 31, 2021 and 2020 was $0.8 million and $0.6 million, respectively. For the years ended December 31, 2021 and 2020, the Company impaired fixed assets and recorded impairment losses of less than $0.1 million and $0.2 million, respectively. Accrued Expenses and Other Liabilities Accrued expenses and other liabilities consisted of the following (in thousands): December 31, 2021 2020 Accrued professional and service fees $ 2,555 $ 54 Accrued employee related expenses 2,665 1,933 Other accrued expenses 111 11 Total accrued expenses and other current liabilities $ 5,331 $ 1,998

Convertible Notes

Convertible Notes	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Convertible Notes	5. Convertible Notes In August 2020, the Company issued $8.0 million in convertible notes to existing investors, including related parties, with a stated annual interest rate of 8%. The principal and accrued interest was payable upon maturity in February 2021. The outstanding balance of principal plus accrued and unpaid interest were automatically convertible at the sale of preferred stock of at least $25.0 million (the “Qualified Financing”). On conversion of the convertible notes in a Qualified Financing, the same class of preferred shares would be issued at a price equal to 90% of the fixed price per share paid by the purchasers of preferred stock participating in the Qualified Financing. In connection with the issuance and sale of Series B redeemable convertible preferred stock in October 2020 (Note 6), all of the outstanding principal and accrued interest of $8.1 million under the convertible notes was converted into 5,485,858 shares of Series B redeemable convertible preferred stock and the related preferred stock tranche liability. For the year ended December 31, 2020, we recorded a fair value loss of $0.7 million that is included in the change in fair value of convertible notes, in the accompanying consolidated statements of operations and comprehensive loss.

Redeemable Convertible Preferre

Redeemable Convertible Preferred Stock	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Temporary Equity Disclosure [Abstract]
Redeemable Convertible Preferred Stock	5. Redeemable Convertible Preferred Stock The Company’s redeemable convertible preferred stock consisted of the following (in thousands, except per share amounts) as of March 31, 2022 and December 31, 2021: Issue Price Shares Shares Issued Net Carrying Aggregate Series A $ 1.6427 35,199,610 35,199,610 $ 57,408 $ 57,822 Series B $ 1.6427 64,534,944 64,534,933 $ 114,425 $ 106,012 Total 99,734,554 99,734,543 $ 171,833 $ 163,834	6. Redeemable Convertible Preferred Stock The Company’s redeemable convertible preferred stock consisted of the following (in thousands, except per share amounts): December 31, 2021 Issue Price Shares Shares Issued Net Carrying Aggregate Series A $ 1.6427 35,199,610 35,199,610 $ 57,408 $ 57,822 Series B $ 1.6427 64,534,944 64,534,933 $ 114,425 $ 106,012 Total 99,734,554 99,734,543 $ 171,833 $ 163,834 December 31, 2020 Issue Price Shares Shares Issued Net Carrying Aggregate Series A $ 1.6427 35,199,610 35,199,610 $ 57,408 $ 57,822 Series B $ 1.6427 64,534,944 23,748,457 $ 32,254 $ 39,012 Total 99,734,554 58,948,067 $ 89,662 $ 96,834 In October 2020, the Company issued 15,624,670 shares of Series B redeemable convertible preferred stock at a price of $1.6427 per share for total proceeds of $25.7 million, net of issuance costs of $0.1 million, and converted the related convertible notes into 5,485,858 shares of Series B redeemable convertible preferred stock. The terms of the Series B redeemable convertible preferred stock included the obligations for the investors to purchase, and the Company to sell, 16,842,176 and 18,668,438 additional shares of Series B redeemable convertible preferred stock in two additional closings (“Tranche 2” and “Tranche 3”) for a price of $1.6427 per share. On December 28, 2020, the Company issued 2,637,929 shares of Series B redeemable convertible preferred stock to new and existing investors for gross proceeds of $4.3 million, net of issuance costs of $0.2 million. These Series B redeemable convertible preferred stock also included obligations for the investors to purchase, and the Company to sell, 2,637,929 additional shares of Series B redeemable convertible preferred stock in both Tranche 2 and Tranche 3 for a price of $1.6427 per share. Also on December 28, 2020, certain investors forfeited their rights and obligations to purchase 1,217,506 and 3,043,768 shares of Series B redeemable convertible preferred stock in Tranche 2 and Tranche 3, respectively. On January 19, 2021, the Company issued 1,420,426 shares of Series B redeemable convertible preferred stock to investors for gross proceeds of $2.3 million, net of issuance costs of $6 thousand. The terms of the Series B redeemable convertible preferred stock sold are the same as the terms of previous issuances of Series B redeemable convertible preferred stock issued in October 2020, and also included obligations for the investors to purchase, and the Company to sell, 1,420,426 additional shares of Series B redeemable convertible preferred stock in each of Tranches 2 and 3 for a price of $1.6427 per share. In April 2021, the Company’s Board of Directors determined that the Series B milestone had been achieved and approved the notice to call tranches 2 and 3, subject to requisite stockholders’ written election and related waivers. The second and third closings occurred on May 14, 2021 and the Company issued 39,366,050 shares of Series B redeemable convertible preferred stock to investors for proceeds of $64.7 million for which no additional issuance costs were incurred. The following is a summary of the rights and privileges of the holders of redeemable convertible preferred stock: Voting Rights Each share of redeemable convertible preferred stock has voting rights equal to the number of shares of common stock into which such preferred stock is convertible. The holders of redeemable convertible preferred stock vote together with the holders of common stock as a single class for most matters. The holders of Series A redeemable convertible preferred stock voting as a separate class are entitled to elect two directors. The holders of Series B redeemable convertible preferred stock voting as a separate class are entitled to elect two directors. The holders of common stock, voting as a separate class, are entitled to elect two directors of the Company. The holders of common stock and redeemable convertible preferred stock, voting as a single class, are entitled to elect the balance of the seven total directors of the Company. Dividends The holders of redeemable convertible preferred stock are entitled to receive, if and when declared by the Company’s board of directors, non-cumulative as-converted Conversion At the option of the holder, each share of redeemable convertible preferred stock is convertible into shares of common stock as determined by dividing the applicable original issue price by the applicable conversion price in effect at the time of conversion. The initial conversion price of both Series A and Series B redeemable convertible preferred stock is equal to the original issue price of $1.6427 per share. The conversion ratio for the redeemable convertible preferred stock shall be subject to appropriate adjustments for stock splits, stock dividends, combinations, recapitalizations, or the like. The conversion ratio at December 31, 2021 and December 31, 2020, respectively, is one-to-one; Each share of redeemable convertible preferred stock automatically converts into the number of shares of common stock into which such shares are convertible at the applicable conversion ratio upon the earlier: (i) the closing of the sale of shares of common stock in a qualified initial public offering (“IPO”) resulting in gross proceeds of at least $50.0 million or (ii) the vote or written consent of the holders of the majority of the then-outstanding shares of redeemable convertible preferred stock, voting together as a single class. If a holder of Series B redeemable convertible preferred stock fails to purchase all of its applicable tranche shares at or prior to the milestone closing, all of the holder’s shares of Series B redeemable convertible preferred stock will automatically convert into the number of shares of common stock into which such shares are convertible at the applicable conversion ratio. Such defaulting holder also forfeits its right to designate a member of or observer to the board of directors and any right to participate in any subsequent debt or equity financing of the Company. Liquidation In the event of any liquidation, dissolution, or winding up of the Company, either voluntary or involuntary, the holders of the Series B redeemable convertible preferred stock shall be entitled to receive, prior and in preference to any distribution of any of the assets of the Company to the holders of the Series A redeemable convertible preferred stock and common stock, an amount per share equal to the greater of (i) the Series B original issuance price, plus any dividends declared but unpaid thereon, or (ii) such amount per share as would have been payable had all shares of Series B redeemable convertible preferred stock been converted into shares of common stock immediately prior to such liquidation, dissolution, winding up or deemed liquidation event. After the distribution to holders of Series B redeemable convertible preferred stock, the holders of the Series A redeemable convertible preferred stock shall be entitled to receive, prior and in preference to any distribution of any of the assets of the Company to the holders of the common stock, an amount per share equal to the greater of (i) the Series A original issuance price, plus any dividends declared but unpaid thereon, or (ii) such amount per share as would have been payable had all shares of Series A redeemable convertible preferred stock been converted into shares of common stock immediately prior to such liquidation, dissolution, winding up or deemed liquidation event. Upon completion of the distribution to the holders of the redeemable convertible preferred stock, all remaining legally available assets will be distributed ratably to the holders of common stock. Classification The Company has classified its redeemable convertible preferred stock as temporary equity on the consolidated balance sheets as the stock is contingently redeemable. Upon the occurrence of certain deemed liquidation events that are outside of the Company’s control, including liquidation, sale, or transfer of the Company, holders of the redeemable convertible preferred stock can cause redemption for cash. During the years ended December 31, 2021 and 2020, the Company did not adjust the carrying value of the redeemable convertible preferred stock to the deemed liquidation value of such shares as a deemed liquidation event was not probable. Additionally, one investor that owns 2,435,016 shares of Series B redeemable convertible preferred stock are redeemable by the holder at the original issuance price in the event that the Company uses any of the proceeds received from such investor for purposes other than operations and research and development activities.

Common Stock

Common Stock	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Common Stock Disclosure [Abstract]
Common Stock	6. Common Stock Holders of common stock are entitled to one vote per share, and to receive dividends and, upon liquidation or dissolution, are entitled to receive all assets available for distribution to stockholders. The holders have no preemptive or other subscription rights, and there are no redemption or sinking fund provisions with respect to such shares. Common stock is subordinate to the redeemable convertible preferred stock with respect to dividend rights and rights upon liquidation, winding up, and dissolution of the Company. Through March 31, 2022, no cash dividends have been declared or paid. At March 31, 2022 and December 31, 2021, the Company was authorized to issue 138,000,000 shares of common stock, all at a par value of $0.0001 per share, and had reserved the following shares for future issuance: March 31, December 31, Series A and B redeemable convertible preferred stock 99,734,543 99,734,543 Stock options to purchase common stock 9,273,083 11,711,174 Common stock options available for future grant under stock option plan 5,646,099 3,666,927 Total 114,653,725 115,112,644 In addition to the stock options to purchase common stock in the above table, in association with the Business Combination Agreement with DYNS, the Company awarded certain performance and market awards with vesting contingent upon the consummation of the SPAC merger. See Note 8 - Stock-Based Compensation	7. Common Stock​​​​​​​ Holders of common stock are entitled to one vote per share, and to receive dividends and, upon liquidation or dissolution, are entitled to receive all assets available for distribution to stockholders. The holders have no preemptive or other subscription rights, and there are no redemption or sinking fund provisions with respect to such shares. Common stock is subordinate to the redeemable convertible preferred stock with respect to dividend rights and rights upon liquidation, winding up, and dissolution of the Company. Through December 31, 2021, no cash dividends have been declared or paid. At December 31, 2021 and 2020, the Company was authorized to issue 138,000,000 shares of common stock, all at a par value of $0.0001 per share, and had reserved the following shares for future issuance: December 31, 2021 2020 Series A and B redeemable convertible preferred stock 99,734,543 58,948,067 Stock options to purchase common stock 11,711,174 4,173,285 Common stock options available for future grant under stock option plan 3,666,927 12,857,369 Total 115,112,644 75,978,721 In addition to the stock options to purchase common stock in the above table, in association with the Business Combination Agreement with DYNS, the Company awarded certain performance and market awards with vesting contingent upon the consummation of the SPAC merger. See Note 9 - Stock-Based Compensation

Revenue

Revenue	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Revenue from Contract with Customer [Abstract]
Revenue	7. Revenue The Company’s revenue consists of amounts received related to research services provided to customers. Contract Revenue In May 2019, the Company entered into a collaborative development agreement. The Company determined that the agreement contained three distinct promises; research and development, design services, and intellectual property, which will be accounted for as a single combined performance obligation of research and development services recognized over time. The development agreement included $0.3 million of fixed consideration allocated to a single performance obligation and an additional $0.3 million of variable consideration. At the inception of the development agreement, it was not probable that a significant reversal of revenue would not occur and therefore the variable consideration was fully constrained. Throughout the development agreement period, several parameters of the research and development services were changed, which increased the uncertainty of achieving the remaining performance obligations. Therefore, in December 2021, the contract asset of $0.3 million was reversed due to this increased uncertainty. In April 2021, the Company entered into a research collaboration and license agreement with Spark Therapeutics, Inc. (“Spark”). Under the agreement, the Company will be responsible for a research program, which includes designing, building and testing five cell type specific-synthetic promoters for use in developing certain gene therapies using the Company’s proprietary technology. The Company received an upfront payment from Spark of $3.0 million and Spark is obligated to reimburse the Company for costs and expenses incurred for the research program. The Company expects to complete the research program over a two-year The Company assessed this agreement in accordance with ASC 606, Revenue Recognition Pursuant to the agreement, once the research program is completed and the Company delivers a data package to Spark, Spark has 24 months (the “evaluation period”) to determine whether Spark will exercise its options to obtain field-limited, royalty-bearing licenses to develop, manufacture and commercialize promoters corresponding to each of the five specified promoters being researched. For each licensed promoter option that is exercised, the Company is eligible to receive a license fee, potential research, development and commercial milestone payments and royalties on product sales. Spark may generally terminate the agreement upon 90 days prior written notice or 180 days prior written notice if the licensed promoter is in clinical trials or is being commercialized at the time of termination. The Company evaluated Spark’s optional rights to license, develop, manufacture and commercialize each of the promoter profiles to determine whether they provide Spark with any material rights to purchase the promoter licenses at an incremental discount. The Company’s proprietary technology used to develop the promoters is in the early stages of development, so technological feasibility and probability of developing a product is highly uncertain. As a result, determining the SSP for the optional rights is subject to significant judgment. Given the subjectivity associated with determining the SSP for the right to a future license related to unproven technology at contract inception, the Company also evaluated whether the contract consideration associated with the research services represents the SSP for those services. The Company determined the transaction price, inclusive of the upfront payment and reimbursement of costs and expenses incurred for the research program, is commensurate with SSP for the research being conducted given the specialized nature and reliance on proprietary technology. Based on the Company’s assessment of the optional consideration and the qualitative factors of feasibility and probability of development combined with the quantitative assessment that research services are priced at their SSP, the Company concluded that the license option does not provide Spark with an incremental discount and therefore does not constitute a material right. The transaction price associated with the research services in this agreement consists of the fixed upfront amount of $3.0 million and variable consideration. For both collaboration agreements, the Company will recognize the transaction price as research and development services are provided, using a cost-based input method to measure the progress toward completion of its performance obligation and to calculate the corresponding amount of revenue to recognize each period. The Company believes that the cost-based input method is the best measure of progress because other measurements would not reflect how the Company transfers the control related to the performance obligation to our customers. For the three months ended March 31, 2022 and 2021, the Company recorded revenue, which was previously included in the deferred revenue at the beginning of each period, of $0.4 million and zero, respectively. Contract asset balances related to unbilled revenue for our collaboration agreements were zero as of March 31, 2022 and 2021, and are presented within prepaid expenses and other current assets on the condensed consolidated balance sheets. Grant Income In 2021, the Small Business Innovation Research awarded the Company a grant in the amount of $2.0 million over two years subject to meeting certain terms and conditions. The purpose of the grant is to support the further development of SENTI-202 Grant income was recognized when qualified research and development costs were incurred and the Company obtained reasonable assurance that the terms and conditions of the grant were met. Entity-wide information During the three months ended March 31, 2022, Customer A and B accounted for 77% and 23%, respectively, of revenue. During the three months ended March 31, 2021, Customer B and C accounted for 39% and 61%, respectively, of revenue. All revenues were generated in the United States for the three months ended March 31, 2022 and 2021.	8. Revenue The Company’s revenue consists of amounts received related to research services provided to customers. Contract Revenue In May 2019, the Company entered into a collaborative development agreement. The Company determined that the agreement contained three distinct promises; research and development, design services, and intellectual property, which will be accounted for as a single combined performance obligation of research and development services recognized over time. The development agreement included $0.3 million of fixed consideration allocated to a single performance obligation and an additional $0.3 million of variable consideration. At inception of the development agreement, it was not probable that a significant reversal of revenue would not occur and therefore the variable consideration was fully constrained. Throughout the development agreement period, several parameters of the research and development services were changed, which increased the uncertainty of achieving the remaining performance obligations. Therefore, in December 2021, the contract asset of $0.3 million was reversed due to this increased uncertainty. In April 2021, the Company entered into a research collaboration and license agreement with Spark Therapeutics, Inc. (“Spark”). Under the agreement, the Company will be responsible for a research program, which includes designing, building and testing five cell type specific-synthetic promoters for use in developing certain gene therapies using the Company’s proprietary technology. The Company received an upfront payment from Spark of $3.0 million and Spark is obligated to reimburse the Company for costs and expenses incurred for the research program. The Company expects to complete the research program over a two-year The Company assessed this agreement in accordance with ASC 606, Revenue Recognition Pursuant to the agreement, once the research program is completed and the Company delivers a data package to Spark, Spark has 24 months (the “evaluation period”) to determine whether Spark will exercise its options to obtain field-limited, royalty-bearing licenses to develop, manufacture and commercialize promoters corresponding to each of the five specified promoters being researched. For each licensed promoter option that is exercised, the Company is eligible to receive a license fee, potential research, development and commercial milestone payments and royalties on product sales. Spark may generally terminate the agreement upon 90 days’ prior written notice or 180 days’ prior written notice if the licensed promoter is in clinical trials or is being commercialized at the time of termination. The Company evaluated Spark’s optional rights to license, develop, manufacture and commercialize each of the promoter profiles to determine whether they provide Spark with any material rights to purchase the promoter licenses at an incremental discount. The Company’s proprietary technology used to develop the promoters is in early stages of development, so technological feasibility and probability of developing a product is highly uncertain. As a result, determining the SSP for the optional rights is subject to significant judgment. Given the subjectivity associated with determining the SSP for the right to a future license related to unproven technology at contract inception, the Company also evaluated whether the contract consideration associated with the research services represents the SSP for those services. The Company determined the transaction price, inclusive of the upfront payment and reimbursement of costs and expenses incurred for the research program, is commensurate with SSP for the research being conducted given the specialized nature and reliance on proprietary technology. Based on the Company’s assessment of the optional consideration and the qualitative factors of feasibility and probability of development combined with the quantitative assessment that research services are priced at their SSP, the Company concluded that the license option does not provide Spark with an incremental discount and therefore does not constitute a material right. The transaction price associated with the research services in this agreement consists of the fixed upfront amount of $3.0 million and variable consideration. For both collaboration agreements, the Company will recognize the transaction price as research and development services are provided, using a cost-based input method to measure the progress toward completion of its performance obligation and to calculate the corresponding amount of revenue to recognize each period. The Company believes that the cost-based input method is the best measure of progress because other measurements would not reflect how the Company transfers the control related to the performance obligation to our customers. The Company has recorded nil and $0.2 million of revenue for the years ended December 31, 2021 and 2020, respectively, which was previously included in the deferred revenue balances at the beginning of each period. Contract asset balances related to unbilled revenue for our collaboration agreements were nil and $0.2 million as of December 31, 2021 and 2020, respectively, and are presented within prepaid expenses and other current assets on the consolidated balance sheets. Grant Income In 2018, the National Institutes of Health awarded the Company a grant in the amount of $0.2 million to be used to support research and development for treating Inflammatory Bowel Disease. Eligible costs under the grant include direct personnel costs and materials and supplies. In 2021, the Small Business Innovation Research awarded the Company a grant in the amount of $2.0 million over two years subject to meeting certain terms and conditions. The purpose of the grant is to support further development of SENTI-202 Grant income was recognized when qualified research and development costs were incurred and the Company obtained reasonable assurance that the terms and conditions of the grant were met. Entity-wide information During the year ended December 31, 2021, when excluding the $0.3 million contract asset reversal for Customer C, Customer A accounted for 84.3% of revenue, and Customer B accounted for 15.7% of revenue. During the year ended December 31, 2020, Customer B and C accounted for 30.4% and 69.6%, respectively, of revenue. All net sales were generated in the United States for the years ended December 31, 2021 and 2020.

Stockholders' Equity (Deficit)

Stockholders' Equity (Deficit)	3 Months Ended	10 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
DYNAMICS SPECIAL PURPOSE [Member]
Stockholders' Equity (Deficit)	NOTE 7. STOCKHOLDERS’ EQUITY (DEFICIT) Preferred stock Class A common stock Non-Redemption Class B common stock Common stockholders of record are entitled to one vote for each share held on all matters to be voted on by stockholders. Holders of the Class A common stock and holders of the Class B common stock will vote together as a single class on all matters submitted to a vote of stockholders, including any vote in connection with an initial Business Combination, except where a vote of each class is required by law. The shares of Class B common stock are convertible into shares of Class A common stock at the option of the holder and will automatically convert into shares of Class A common stock at the time of an initial Business Combination on a one-for-one recapitalizations and the like). In the case that additional shares of Class A common stock, or equity-linked securities, are issued or deemed issued in excess of the amounts offered in the Initial Public Offering and related to the closing of an initial Business Combination, the ratio at which shares of Class B common stock shall convert into shares of Class A common stock will be adjusted (unless the holders of a majority of the outstanding shares of Class B common stock agree to waive such adjustment with respect to any such issuance or deemed issuance, as is the case for the proposed Senti Business Combination) so that the number of shares of Class A common stock issuable upon conversion of all shares of Class B common stock will equal, in the aggregate, on an as-converted	NOTE 7. STOCKHOLDERS’ DEFICIT Preferred stock Class A Common Stock Common Stock Common Stock Common Stock shares of Class A common stock subject to possible redemption. Despite the Non-Redemption Agreements discussed in Note 1, it is possible, in certain limited circumstances, for the Investors to transfer their Public Shares, and a transfer of such shares to a third party who is not bound by a Non-Redemption Agreement would render such shares subject to possible redemption. Class B Common Stock Common Stock Common Stock Common Stock Common Stock initially issued and outstanding Common stockholders of record are entitled to one vote for each share held on all matters to be voted on by stockholders. Holders of the Class A Common Stock and holders of the Class B Common Stock will vote together as a single class on all matters submitted to a vote of stockholders, including any vote in connection with an initial Business Combination, except where a vote of each class is required by law. The shares of Class B Common Stock are convertible into shares of Class A Common Stock at the option of the holder and will automatically convert into shares of Class A Common Stock at the time of an initial Business Combination on a one-for-one as-converted outstanding upon the completion of the Initial Public Offering (excluding the Private Placement Shares), plus (ii) all shares of Class A Common Stock and equity-linked securities issued or deemed issued in connection with an initial Business Combination (excluding any shares of Class A Common Stock or equity-linked securities issued, or to be issued, to any seller in an initial Business Combination and any Private Placement Shares issued to the Sponsor or its affiliates upon conversion of any Working Capital Loans).

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation	8. Stock-Based Compensation In 2016, the Company adopted the 2016 Stock Incentive Plan (the “2016 Stock Incentive Plan”) authorizing the grant of incentive stock options (“ISOs”) and non-statutory The following table summarizes the Company’s stock option activity, excluding performance and market awards: Number of Weighted- Weighted- Remaining Aggregate Outstanding at December 31, 2021 11,711,174 $ 0.86 9.1 $ 11,304 Exercised (881,993 ) 0.48 — — Forfeited (1,556,098 ) 0.53 — — Outstanding at March 31, 2022 9,273,083 $ 0.95 8.6 $ 8,130 Vested and exercisable at March 31, 2022 1,978,319 $ 0.54 6.8 $ 2,541 The aggregate intrinsic values of options exercised during the three months ended March 31, 2022 and 2021 were $1.2 million and $0.5 million, respectively. The weighted-average grant-date fair values of options granted during the three months ended March 31, 2022 and 2021 were zero and $0.90, respectively. Early Exercise of Stock Options into Restricted Stock For the three months ended March 31, 2022 and 2021, the Company issued zero and 2,619,677 shares of common stock upon exercise of unvested stock options, respectively, and as of March 31, 2022 and December 31, 2021, 1,685,479 and 2,418,871 shares were held by employees subject to repurchase at an aggregate price of $0.9 million and $1.2 million, respectively. Stock-Based Compensation Expense In determining the fair value of the stock-based awards, the Company uses the assumptions below for the Black-Scholes option pricing model, which are subjective and generally require significant judgment. Fair Value of Common Stock Expected Term mid-point Volatility Risk-free Rate zero-coupon Dividends The assumptions used to determine the grant date fair value of stock options granted to grantees were as follows, presented on a weighted-average basis: Three Months Ended March 31, 2022 2021 Expected term (in years) — 6.03 Expected volatility — % 82.9% Risk-free interest rate — % 0.6% Dividend yield — % — % Total stock-based compensation expense was as follows (in thousands): Three Months Ended March 31, 2022 2021 General and administrative $ 458 $ 317 Research and development 203 55 Total stock-based compensation expense $ 661 $ 372 As of March 31, 2022, the total unrecognized stock-based compensation was approximately $7.2 million, which is expected to be recognized over a weighted-average period of 3.0 years. Performance Awards In connection with the Business Combination Agreement with DYNS, on December 19, 2021, the Company awarded 42,927,654 performance awards to existing employees that vest contingent upon the satisfaction of both a four-year service condition and a performance condition tied to the consummation of the SPAC merger. The award and the associated recognition of stock-based compensation are contingent on the SPAC merger being consummated which is subject to DYNS shareholder approval. As of March 31, 2022 and December 31, 2021, 42,486,017 and 42,909,091 performance awards remain outstanding, respectively, after the forfeiture of 423,074 performance awards during the three months ended March 31, 2022. Market Awards In connection with the Business Combination Agreement with DYNS, on December 19, 2021, the Company awarded 3,093,776 market awards to the co-founder Option Amendment On February 12, 2022, the Company entered into Amendment No. 1 to the Business Combination Agreement, to restructure the performance and market awards made at the time the Business Combination Agreement was signed. In particular, certain Senti executives agreed to forfeit certain options awarded to them at the time the Business Combination Agreement was signed depending on the level of redemptions of DYNS Class A Common Stock upon closing of the merger. In addition, it was agreed that the vesting period for the options held by executives whose options may be subject to forfeiture (as described above) will commence upon closing of the merger instead of on December 19, 2021.	9. Stock-Based Compensation In 2016, the Company adopted the 2016 Stock Incentive Plan (the “2016 Stock Incentive Plan”) authorizing the grant of incentive stock options (“ISOs”) and non-statutory exercise price of an ISO and NSO shall not be less than 100% of the estimated fair value of the shares on the date of grant, as determined by the board of directors. The exercise price of an ISO granted to a 10% stockholder shall not be less than 110% of the estimated fair value of the shares on the date of grant, as determined by the board of directors. Options generally vest over four years and are exercisable for up to 10 years after the date of the grant. The following table summarizes the Company’s stock option activity, excluding performance and market awards: Number of Weighted- Weighted- Remaining Aggregate Outstanding at December 31, 2020 4,173,285 $ 0.49 8.9 $ 199 Granted 10,800,000 $ 0.89 Exercised (3,103,769 ) $ 0.43 Forfeited (158,342 ) $ 0.65 Expired — Outstanding at December 31, 2021 11,711,174 $ 0.86 9.1 $ 11,304 Vested and exercisable at December 31, 2021 1,381,326 $ 0.48 7.7 $ 1,781 The aggregate intrinsic values of options exercised during the years ended December 31, 2021 and 2020 were $0.8 million and $0.2 million, respectively. The weighted-average grant-date fair values of options granted during the years ended December 31, 2021 and 2020 were $0.96 and $0.38, respectively. Early Exercise of Stock Options into Restricted Stock For the year ended December 31, 2021, the Company issued 2,619,677 shares of common stock upon exercise of unvested stock options, and as of December 31, 2021, 2,418,871 shares held by employees were subject to repurchase at an aggregate price of $1.2 million. As of December 31, 2020, no options were early exercised and accordingly, the liability related to the payments for unvested shares was nil at each date. Stock-Based Compensation Expense In determining the fair value of the stock-based awards, the Company uses the assumptions below for the Black-Scholes option pricing model, which are subjective and generally requires significant judgment. Fair Value of Common Stock Expected Term mid-point Volatility Risk-free Rate zero-coupon Dividends The assumptions used to determine the grant date fair value of stock options granted to grantees were as follows, presented on a weighted-average basis: Year Ended 2021 2020 Expected term (in years) 6.03 6.03 Expected volatility 82.3% 83.3% Risk-free interest rate 0.9% 0.7% Dividend yield — % — % Total stock-based compensation expense was as follows (in thousands): Year Ended 2021 2020 General and administrative $ 1,940 $ 201 Research and development 355 71 Total stock-based compensation expense $ 2,295 $ 272 As of December 31, 2021, the total unrecognized stock-based compensation was approximately $9.2 million, which is expected to be recognized over a weighted-average period of 3.1 years. Performance Awards In connection with the Business Combination Agreement with DYNS, on December 19, 2021, the Company awarded 42,927,654 performance awards to existing employees that vest contingent upon the satisfaction of both a four-year service condition and a performance condition tied to the consummation of the SPAC merger. The grant and the associated recognition of stock-based compensation is contingent on the SPAC merger being consummated which is subject to DYNS shareholder approval. As of December 31, 2021, 42,909,091 performance awards remain outstanding after the forfeiture of 18,563 performance awards during the year. Market Awards In connection with the Business Combination Agreement with DYNS, on December 19, 2021, the Company awarded 3,093,776 market awards to the co-founder options will vest when the trading price of the Company’s stock is above various thresholds of price per share. The grant and the associated recognition of stock-based compensation is contingent on the SPAC merger being consummated which is subject to DYNS shareholder approval.

Operating Leases

Operating Leases	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Leases [Abstract]
Operating Leases	9. Operating Leases The Company’s operating leases are primarily for its corporate headquarters located in South San Francisco, California and for additional office and laboratory space located in Alameda, California (“Alameda lease”) that commenced on July 30, 2021. The corporate headquarters lease has an initial term of eight years expiring in 2027, with an option to renew for additional eight years unless canceled by either party thereafter. The Alameda lease has an initial term of eleven years expiring in 2032, with an option to renew the lease for up to two additional terms of five years. The exercise of these renewal options is not recognized as part of the ROU assets and lease liabilities, as the Company did not conclude, at the commencement date of the leases, that the exercise of renewal options or termination options was reasonably certain. The Alameda lease provides for a tenant improvement allowance of up to $17.5 million for the costs relating to the design, permitting and construction of the improvements, to be disbursed by the landlord no later than December 31, 2023. The Company was deemed to be the accounting owner of the tenant improvements primarily because the Company is the principal in the construction and design of the assets, is responsible for costs overruns and retains substantially all economic benefits from the leasehold improvements over their economic lives . The Company’s operating lease cost was $1.3 million and $0.7 million for the three months ended March 31, 2022 and 2021, respectively. Variable lease payments such as common area maintenance and parking fees were included in operating expenses and were $0.2 million and $0.2 million for the three months ended March 31, 2022 and 2021, respectively. The Company did not record any short-term lease expenses during the three months ended March 31, 2022 and 2021. As of March 31, 2022, the Company had utilized $2.5 million associated with the tenant improvements allowance. Supplemental cash flow and noncash information related to the operating leases were as follows (in thousands): Three Months Ended March 31, 2022 2021 Supplemental cash flow information: Operating cash flows from operating lease $ 1,874 $ (653 ) Remeasurement of ROU and lease liabilities due to changes in the timing of receipt of lease incentives $ 239 $ — The following summarizes additional information related to the operating leases as of March 31, 2022 and 2021: March 31, 2022 2021 Weighted-average remaining lease term 7.91 years 6.08 years Weighted-average discount rate 9.08% 8.91% As of March 31, 2022 and 2021, amounts disclosed for ROU assets obtained in exchange for lease obligations include amounts added to the carrying amount of ROU assets resulting from lease modifications and reassessments. Maturities of the Company’s lease liabilities as of March 31, 2022, were as follows (in thousands): 2022 $ 2,090 2023 6,272 2024 7,265 2025 7,489 2026 7,723 Thereafter 30,229 Total undiscounted lease payments 61,068 Less imputed interest (20,759 ) Tenant improvement reimbursements (14,914 ) Total lease liabilities $ 25,395	10. Operating Leases The Company’s operating leases are primarily for its corporate headquarters located in South San Francisco, California and for additional office and laboratory space located in Alameda, California (“Alameda lease”) that commenced on July 30, 2021. The corporate headquarters lease has an initial term of eight years expiring in 2027, with an option to renew for additional eight years unless canceled by either party thereafter. The Alameda lease has an initial term of eleven years expiring in 2032, with an option to renew the lease for up to two additional terms of five years. The exercise of these renewal options are not recognized as part of the ROU assets and lease liabilities, as the Company did not conclude, at the commencement date of the leases, that the exercise of renewal options or termination options was reasonably certain. The Alameda lease provides for a tenant improvement allowance of up to $17.5 million for the costs relating to the design, permitting and construction of the improvements, to be disbursed by the landlord no later than December 31, 2023. The Company was deemed to be the accounting owner of the tenant improvements primarily because the Company is the principal in the construction and design of the assets, is responsible for costs overruns and retains substantially all economic benefits from the leasehold improvements over their economic lives . The Company’s operating lease cost was $3.8 million and $2.7 million for the years ended December 31, 2021 and 2020, respectively. Variable lease payments such as common area maintenance and parking fees were included in operating expenses and were $0.7 million and $0.6 million for the years ended December 31, 2021 and 2020, respectively. The Company did record any short-term lease expense during the years ended December 31, 2021 and 2020. No reimbursements have been received from th e Supplemental cash flow and noncash information related to the operating leases were as follows (in thousands): Year Ended 2021 2020 Supplemental cash flow information: Operating cash flows from operating lease $ (2,669 ) $ (2,577 ) ROU assets obtained in exchange for operating lease obligations 10,153 513 The following summarizes additional information related to the operating leases as of December 31, 2021 and 2020: December 31, 2021 2020 Weighted-average remaining lease term 7.76 years 6.33 years Weighted-average discount rate 9.06 % 8.91 % As of December 31, 2021 and 2020, amounts disclosed for ROU assets obtained in exchange for lease obligations include amounts added to the carrying amount of ROU assets resulting from lease modifications and reassessments. Maturities of the Company’s lease liabilities as of December 31, 2021, were as follows (in thousands): 2022 $ 2,770 2023 6,272 2024 7,266 2025 7,489 2026 7,723 Thereafter 30,229 Total undiscounted lease payments 61,749 Less imputed interest (21,555 ) Tenant improvement reimbursements (17,463 ) Total lease liabilities $ 22,731

Related Parties

Related Parties	3 Months Ended	10 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2021
Related Parties	12. Related Parties The Company issued Series A convertible redeemable preferred stock and Series B redeemable convertible preferred stock in February 2018 and October 2020, respectively, to certain related parties, including New Enterprise Associates 15, L.P. and its affiliates (“NEA”) and 8VC and its affiliates (“8VC”). In February 2018, the outstanding convertible notes held by NEA and 8VC, as well as Timothy Lu, Chief Executive Officer, converted into additional shares of Series A redeemable convertible preferred stock while in October 2020, the outstanding convertible notes held by NEA and 8VC converted into additional shares of Series B redeemable convertible preferred stock, both in accordance with the terms of the note agreements. NEA held 13,505,035 shares of outstanding Series A redeemable convertible preferred stock as of March 31, 2022 and December 31, 2021, as well as 2,742,931 of outstanding Series B redeemable convertible preferred stock as of March 31, 2022 and December 31, 2021, respectively. 8VC held 9,052,387 of outstanding Series A redeemable convertible preferred stock as of March 31, 2022 and December 31, 2021, respectively, as well as 1,662,398 of outstanding Series B redeemable convertible preferred stock as of March 31, 2022 and December 31, 2021, respectively. Timothy Lu held 158,950 of outstanding redeemable convertible preferred stock as of March 31, 2022 and December 31, 2021, respectively. Timothy Lu and family held 8,100,000 of common stock as of March 31, 2022 and December 31, 2021, respectively. Timothy Lu, NEA, and 8VC held three of the seven seats on the Company’s Board of Directors as of March 31, 2022 and December 31, 2021. As Chief Executive Officer, Timothy Lu was paid $0.1 million as compensation for the three months ended March 31, 2022 and 2021, and less than $0.1 million and $0.2 million were accrued as a bonus on March 31, 2022 and December 31, 2021. On May 21, 2021, the Company entered into a collaboration and option agreement (“BlueRock Agreement”) with BlueRock Therapeutics LP (“BlueRock”), pursuant to which the Company granted to BlueRock an option (“BlueRock Option”), on a collaboration program-by-collaboration non-exclusive The Company concluded that the Agreement is not within the scope of ASC 808, Collaborative Arrangements BlueRock is a wholly-owned subsidiary of Bayer Healthcare LLC which held 27,393,924 shares of outstanding Series B redeemable convertible preferred stock as of March 31, 2022 and December 31, 2021, and holds one of the seven seats on the Company’s Board of Directors as of March 31, 2022 and December 31, 2021. Bayer Healthcare LLC’s parent company is Bayer AG, which served as the lead investor in our Series B financing through its Leaps by Bayer unit. Accordingly, BlueRock is considered a related party. NEA held 13,505,035 shares of outstanding Series A redeemable convertible preferred stock as of December 31, 2021 and 2020, as well as 2,742,931 of outstanding Series B redeemable convertible preferred stock as of December 31, 2021 and 2020. 8VC held 9,052,387 of outstanding Series A redeemable convertible preferred stock as of December 31, 2021 and 2020 as well as 1,662,398 of outstanding Series B redeemable convertible preferred stock as of December 31, 2021 and 2020. Timothy Lu held 158,950 of outstanding redeemable convertible preferred stock as of December 31, 2021 and 2020. Timothy Lu and family held 8,100,000 of common stock as of December 31, 2021 and 2020. Timothy Lu, NEA, and 8VC held three of the seven seats on the Company’s Board of Directors as of December 31, 2021 and three of the five seats on the Company’s Board of Directors as of December 31, 2020. As Chief Executive Officer, Timothy Lu was paid $0.4 million as compensation, and an additional sum of $0.2 million was accrued as a bonus for both the years ended December 31, 2021 and 2020. On May 21, 2021, the Company entered into a collaboration and option agreement (“BlueRock Agreement”) with BlueRock Therapeutics LP (“BlueRock”), pursuant to which the Company granted to BlueRock an option (“BlueRock Option”), on a collaboration program-by-collaboration non-exclusive The Company concluded that the Agreement is not within the scope of ASC 808, Collaborative Arrangements BlueRock is a wholly-owned subsidiary of Bayer Healthcare LLC which held 27,393,924 and 9,131,308 shares of outstanding Series B redeemable convertible preferred stock as of December 31, 2021 and 2020, respectively, and holds one of the seven seats on the Company’s Board of Directors as of December 31, 2021 and one of the five seats as of December 31, 2020. Bayer Healthcare LLC’s parent company is Bayer AG, which served as the lead investor in our Series B financing through its Leaps by Bayer unit. Accordingly, BlueRock is considered a related party. The Company concluded that the BlueRock Agreement should not be combined with the issuance of the Series B redeemable convertible preferred stock on May 14, 2021 as the price paid per share of $1.6427 was lower than the fair value of $2.03 (Note 3) and therefore, there was no excess value to allocate to the BlueRock Agreement.		14. Related Parties As discussed in Note 6, the Company issued Series A convertible redeemable preferred stock and Series B redeemable convertible preferred stock in February 2018 and October 2020, respectively, to certain related parties, including New Enterprise Associates 15, L.P. and its affiliates (“NEA”) and 8VC and its affiliates (“8VC”). In February 2018, the outstanding convertible notes held by NEA and 8VC, as well as Timothy Lu, Chief Executive Officer, converted into additional shares of Series A redeemable convertible preferred stock while in October 2020, the outstanding convertible notes held by NEA and 8VC converted into additional shares of Series B redeemable convertible preferred stock, both in accordance with the terms of the note agreements.
DYNAMICS SPECIAL PURPOSE [Member]
Related Parties	NOTE 5. RELATED PARTY TRANSACTIONS Founder Shares On March 8, 2021, the Sponsor was issued 5,750,000 shares (the “Founder Shares”) of Class B Common Stock for an aggregate price of $25,000. The Founder Shares included an aggregate of up to 750,000 shares of Class B Common Stock subject to forfeiture by the Sponsor to the extent that the underwriter’s over-allotment option was not exercised in full or in part, so that the Sponsor would own, on an as-converted In connection with the Non-Redemption Founder Shares and the Company will cancel such Founder Shares and concurrently issue to the Investors an equivalent number of shares of Class A Common Stock, in each case, at or promptly following the consummation of the Merger. The Company evaluated the forfeiture and cancellation of the Founder Shares by the Sponsor and concurrent issuance of an equivalent number of shares of Class A Common Stock to the Investors in accordance with Staff Accounting Bulletin Topic A. The forfeiture and cancellation of the Founder Shares by the Sponsor and concurrent issuance of an equivalent number of shares of Class A Common Stock to the Investors has t been transacted as of March , and will not occur until at or promptly following the consummation of the Merger. As such, any expense associated with the issuance of the shares of Class A Common Stock to the Investors would be recognized at the date of issuance (i.e., upon consummation of the Merger). Promissory Note - Related Party On March 8, 2021, the Company issued an unsecured promissory note to the Sponsor (the “Promissory Note”), pursuant to which the Company could borrow an aggregate of up to $300,000 to cover expenses related to the Initial Public Offering. The Promissory Note was non-interest Related Party Loans In addition, in order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”). If the Company completes a Business Combination, the Company would repay the Working Capital Loans out of the proceeds held in the Trust Account released to the Company. Otherwise, the Working Capital Loans would be repaid only out of funds held outside the Trust Account. In the event that a Business Combination is not completed, the Company may use a portion of the proceeds held outside the Trust Account to repay the Working Capital Loans, but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. Except for the foregoing, the terms of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such loans. Up to $2,000,000 of such Working Capital Loans may be convertible into shares at a price of $10.00 per share at the option of the lender. The shares would be identical to the Private Placement Shares. There was no outstanding balance of Working Capital Loans as of March 31, 2022 and December 31, 2021. Administrative Support Agreement The Company entered into an agreement, commencing on the effective date of the Initial Public Offering, to pay the Sponsor up to a total of $10,000 per month for office space, administrative and support services. Upon the	NOTE 5. RELATED PARTY TRANSACTIONS Founder Shares On March 8, 2021, the Sponsor was issued 5,750,000 shares (the “Founder Shares”) of Class B Common Stock Common Stock as-converted assuming the Sponsor did not purchase any Public Shares in the Initial Public Offering, which it did not In connection with the Non-Redemption equivalent number of shares of Class A Common Stock to the Investors in accordance with Staff Accounting Bulletin Topic The forfeiture and cancellation of the Founder Shares by the Sponsor and concurrent issuance of an equivalent number of shares of Class A Common Stock to the Investors has and will not occur until at or promptly following the consummation of the Merger. As such, any expense associated with the issuance of the shares of Class A Common Stock to the Investors would be recognized at the date of issuance (i.e., upon consummation of the Merger). Promissory Note—Related Party On March 8, 2021, the Company issued an unsecured promissory note to the Sponsor (the “Promissory Note”), pursuant to which the Company could borrow an aggregate of up to $300,000 to cover expenses related to the Initial Public Offering. The Promissory Note was non-interest Promissory Note which was repaid in full on May 26, 2021 . Related Party Loans In addition, in order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”). If the Company completes a Business Combination, the Company would repay the Working Capital Loans out of the proceeds held in the Trust Account released to the Company. Otherwise, the Working Capital Loans would be repaid only out of funds held outside the Trust Account. In the event that a Business Combination is not completed, the Company may use a portion of the proceeds held outside the Trust Account to repay the Working Capital Loans, but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. Except for the foregoing, the terms of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such loans. Up to $2,000,000 of such Working Capital Loans may be convertible into shares at a price of $10.00 per share at the option of the lender. The shares would be identical to the Private Placement Shares. Administrative Support Agreement The Company entered into an agreement, commencing on the effective date of the Initial Public Offering, to pay the Sponsor up to a total of $10,000 per month for office space, administrative and support services. Upon the completion of an initial Business Combination, the Company will cease paying these monthly fees (if any). To date, the Company has not exercised its option to use such services.

Net Loss Per Share

Net Loss Per Share	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Earnings Per Share [Abstract]
Net Loss Per Share	10. Net Loss Per Share A reconciliation of net loss available to common stockholders and the number of shares in the calculation of basic and diluted loss per share is as follows: Three Months Ended March 31, 2022 2021 Net loss $ (11,808 ) $ (21,002 ) Weighted-average shares used in computing net loss per share, basic and diluted 16,204,614 14,602,926 Net loss per share attributable to common stockholders, basic and diluted $ (0.73 ) $ (1.44 ) The following potential common shares securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been anti-dilutive (on an as-converted Three Months Ended March 31, 2022 2021 Series A and B redeemable convertible preferred stock 99,734,543 60,368,493 Potential issuance of Series B redeemable convertible preferred stock under Tranche 2 — 19,683,025 Potential issuance of Series B redeemable convertible preferred stock under Tranche 3 — 19,683,025 Stock options to purchase common stock 9,273,083 8,119,579 Unvested early exercised options 1,685,478 — Total 110,693,104 107,854,122	12. Net Loss Per Share A reconciliation of net loss available to common stockholders and the number of shares in the calculation of basic and diluted loss per share is as follows: Year Ended December 31, 2021 2020 Net loss $ (55,319 ) $ (19,862 ) Denominator: Weighted-average shares used in computing net loss per share, basic and diluted 14,881,325 13,862,582 Net loss per share attributable to common stockholders, basic and diluted $ (3.72 ) $ (1.43 ) The following potential common shares securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been anti-dilutive (on an as-converted Year Ended December 31, 2021 2020 Series A and B redeemable convertible preferred stock 99,734,543 58,948,067 Potential issuance of Series B redeemable convertible preferred stock under Tranche 2 — 19,683,025 Potential issuance of Series B redeemable convertible preferred stock under Tranche 3 — 19,683,025 Stock options to purchase common stock 11,711,174 4,173,285 Unvested early exercised options 2,418,871 — Total 113,864,588 102,487,402

Commitments And Contingencies

Commitments And Contingencies	3 Months Ended	10 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2021
Commitments And Contingencies	11. Commitments and Contingencies In the ordinary course of business, the Company enters into contractual agreements with third parties that include non-cancelable On June 3, 2021, the Company entered into a lease agreement for a new cGMP facility in Alameda, California to support planned initial clinical trials for our product candidates (Note 9). The lease will expire in 2032 with future undiscounted operating lease payments of $46.0 million over an initial lease period of eleven years. In 2021, the Company began construction of the cGMP facility. As of March 31, 2022 the Company paid $8.2 million in construction costs and the purchase commitments amounted to approximately $35.5 million. The agreements with the construction company provide for termination following a certain period after notice. Upon termination, the Company will be responsible for payment for work performed to date. In 2021, the Company entered into a three-year collaboration and option agreement with BlueRock Therapeutics LP (“BlueRock”) under which the Company granted BlueRock an option to acquire an exclusive or non-exclusive As of March 31, 2022, purchase commitments related to sponsored research agreements amounted to approximately $2.1 million. The Company has entered into license agreements under which they are obligated to make annual maintenance payments of $0.1 million and specified milestone and royalty payments. Future milestone and royalty payments under these agreements are not considered contractual obligations since the payments under these agreements are contingent upon future events, such as the Company’s achievement of specified development, regulatory, and sales milestones, or generating product sales. As of March 31, 2022, the Company is unable to estimate the timing or likelihood of achieving these milestones or generating future product sales. Legal Proceedings The Company is subject to claims and assessments from time to time in the ordinary course of business but does not believe that any such matters, individually or in the aggregate, will have a material adverse effect on the Company’s financial position, results of operations, or cash flows. Indemnifications In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third-party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has never incurred material costs to defend lawsuits or settle claims related to these indemnification provisions and has never accrued any liabilities related to such obligations in its condensed consolidated financial statements. The Company has also entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers to the fullest extent permitted by Delaware corporate law. The Company currently has directors’ and officers’ insurance.		13. Commitments and Contingencies In the ordinary course of business, we enter into contractual agreements with third parties that include non-cancelable On June 3, 2021, the Company entered into a lease agreement for a new cGMP facility in Alameda, California to support planned initial clinical trials for our product candidates (Note 10). The lease will expire in 2032 with future undiscounted operating lease payments of $46.0 million over an initial lease period of eleven years. In 2021, the Company began construction of the cGMP facility. As of December 31, 2021 the Company paid $2.6 million in construction costs and the purchase commitments amounted to approximately $35.5 million. The agreements with the construction company provide for termination following a certain period after notice. Upon termination the Company will be responsible for payment for work performed to date. During the year ended December 31, 2021, the Company entered into a three-year collaboration and option agreement with BlueRock Therapeutics LP (“BlueRock”) under which the Company granted BlueRock an option to acquire an exclusive or non-exclusive As of December 31, 2021, purchase commitments related to sponsored research agreements amounted to approximately $2.2 million. The Company has entered into license agreements under which they are obligated to make annual maintenance payments of $0.1 million and specified milestone and royalty payments. Future milestone and royalty payments under these agreements are not considered contractual obligations since the payments under these agreements are contingent upon future events, such as the Company’s achievement of specified development, regulatory, and sales milestones, or generating product sales. As of December 31, 2021, the Company is unable to estimate the timing or likelihood of achieving these milestones or generating future product sales. Leases The Company’s commitments under its leases are described in Note 10. Legal Proceedings The Company is subject to claims and assessments from time to time in the ordinary course of business but does not believe that any such matters, individually or in the aggregate, will have a material adverse effect on the Company’s financial position, results of operations, or cash flows. Indemnifications In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has never incurred material costs to defend lawsuits or settle claims related to these indemnification provisions and has never accrued any liabilities related to such obligations in its consolidated financial statements. The Company has also entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers to the fullest extent permitted by Delaware corporate law. The Company currently has directors’ and officers’ insurance.
DYNAMICS SPECIAL PURPOSE [Member]
Commitments And Contingencies	NOTE 6. COMMITMENTS AND CONTINGENCIES Registration Rights The holders of the Founder Shares, Private Placement Shares and any Class A Common Stock issuable upon conversion of any Working Capital Loans have registration rights pursuant to a registration and stockholder rights agreement signed in connection with the Company’s Initial Public Offering. The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company register such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the completion of an initial Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements. In addition, it is anticipated that each signatory to the Investor Rights Agreement (see Note 1), other than the Company, will be granted certain registration rights with respect to their respective shares of Class A Common Stock when that agreement is signed (which is expected to occur at Closing). Further, shares of Class A Common Stock issued to the private investors making Subscriptions will have registration rights pursuant to the Subscription Agreements following the consummation of the Business Combination. Underwriters Agreement The Company granted the underwriter of its Initial Public Offering a 45-day The underwriter was paid a cash underwriting fee of $0.20 per share, or $4,600,000 in the aggregate, upon the closing of the Initial Public Offering. In addition, $0.35 per share, or $8,050,000 in the aggregate was payable to the underwriter for deferred underwriting commissions. On December 17, 2021, the underwriter agreed to waive its right to $1,000,000 of the fee payable by the Company for deferred underwriting commissions. The waived fee was recorded to accumulated deficit. The revised deferred underwriting fee of $7,050,000 will become payable to the underwriter from the amount held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement. Financial Advisor Agreement On December 16, 2021, the Company entered into an agreement (the “Financial Advisor Agreement”) with Morgan Stanley & Co. LLC (“Morgan Stanley”) for financial advisory services in connection with the Senti Business Combination, which services Morgan Stanley had been engaged to provide, and which services Morgan Stanley had provided, since August 4, 2021. The Financial Advisor Agreement shall terminate automatically on December 16, 2022 unless terminated earlier, with or without cause, by either the Company or Morgan Stanley. The Company will pay Morgan Stanley a fee of $1,000,000 upon the consummation of the Company’s proposed initial business combination with Senti. Placement Agent Agreement On September 21, 2021, the Company entered into an agreement (the “Placement Agent Agreement”) with Morgan Stanley, J.P. Morgan Securities LLC and BofA Securities, Inc. (together, the “Placement Agents”) for services in connection with the placement of shares of the Company’s Class A Common Stock to certain private investors which is anticipated to occur concurrently with the completion the Senti Business Combination (i.e. the Subscriptions – see Note 1). The Placement Agent Agreement shall terminate automatically on August 28, 2022 unless terminated earlier, with or without cause, by either the Company or any Placement Agent (as to itself only). The Company will pay to the Placement Agents a total fee equal to 4.0% of the aggregate price at which the shares of the Company’s Class A Common Stock are sold to the private investors in the Subscriptions, which fee shall be payable upon the consummation of the placement of the shares. Each of the Placement Agents will receive 33.3% of the fee. Business Combination Agreement As set forth in Note 1, the Company has entered into the Business Combination Agreement with Merger Sub and Senti pursuant to which, among other things, Merger Sub will merge with and into Senti, with Senti surviving as a wholly-owned subsidiary of the Company. The Company has also entered into various ancillary transaction documents to give effect to the Merger, which are described throughout this Quarterly Report.	NOTE 6. COMMITMENTS AND CONTINGENCIES Registration Rights The holders of the Founder Shares, Private Placement Shares and any Class A Common Stock issuable upon conversion of any Working Capital Loans have registration rights pursuant to a registration and stockholder rights agreement signed in connection with our Initial Public Offering. The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company register such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the completion of an initial Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements. In addition, it is anticipated that each signatory to the Investor Rights Agreement (see Note 1), other than the Company, will be granted certain registration rights with respect to their respective shares of Class A Common Stock when that agreement is signed (which is expected to occur at Closing). Underwriting Agreement The Company granted the underwriter of its Initial Public Offering a 45-day option to purchase up to additional shares of Class A Common Stock to cover over-allotments at the Initial Public Offering price, less the underwriting discounts and commissions. The underwriter exercised the over-allotment option in full on , . The underwriter was paid a cash underwriting fee of $0.20 per share, or $4,600,000 in the aggregate, upon the closing of the Initial Public Offering. In addition, $0.35 per share, or $8,050,000 in the aggregate was payable to the underwriter for deferred underwriting commissions. On December 17, 2021 , the underwriter agreed to waive its right of the fee payable by the Company for deferred underwriting commissions. The waived fee was recorded to accumulated deficit. The revised deferred underwriting fee of $ will become payable to the underwriter from the amount held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement. Financial Advisor Agreement On December 16, 2021, the Company entered into an agreement (the “Financial Advisor Agreement”) with Morgan Stanley & Co. LLC (“Morgan Stanley”) for financial advisory services in connection with the Senti Business Combination, which services Morgan Stanley had been engaged to provide, and which services Morgan Stanley had provided, since August 4, 2021. The Financial Advisor Agreement shall terminate automatically on December 16, 2022 unless terminated earlier, with or without cause, by either the Company or Morgan Stanley. The Company will pay Morgan Stanley a fee of $1,000,000 upon the consummation of our proposed initial business combination with Senti. Placement Agent Agreement On September 21, 2021, the Company entered into an agreement (the “Placement Agent Agreement”) with Morgan Stanley, J.P. Morgan Securities LLC and BofA Securities, Inc. (together, the “Placement Agents”) for services in connection with the placement of shares of our Class A Common Stock to certain private investors which is anticipated to occur concurrently with the completion the Senti Business Combination (i.e. the Subscriptions – see Note 1). The Placement Agent Agreement shall terminate automatically on August 28, 2022 unless terminated earlier, with or without cause, by either the Company or any Placement Agent (as to itself only). The Company will pay to the Placement Agents a total fee equal to 4.0% of the aggregate price at which the shares of our Class A Common Stock are sold to the private investors in the Subscriptions, which fee shall be payable upon the consummation of the placement of the shares. Each of the Placement Agents will receive 33.3% of the fee. Business Combination Agreement As set forth in “Part I, Item 1. Business” of this Report, we have entered into the Business Combination Agreement with Merger Sub and Senti pursuant to which, among other things, Merger Sub will merge with and into Senti, with Senti surviving as a wholly-owned subsidiary of the Company. We have also entered into various ancillary transaction documents to give effect to the Merger, which are described throughout this Report.

Income Tax

Income Tax	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Income Tax	11. Income Taxes For the calendar years ended December 31, 2021 and 2020, the tax effects of significant items comprising the Company’s deferred taxes are as follows: December 31, 2021 2020 Deferred tax assets: Net operating losses $ 23,104 $ 15,543 Tax credits 4,915 2,775 Lease Liability 6,350 3,930 Accruals and reserves 738 526 Stock-based compensation 28 17 Other 600 2 Total deferred tax assets 35,735 22,793 Deferred tax liabilities: Operating lease right-of-use (5,789 ) (3,590 ) Fixed asset basis (236 ) (178 ) Total deferred tax liabilities (6,025 ) (3,768 ) Valuation allowance (29,710 ) (19,025 ) Net deferred taxes $ — $ — The Company records the tax benefit of net operating losses, temporary differences, and credit carryforwards as assets to the extent that management assesses that realization is “more likely than not.” Realization of the future tax benefits is dependent on the Company’s ability to generate sufficient taxable income within the carryforward period. Because of the Company’s recent history of operating losses, management believes that recognition of the deferred tax assets arising from the above-mentioned future tax benefits is currently not likely to be realized and, accordingly, has provided a valuation allowance. The valuation allowance increased by approximately $10.7 million and $7.9 million during 2021 and 2020, respectively, and the Company’s deferred tax assets continue to be fully offset by the valuation allowance as at December 31, 2021. For the years ended December 31, 2021 and 2020, the Company did not record an income tax provision. Net operating losses and tax credit carryforwards as of December 31, 2021 are as follows (in thousands): Amount Expiration Years Net operating losses, federal (Post December 31, 2017) $ 86,602 Do Not Expire Net operating losses, federal (Pre January 1, 2018) $ 3,508 12/31/2031 Net operating losses, state $ 55,023 12/31/2032 Tax credits, federal $ 3,573 12/31/2032 Tax credits, state $ 3,120 Do Not Expire Net operating losses, foreign $ 1,146 Do Not Expire Utilization of the net operating loss carryforwards may be subject to a substantial annual limitation due to the ownership change limitations provided by the Internal Revenue Code of 1986, as amended, and similar state provisions. This annual limitation may result in the expiration of net operating losses and credits before utilization. We have not performed an analysis to determine the limitation of our net operating loss carryforwards. The effective tax rate of the Company’s provision (benefit) for income taxes differs from the federal statutory rate as follows: December 31, 2021 2020 Statutory rate 21.00 % 21.00 % State tax 2.98 % 11.68 % Other (0.80 )% (0.05 )% Tax credits 2.29 % 2.81 % Fair value of series B preferred stock tranche liability (5.60 )% 6.04 % Valuation allowance (19.87 )% (41.48 )% Total 0.00 % 0.00 % As of December 31, 2020, gross unrecognized tax benefits were $1.3 million, all of which would not impact the Company’s effective tax rate if recognized. The Company has elected to include interest and penalties as a component of tax expense. For the years ended December 31, 2021 and 2020, the Company did not The Company files income tax returns in the U.S. federal and California tax jurisdictions. The federal and state income tax returns from inception to December 31, 2021 remain subject to examination.

Fair Value Measurements

Fair Value Measurements	3 Months Ended	10 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2021
Fair Value Measurements	3. Fair Value Measurements The following tables summarize the estimated value of cash equivalents and restricted cash (in thousands): March 31, 2022 Amortized Unrealized Unrealized Estimated Fair Cash equivalents: Money market fund $ 38,140 $ — $ — $ 38,140 Restricted cash: Money market fund 3,257 — — 3,257 Total $ 41,397 $ — $ — $ 41,397 December 31, 2021 Amortized Unrealized Unrealized Estimated Fair Cash equivalents: Money market fund $ 56,034 $ — $ — $ 56,034 Restricted cash: Money market fund 3,257 — — 3,257 Total $ 59,291 $ — $ — $ 59,291 Financial assets and liabilities measured and recognized at fair value are as follows (in thousands): March 31, 2022 Level 1 Level 2 Level 3 Total Assets: Cash equivalents: Money market fund $ 38,140 $ — $ — $ 38,140 Restricted cash: Money market fund 3,257 — — 3,257 Total Assets $ 41,397 $ — $ — $ 41,397 December 31, 2021 Level 1 Level 2 Level 3 Total Assets: Cash equivalents: Money market fund $ 56,034 $ — $ — $ 56,034 Restricted cash: Money market fund 3,257 — — 3,257 Total Assets $ 59,291 $ — $ — $ 59,291 No securities have contractual maturities of longer than one year. There were no transfers between Levels 1, 2, or 3 for any of the periods presented. Preferred Stock Tranche Liability The initial and subsequent fair values of the preferred stock tranche liability recognized in connection with the issuance of Series B redeemable convertible preferred stock financing were determined with the assistance of a third-party valuation specialist using significant inputs not observable in the market which constitute Level 3 measurements within the fair value hierarchy. The following reflects the significant quantitative inputs used in the valuation of the preferred stock tranche liability for fiscal year 2020 on initial closing on October 22, 2020, second closing on December 28, 2020 and subsequent measurement as of December 31, 2020 using a Monte Carlo valuation model and/or Black-Scholes option pricing model: October 22, 2020 Initial Measurement Date December 28 and December 31, 2020 Subsequent Measurement Dates Tranche 2 Call Tranche 3 Call Tranche Features Option Tranche 2 and Estimated fair value of Series B redeemable convertible preferred stock(1) $ 1.25 $ 1.25 $ 1.62 $ 1.62 Discount rate 0.12 % 0.17 % 0.11 % 0.11 % Time to liquidity (years) 0.9 2.2 0.5 0.5 Expected volatility 54.9 % 54.9 % 73.8 % N/A Probability of call option and forward contract N/A N/A 10 % 90 % Strike Price $ 1.6427 $ 1.6427 $ 1.6427 $ 1.6427 Value of each tranche feature $ 0.143 $ 0.199 $ 0.326 $ (0.023 ) (1) Fair value of the Series B redeemable convertible preferred stock was estimated using the Backsolve method. The weighted-average fair value of the tranche features on a per share basis was $0.172 as of October 22, 2020, $0.012 as of December 28, 2020 and December 31, 2020 for a preferred stock tranche liability of $0.4 million as of December 31, 2020. For the October 2020 issuance of Series B redeemable convertible preferred stock, certain investors received the right to participate in two additional closings at a fixed price which were valued as a call option (Note 6) when issued. In connection with the December 2020 issuance of Series B redeemable convertible preferred stock, certain investors of Series B redeemable convertible preferred stock that held 48.65% of the Company’s outstanding shares and have 2 seats on the Company’s board of directors, forfeited their rights to participate in two additional closings of Series B redeemable convertible preferred stock which resulted in the measurement of the preferred stock tranche liability as a combination of a call option and forward contract. In January 2021, the Company issued additional Series B redeemable convertible preferred stock and recorded an addition to the tranche liability of $33 thousand in recognition of the obligation to sell additional shares at a fixed price in the event that certain agreed-upon milestones are achieved or at the election of investors. The following reflects the significant quantitative inputs used in the valuation of the preferred stock tranche liability as of March 31, 2021 using a Black-Scholes pricing model and a scenario analysis: March 31, 2021 (unaudited) Tranche 2 Tranche 3 (Public) Tranche 3 (Staying Private) Forward Call No Value Call Forward No Value Estimated fair value of Series B redeemable convertible preferred stock(1) $ 2.0796 $ 2.3386 N/A $ 1.3023 $ 1.3023 N/A Discount rate 0.03 % 0.05 % N/A 0.06 % 0.06 % N/A Time to liquidity (years) 0.08 0.50 N/A 0.75 0.75 N/A Probability of call option and forward contract 100.0 % 25.0 % 75.0 % 45.0 % 5.0 % 50.0 % Strike price $ 1.6427 $ 1.6427 N/A $ 1.6427 $ 1.6427 N/A Expected volatility N/A 80.00 % N/A 80.00 % N/A N/A Value of each tranche feature $ 0.437 $ 0.873 $ — $ 0.251 $ (0.340 ) $ — Total value of tranche feature (in millions) $ 8.6 $ 4.3 $ 1.9 (1) Fair value of the Series B redeemable convertible preferred stock for Tranche 3 was estimated using guideline IPO transactions for the public scenario and the Black-Scholes based option pricing model for the staying-private scenario, and for Tranche 2 was based on a weighting of the public and staying-private scenarios used for Tranche 3. The total value of Tranche 2 was determined as a forward contract for a total of $8.6 million. The value of Tranche 3 was determined using public company and staying-private scenarios for a total value of $4.3 million and $1.9 million, respectively. The Company applied a 75% weighting to the public scenario and a 25% weighting to the staying-private scenario, resulting in a value of Tranche 3 rights of $3.7 million. The weighted average fair value of the tranche feature on a per share basis was $0.312 as of March 31, 2021 for a total preferred stock tranche liability of $12.3 million resulting in a change in fair value of the preferred stock tranche liability of $11.8 million for the three months ended March 31, 2021. In April 2021, the Company’s Board of Directors determined that certain technical milestones within the Series B agreements had been achieved and approved the notice to call tranches 2 and 3, subject to requisite stockholders’ written election and related waivers. The second and third closings occurred on May 14, 2021 and all shares of the Series B redeemable convertible preferred stock were acquired, thereby extinguishing the preferred stock tranche liability.		3. Fair Value Measurements The following tables summarize the estimated value of cash equivalents, restricted cash and short-term investments (in thousands): December 31, 2021 Amortized Unrealized Unrealized Estimated Fair Cash equivalents: Money market fund $ 56,034 $ — $ — $ 56,034 Restricted cash: Money market fund 3,257 $ — $ — 3,257 Total $ 59,291 $ — $ — $ 59,291 December 31, 2020 Amortized Unrealized Unrealized Estimated Fair Cash equivalents: Money market fund $ 30,387 $ — $ — $ 30,387 Restricted cash: Money market fund 497 — — 497 Total $ 30,884 $ — $ — $ 30,884 Financial assets and liabilities measured and recognized at fair value are as follows (in thousands): December 31, 2021 Level 1 Level 2 Level 3 Total Assets: Cash equivalents: Money market fund $ 56,034 $ — $ — $ 56,034 Restricted cash: Money market fund 3,257 — — 3,257 Total Assets $ 59,291 $ — $ — $ 59,291 December 31, 2020 Level 1 Level 2 Level 3 Total Assets: Cash equivalents: Money market fund $ 30,387 $ — $ — $ 30,387 Restricted cash: Money market fund 497 497 Total Assets $ 30,884 $ — $ — $ 30,884 Liabilities: Preferred stock tranche liability $ — $ — $ 435 $ 435 Total Liabilities $ — $ — $ 435 $ 435 No securities have contractual maturities of longer than one year. There were no transfers between Levels 1, 2, or 3 for any of the periods presented. Convertible Notes Due to certain embedded features within the convertible notes (Note 5), the Company elected to account for the convertible notes under the fair value option. At issuance in August 2020, the convertible notes were recorded at fair value of $8.9 million, resulting in a loss on issuance of $0.9 million which is included in the change in fair value of convertible note. The fair value of the convertible notes at issuance was determined using a probability-weighted income approach as the convertible notes contained various settlement outcomes. The following reflects the significant quantitative inputs used to fair value the convertible notes at issuance. On Issuance Interest rate 8.00 % Discount rate 6.78 % Time to maturity (years) 0.49 Probability of automatic conversion upon qualified financing 95.0 % Probability of optional conversion 2.5 % Probability of no conversion 2.5 % Conversion Price $ 1.4784 In connection with the issuance and sale of Series B redeemable convertible preferred stock in October 2020 (Note 6), all of the outstanding principal and accrued interest of $8.1 million under the convertible notes was converted into 5,485,858 shares of Series B redeemable convertible preferred stock and the related preferred stock tranche liability. The fair value of the convertibles notes of $8.7 million on the date of conversion was determined using the Backsolve method based on the price of the Series B redeemable convertible preferred stock and, if purchased, the related preferred stock tranche liability. The following table provides a roll-forward of the fair value of the convertible notes (in thousands): Fair Value Proceeds from issuance in August 2020 $ 8,000 Change in fair value of convertible notes 720 Conversion to Series B redeemable convertible preferred stock (7,940 ) Recognition of preferred stock tranche liability (780 ) Balance as of December 31, 2020 $ — Preferred Stock Tranche Liability The initial and subsequent fair values of the preferred stock tranche liability recognized in connection with the issuance of Series B redeemable convertible preferred stock financing were determined with the assistance of a third-party valuation specialist using significant inputs not observable in the market which constitute Level 3 measurements within the fair value hierarchy. The following reflects the significant quantitative inputs used in the valuation of the preferred stock tranche liability for fiscal year 2020 on initial closing on October 22, 2020, second closing on December 28, 2020 and subsequent measurement as of December 31, 2020 using a Monte Carlo valuation model and/or Black-Scholes option pricing model: October 22, 2020 Initial Measurement Date December 28 and December 31, 2020 Subsequent Measurement Dates Tranche 2 Call Tranche 3 Call Tranche Features Tranche 2 and 3 Estimated fair value of Series B redeemable convertible preferred stock (1) $1.25 $1.25 $1.62 $1.62 Discount rate 0.12% 0.17% 0.11% 0.11% Time to liquidity (years) 0.9 2.2 0.5 0.5 Expected volatility 54.9% 54.9% 73.8% N/A Probability of call option and forward contract N/A N/A 10% 90% Strike Price $1.6427 $1.6427 $1.6427 $1.6427 Value of each tranche feature $0.143 $0.199 $0.326 $(0.023) (1) Fair value of the Series B redeemable convertible preferred stock was estimated using the Backsolve method. The weighted-average fair value of the tranche features on a per share basis was $0.172 as of October 22, 2020, $0.012 as of December 28, 2020 and December 31, 2020. For the October 2020 issuance of Series B redeemable convertible preferred stock, certain investors received the right to participate in two additional closings at a fixed price which were valued as a call option (Note 6) when issued. In connection with the December 2020 issuance of Series B redeemable convertible preferred stock, certain investors of Series B redeemable convertible preferred stock that held 48.65 In January 2021, the Company issued additional Series B redeemable convertible preferred stock, and recorded an addition to the tranche liability of $ 33 thousand In April 2021, the Company’s Board of Directors determined that certain technical milestones within the Series B agreements had been achieved and approved the notice to call tranches 2 and 3, subject to requisite stockholders’ written election and related waivers. The second and third closings occurred on May 14, 2021 and all 39,366,050 shares of Series B redeemable convertible preferred stock were acquired thereby extinguishing the preferred stock tranche liability. The value of the tranche rights acquired on May 14, 2021 was determined using the current value method as both tranches were called by the Company on the valuation date. The following reflects the significant quantitative inputs used in the valuation of the preferred stock tranche liability as of May 14, 2021 using a weighted comparable guideline IPO (high and low) and SPAC transactions for the public scenario and the Black-Scholes pricing model for the staying private scenario: May 14, 2021 Tranches 2 and 3 Public Scenario Staying Private Call Call Estimated fair value of Series B redeemable convertible preferred stock $2.18 $1.58 Scenario weighting 75.0% 25.0% Value of each tranche feature $1.637 $0.395 Weighted-average value of Series B redeemable convertible preferred stock $2.032 The difference between the weighted-average value of Series B redeemable convertible preferred stock of $2.032 and the strike price of $1.6427 is the $0.3893 weighted-average fair value of the tranche feature on a per share basis as of May 14, 2021 for a total fair value of $15.2 million. The following table provides a roll-forward of the change in the preferred stock tranche liability (in thousands): Preferred Stock Initial closing on October 22, 2020 $ 6,120 Forfeiture of tranche rights (780 ) Change in fair value (4,968 ) Second closing on December 28, 2020 $ 63 Balance as of December 31, 2020 435 Recognition of tranche rights from January 2021 issuance 33 Change in fair value 14,742 Tranche liability extinguishment (15,210 ) Balance as of December 31, 2021 $ —
DYNAMICS SPECIAL PURPOSE [Member]
Fair Value Measurements	NOTE 8. FAIR VALUE MEASUREMENTS The following table presents information about the Company’s financial assets that are measured at fair value on a recurring basis as of March 31, 2022 and December 31, 2021, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: Description Amount at Fair Level 1 Level 2 Level 3 March 31, 2022 Assets Investments held in Trust Account: U.S. Treasury Securities $ 230,031,946 $ 230,031,946 $ — $ — December 31, 2021 Assets Investments held in Trust Account: U.S. Treasury Securities $ 230,008,784 $ 230,008,784 $ — $ —	NOTE 9. FAIR VALUE MEASUREMENTS The following table presents information about the Company’s financial assets that are measured at fair value on a recurring basis as of December 31, 2021, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: Description Amount at Fair Level 1 Level 2 Level 3 December 31, 2021 Assets Investments held in Trust Account: U.S. Treasury Securities $ 230,008,784 $ 230,008,784 $ 0 $ 0

Subsequent Events

Subsequent Events	3 Months Ended	10 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2021
Subsequent Events	13. Subsequent Events The Company has evaluated subsequent events from the March 31, 2022 balance sheet date through May 20, 2022, the date at which the unaudited condensed consolidated financial statements were available to be issued, and determined that there have been no events that have occurred that would require adjustments to our disclosures in the condensed consolidated financial statements except for the transaction described below. On May 19, 2022, the Company issued a convertible note to Bayer HealthCare LLC for aggregate cash proceeds of approximately $5.2 million. The convertible note accrues interest at 3% per year and has an original maturity date of two years from issuance. The convertible note will automatically convert into shares of DYNS Class A Common Stock upon the closing of the Business Combination Agreement with DYNS at a conversion price of $10.00 per share, and all accrued interest at such time will be canceled and forgiven. The shares of Class A Common Stock will have the same registration rights as the shares to be issued in the $66.8 million private placement discussed in Note 1, Organization and Description of Business and Basis of Presentation		15. Subsequent Events The Company has evaluated subsequent events from the December 31, 2021 balance sheet date through April 1, 2022, the date at which the audited consolidated financial statements were available to be issued. Option Modification On February 12, 2022, the Company entered into Amendment No. 1 to the Business Combination Agreement, to restructure the performance and market awards made at the time the Business Combination Agreement was signed. In particular, certain Senti executives agreed to forfeit certain options awarded to them at the time the Business Combination Agreement was signed depending on the level of redemptions of DYNS Class A Common Stock upon closing of the merger. In addition, it was agreed that the vesting period for the options held by executives whose options may be subject to forfeiture (as described above) will commence upon closing of the merger instead of on December 19, 2021.
DYNAMICS SPECIAL PURPOSE [Member]
Subsequent Events	NOTE 9. SUBSEQUENT EVENTS The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statements were issued. Based upon this review, other than the amendments to the Non-Redemption Agreements discussed in Note 1, the Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements.	NOTE 10. SUBSEQUENT EVENTS The Company evaluated subsequent events and transactions that occurred after the consolidated balance sheet date up to the date that the consolidated financial statements were issued. Based upon this review, other than the amendments to the Business Combination Agreement and Senti Support Agreements as discussed in Note 1, the Company did not identify any subsequent events that would have required adjustment or disclosure in the consolidated financial statements.

Events (Unreviewed) Subsequent

Events (Unreviewed) Subsequent	3 Months Ended
	Mar. 31, 2022
Subsequent Events [Abstract]
Events (Unreviewed) Subsequent	14. Events (Unreviewed) Subsequent to May 20, 2022 On June 6, 2022, the Company changed its corporate name from Senti Biosciences, Inc. to Senti Sub I, Inc. On June 8, 2022 (the “Closing Date”), the Company and DYNS consummated the transactions contemplated under the previously announced Business Combination Agreement, dated December 19, 2021 and amended on February 12, 2022 and May 19, 2022 (as amended, the “Business Combination Agreement”) by and among the Company, DYNS and Explore Merger Sub Inc., a wholly-owned subsidiary of DYNS. Pursuant to the terms of the Business Combination Agreement, Merger Sub merged with and into the Company, with the Company surviving the merger as a wholly-owned subsidiary of DYNS (the “Business Combination”). In connection with the consummation of the Business Combination, DYNS changed its corporate name to Senti Biosciences, Inc. (the “Combined Company”). At the effective time of the Business Combination (the “Effective Time”): • each outstanding share of common stock of the Company (“Senti Common Stock”) was cancelled and converted into the right to receive a number of shares of Class A common stock of DYNS (“Class A Common Stock”), rounded down to the nearest whole share, equal to the number of shares of Senti Common Stock multiplied by the exchange ratio of 0.1957 (the “Exchange Ratio”); • each outstanding share of preferred stock of the Company (“Senti Preferred Stock”) was cancelled and converted into the right to receive a number of shares of Class A Common Stock, rounded down to the nearest whole share, equal to the aggregate number of shares of Senti Common Stock issuable upon conversion of the shares of Senti Preferred Stock based on the applicable conversion ratio immediately prior to the Effective Time, which was 1:1, multiplied by the Exchange Ratio; and • each outstanding option in the Company (whether vested or unvested) was converted into an option to purchase a number of shares of Class A Common Stock (rounded down to the nearest whole share) equal to the number of shares of Senti Common Stock subject to such option immediately prior to the Effective Time, multiplied by the Exchange Ratio, at an exercise price per share equal to the current exercise price per share for such option divided by the Exchange Ratio, rounded up to the nearest whole cent. As additional consideration, holders of shares of Senti Common Stock and Senti Preferred Stock immediately prior to the Effective Time became eligible to receive contingent consideration of up to an aggregate of 2,000,000 shares of Common Stock (as defined below), subject to the achievement of certain share price milestones within the first two or three calendar years after the Closing Date or, in certain circumstances, upon a change of control of the Combined Company. Following the closing of the Business Combination, all shares of Class A Common Stock were redesignated as common stock, par value $0.0001 per share, of the Combined Company (“Common Stock”). On the Closing Date, the Common Stock was listed on the Nasdaq Global Market under the new trading symbol “SNTI”. The Combined Company received gross proceeds of approximately $140.3 million of the expected $156.5 million in connection with the Business Combination, which included funds held in DYNS’s trust account of $84.5 million (net of the Redemption, as defined below), $50.6 million of the expected $66.8 million in proceeds from the PIPE Investment that closed concurrently with the consummation of the Business Combination, and a recent $5.2 million investment by Bayer Healthcare LLC (“Bayer”) through a Convertible Note Exchange (as defined below). On the Closing Date, certain investors (the “PIPE Investors”) purchased from the Combined Company an aggregate of 5,060,000 shares of Class A Common Stock (the “PIPE Shares”), for a purchase price of $10.00 per share and an aggregate purchase price of $50.6 million, pursuant to separate subscription agreements (each, a “Subscription Agreement”) entered into and effective as of December 19, 2021 (the “PIPE Investment”). The Combined Company received original commitments under the Subscription Agreements totaling $66.8 million; however, $16.2 million had yet to be funded as of the Closing Date. On the Closing Date, an unsecured convertible promissory note (the “Note”) in the principal amount of $5,175,000 that was previously issued by the Company to Bayer Healthcare LLC (“Bayer”) on May 19, 2022 was automatically cancelled and exchanged for 517,500 shares of Class A Common Stock (the “Convertible Note Exchange”). All interest accrued on the Note was also cancelled as part of the Convertible Note Exchange.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended	10 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2021
Accounting Policies [Line Items]
Basis of Presentation			Basis of Presentation The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and as amended by Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”). The consolidated financial statements include the accounts of Senti Biosciences, Inc., and its wholly-owned subsidiary. All intercompany balances and transactions have been eliminated in consolidation. We have one business activity and operate in one reportable segment.
Use of Estimates			Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates, judgments, and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual for research and development expenses, the valuation of stock-based awards, the valuation of convertible notes, the valuation of common and redeemable convertible preferred stock, the valuation of preferred stock tranche liability, standalone selling price (“SSP”) and the determination of the incremental borrowing rate. Actual results could differ from those estimates, and such differences could be material to the financial position and consolidated statements of operations and comprehensive loss.
Cash and Cash Equivalents			Cash, Cash Equivalents, and Restricted Cash Cash equivalents consist of amounts deposited in money market funds and securities with original maturity dates of three months or less, which are stated at fair value. The Company’s restricted cash consists of cash deposited with a financial institution as collateral for a letter of credit required under the Company’s headquarters and research facility leases. The restricted cash is presented separately from cash and cash equivalents and classified as non-current The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that total to the amounts shown in the consolidated statements of cash flows for the Company: December 31, 2021 2020 Cash and cash equivalents 56,034 30,537 Restricted cash 3,257 497 Total $ 59,291 $ 31,034
Offering Costs Associated with the Initial Public Offering	Offering Costs Associated with the Initial Public Offering The Company complies with the requirements of ASC 340-10-S99-1 5A - Expenses As noted in Note 1, subsequent to the Initial Public Offering, the underwriter agreed on December 17, 2021 to waive $1,000,000 of its deferred underwriting fees of $8,050,000, thereby reducing those fees to $7,050,000; thus, the offering costs related to the Company’s Initial Public Offering amounted to $12,198,430.
Deferred Offering Costs			Deferred Offering Costs Deferred offering costs consists of incremental legal, accounting and other fees directly attributable to equity offerings. Deferred offering costs are capitalized within prepaid and other current assets on the consolidated balance sheets and are offset against proceeds of the offering in the consolidated statements of redeemable convertible preferred stock and stockholders’ deficit as a reduction of additional paid-in
Income Taxes			Income Taxes The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the consolidated statement of operations in the period that includes the enactment date. The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning The Company records uncertain tax positions on the basis of a two-step more-likely-than-not
Net Loss Per Share			Net Loss Per Share The Company follows the two-class two-class two-class Basic net loss per share attributable to common stockholders is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period. Diluted net loss per share attributable to common stockholders is computed by adjusting net loss attributable to common stockholders for an allocation of the undistributed earnings and dividing it by the weighted-average number of common shares outstanding for the period, including potential dilutive common shares. For purposes of this calculation, the Company’s outstanding stock options, redeemable convertible preferred stock, and potential issuance of redeemable convertible preferred stock under existing preferred stock tranches, are considered potential dilutive common shares. The Company’s participating securities contractually entitle the holders of such securities to participate in dividends but do not contractually require the holders of such securities to participate in losses of the Company.
Concentration of Credit Risk			Concentration of Credit Risk Financial instruments that potentially subject the Company to a significant concentration of credit risk consist of cash, cash equivalents, and short-term investments that are maintained in checking and money market
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements In November 2021, the FASB issued Accounting Standards Update (ASU) No. 2021-10, In May 2021, the FASB issued ASU 2021-04 Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 370-50), 815-40); Task Force) In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) 815-40): In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes		Recently Adopted Accounting Pronouncements In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326) In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820) In November 2018, the FASB issued ASU No. 2018-18, Collaborative Arrangements
Impact of the COVID-19 Coronavirus			Impact of the COVID-19 During 2021, widespread availability of COVID-19 re-open COVID-19 COVID-19 pre-pandemic
Short-term Investments			Short-term Investments Investments in marketable securities with original maturities less than 12 months from the balance sheet date, if any, are classified as short-term investments. Investments with original maturities of greater than 12 months from the balance sheet date, if any, are classified as long-term. The Company classifies all of its investments as available-for-sale available-for-sale
Fair Value Measurements			Fair Value Measurements Certain assets and liabilities of the Company are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows: • Level 1 – Quoted prices in active markets for identical assets or liabilities. • Level 2 – Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. • Level 3 – Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies, and similar techniques. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The estimated fair values of the Company’s cash and cash equivalents, restricted cash, trade, and other receivables and accounts payable approximate their carrying values given their short-term nature. The Company’s convertible notes and preferred stock tranche liability were carried at fair value from the date of issuance through their respective extinguishment in October 2020 and May 2021, and were determined using Level 3 inputs in the fair value hierarchy described above.
Property and Equipment, Net			Property and Equipment, Net Property and equipment, net is stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, which are as follows: Small equipment 2 years Computer equipment and software 3 years Laboratory equipment 5-7 Furniture and fixtures 5-7 Leasehold improvements Shorter of the lease term and the useful life The Company capitalizes certain costs incurred during the construction phase of a project or asset into construction-in-progress. When assets are retired or disposed of, any resulting gain or loss is included in net loss. Expenditures for maintenance and repairs are expensed as incurred.
Impairment of Long-Lived Assets			Impairment of Long-Lived Assets The Company evaluates its long-lived assets, such as property and equipment, net, for impairment whenever events or changes in circumstances indicate that the carrying value of assets may not be recoverable.
Leases			Leases The Company determines if an arrangement is or contains a lease at inception. Operating leases are recorded on the consolidated balance sheets with right-of-use The Company has elected to not separate lease and non-lease non-lease
Revenue Recognition			Revenue Recognition Contract Revenue Revenue is recognized when a customer obtains control of promised goods or services. The Company applies the following five steps to recognize revenue: (i) identify the contract with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to performance obligations in the contract; and (v) recognize revenue when (or as) the performance obligations are satisfied. A performance obligation is defined as a promise to transfer a product or a service to a customer that is distinct. A product or a service is distinct if both (i) the customer can benefit from the product or the service either on its own or together with other resources that are readily available to the customer and (ii) the Company’s promise to transfer the product or the service to the customer is separately identifiable from other promises in the contract. Each distinct promise to transfer a product or a service is a unit of accounting for revenue recognition. If a promise to transfer a product or a service is not distinct from other promises in the contract, such promises should be combined into a single performance obligation. The assessment of each of these elements may require significant judgments. Arrangements that include rights to additional goods or services that are exercisable at a customer’s discretion are generally considered options. If these options provide a material right to the customer, they are considered performance obligations. The identification of material rights requires judgments related to the determination of the value of the underlying license relative to the option exercise price, including assumptions about technical feasibility and the probability of developing a candidate that would be subject to the option rights. The transaction price is the amount of consideration the Company is entitled to receive in exchange for the transfer of control of a product or a service to a customer. The Company’s agreements may include both fixed and variable consideration. Fixed payments are included in the transaction price, while variable consideration, such as milestone payments and fees for research services, are estimated and constrained (if required) at the inception of the contract and evaluated on a periodic basis thereafter. If a contract has multiple performance obligations, the Company allocates the transaction price to each distinct performance obligation based on the relative stand-alone selling price (“SSP”) of the performance obligation. The Company determines SSP at contract inception and at contract modification. Determining the SSP for performance obligations requires significant judgment. Changes in the key assumptions used to determine the SSP could have a significant effect on the allocation of arrangement consideration between multiple performance obligations. For each distinct performance obligation, revenue is recognized as the Company transfers control of the product or the service applicable to such performance obligations. In instances where the Company first receives consideration in advance of satisfying its performance obligation, the Company classifies such consideration as deferred revenue until the Company satisfies such performance obligations. In instances where the Company first satisfies its performance obligation prior to its receipt of consideration, the consideration is a contract asset recorded in prepaid expenses and other current assets on the consolidated balance sheets.
Research and Development Expenses			Research and Development Expenses Research and development costs are expensed as incurred. Research and development costs consist of salaries and other personnel-related expenses, including associated stock-based compensation, lab supplies and services, in-license Nonrefundable advance payments for goods and services that will be used or received in future research and development activities are deferred and recognized as an expense in the period in which the related goods are delivered, or services are performed.
Commitments and Contingencies			Commitments and Contingencies The Company recognizes a liability with regard to loss contingencies when it believes it is probable a liability has occurred and the amount can be reasonably estimated. If some amount within a range of loss appears at the time to be a better estimate than any other amount within the range, the Company accrues that amount. When no amount within the range is a better estimate than any other amount, the Company accrues the minimum amount in the range. The Company has not recorded any such liabilities as of December 31, 2021 and 2020.
Fair Value Option for Convertible Notes			Fair Value Option for Convertible Notes The Company elected to account for its convertible notes at fair value as of the issuance date in order to measure those liabilities at amounts that more accurately reflect the current economic environment in which the Company operates. Accordingly, the Company recorded these convertible notes issued in August 2020 at fair value with changes in fair value recognized in change in fair value of convertible notes in the consolidated statements of operations and comprehensive loss. As a result of applying the fair value option, direct costs and fees related to the convertible notes were expensed in the period incurred.
Accretion and Classification of Redeemable Convertible Preferred Stock			Accretion and Classification of Redeemable Convertible Preferred Stock The Company’s redeemable convertible preferred stock is recorded based on proceeds received, net of the related preferred stock tranche liability and issuance costs, and is classified outside of stockholders’ deficit on the consolidated balance sheets because the holders of such shares have liquidation rights in the event of a deemed liquidation that, in certain situations, are not solely within the control of the Company and would require the redemption of the then-outstanding redeemable convertible preferred stock. The Company’s Series A and Series B redeemable convertible preferred stock are subject to liquidation, dissolution, or winding up of the Company, either voluntary or involuntary (Note 6). Because the occurrence of a deemed liquidation event is not currently probable as of December 31, 2021, the carrying values of the redeemable convertible preferred stock are not being accreted to their redemption values. Subsequent adjustments to accrete the carrying values of the redeemable convertible preferred stock to its redemption price would be made only when a deemed liquidation event becomes probable.
Stock-Based Compensation			Stock-Based Compensation The Company recognizes stock-based compensation expense related to employees and non-employees The Company has allowed specified option holders to exercise unvested options. The options that are exercised prior to vesting continue to vest according to the respective option agreement, and such unvested shares are subject to repurchase by the Company at the option holder’s original exercise price in the event the option holder’s service with the Company voluntarily or involuntarily terminates. The Company records proceeds from the early exercise of options as a current and long-term liability in the consolidated balance sheet, and reclassifies this liability to additional paid-in
Accounting Pronouncements Not Yet Adopted			Accounting Pronouncements Not Yet Adopted In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes In March 2020, the Financial Accounting Standards Board issued ASU No. 2020-03, Codification Improvements to Financial Instruments In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) 815-40): In October 2020, the FASB issued ASU No. 2020-10, Codification Improvements In November 2021, the FASB issued ASU 2021-10, Government Assistance (Topic 832) - Disclosures by Business Entities about Government Assistance, 2021-10 In May 2021, the FASB issued ASU 2021-04 Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 370-50), Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40);
Grant Income			Grant Income The Company receives government grants that reimburse the Company for certain allowable costs for funded projects. Grant income is recognized on a systematic basis over the period in which the Company recognizes qualified research and development costs that grant is intended to compensate and there is reasonable assurance that the Company will meet the terms and conditions of the grant. This income is recorded as grant income in the consolidated statements of operations and comprehensive loss. Grant payments received in excess of grant revenue earned are recognized as deferred revenue on the balance sheets, and grant income earned in excess of grant payments received is recognized as trade and other receivables on the consolidated balance sheets.
Preferred Stock Tranche Liability			Preferred Stock Tranche Liability The Company’s Series B redeemable convertible preferred stock included an obligation whereby the investors agreed to buy, and the Company agreed to sell additional shares at a fixed price in the event that certain agreed-upon milestones were achieved or at the election of investors. This obligation was determined to be a freestanding financial instrument that should be accounted for as a liability at fair value (Notes 3 and 6). This preferred stock tranche liability was revalued at each reporting period through settlement with changes in the fair value recorded as a change in preferred stock tranche liability in the consolidated statements of operations and comprehensive loss. The fair value at settlement was reclassified to redeemable convertible preferred stock at such time.
DYNAMICS SPECIAL PURPOSE [Member]
Accounting Policies [Line Items]
Principles of Consolidation and Financial Statement Presentation	Principles of Consolidation and Financial Statement Presentation The accompanying unaudited condensed consolidated financial statements of the Company are presented in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and pursuant to the rules and regulations of the SEC. The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned and controlled subsidiary, Merger Sub, after elimination of any intercompany transactions and balances as of March 31, 2022 and December 31, 2021. Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a comprehensive presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company’s annual report on Form 10-K	Principles of Consolidation and Financial Statement Presentation The accompanying consolidated financial statements of the Company are presented in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and pursuant to the rules and regulations of the SEC. The consolidated financial statements include the accounts of the Company and its wholly-owned and controlled subsidiary, Merger Sub, after elimination of any intercompany transactions and balances as of December 31, 2021.
Emerging Growth Company	Emerging Growth Company The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging	Emerging Growth Company The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging
Use of Estimates	Use of Estimates The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the unaudited condensed consolidated financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ from those estimates.	Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the consolidated financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ from those estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The	Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of December 31, 2021. As of December 31, 2021, we had operating cash (i.e. cash held outside the Trust Account) of $889,323.
Investments Held in Trust Account	Investments Held in Trust Account As of March 31, 2022 and December 31, 2021, the assets held in the Trust Account were comprised of U.S. government securities, within the meaning set forth in Section 2(a) (16) of the Investment Company Act, with maturities of 185 days or less, or investments in money market funds that invest in U.S. government securities and generally have a readily determinable fair value, or a combination thereof. When the Company’s investments held in the Trust Account are comprised of U.S. government securities, the investments are classified as trading securities. When the Company’s investments held in the Trust Account are comprised of money market funds, the investments are recognized at fair value. Trading securities and investments in money market funds are presented on the unaudited condensed consolidated balance sheet at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of these securities are reported in the statements of operations. The estimated fair values of investments held in the Trust Account are determined using available market information.	Investments Held in Trust Account As of December 31, 2021, the assets held in the Trust Account were comprised of U.S. government securities, within the meaning set forth in Section 2(a) (16) of the Investment Company Act, with maturities of 185 days or less, or investments in money market funds that invest in U.S. government securities and generally have a readily determinable fair value, or a combination thereof. When the Company’s investments held in the Trust Account are comprised of U.S. government securities, the investments are classified as trading securities. When the Company’s investments held in the Trust Account are comprised of money market funds, the investments are recognized at fair value. Trading securities and investments in money market funds are presented on the consolidated balance sheet at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of these securities are reported in the statements of operations. The estimated fair values of investments held in the Trust Account are determined using available market information.
Class A Common Stock Subject to Possible Redemption	Class A Common Stock Subject to Possible Redemption The Public Shares sold in the Initial Public Offering contain a redemption feature which allows for the redemption of such Public Shares in connection with the Company’s liquidation, if there is a stockholder vote or tender offer in connection with the Business Combination and in connection with certain amendments to the Company’s Amended and Restated Certificate of Incorporation. In accordance with SEC and its staff’s guidance on redeemable equity instruments, which has been codified in Accounting Standards Codification (“ASC”) Topic 480, Distinguishing Liabilities from Equity, redemption provisions not solely within the control of the Company require common stock subject to redemption to be classified outside of permanent equity. Therefore, all Class A Common Stock has been classified outside of permanent equity. The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable common stock to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying amount of redeemable common stock are affected by charges against additional paid in capital and accumulated deficit. As of March 31, 2022 and December 31, 2021, the Investor Shares (see Note 1) are classified as temporary equity within Class A Common Stock subject to redemption in the Company’s unaudited condensed consolidated balance sheet. The Non-Redemption Non-Redemption Non-Redemption Company Non-Redemption As of March 31, 2022 and December 31, 2021, the Class A common stock subject to redemption reflected in the balance sheet are reconciled in the following table: Gross proceeds $ 230,000,000 Less: Issuance costs allocated to Class A common stock (13,181,867 ) Plus: Accretion of carrying value to redemption value 13,181,867 Class A common stock subject to possible redemption $ 230,000,000	Class A Common Stock Subject to Possible Redemption The Public Shares sold in the Initial Public Offering contain a redemption feature which allows for the redemption of such Public Shares in connection with the Company’s liquidation, if there is a stockholder vote or tender offer in connection with the Business Combination and in connection with certain amendments to the Company’s Amended and Restated Certificate of Incorporation. In accordance with SEC and its staff’s guidance on redeemable equity instruments, which has been codified in Accounting Standards Codification (“ASC”) Topic 480, Distinguishing Liabilities from Equit Therefore, all Class A Common Stock has been classified outside of permanent equity. The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable common stock to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying amount of redeemable common stock are affected by charges against additional paid in capital and accumulated deficit. As of December 31, 2021, the Investor Shares (see Note 1) are classified as temporary equity within Class A Common Stock subject to redemption in the Company’s consolidated balance sheet. The Non-Redemption Non-Redemption Non-Redemption Non-Redemption As of December 31, 2021, the Class A Common Stock subject to redemption reflected in the consolidated balance sheet is reconciled in the following table: Gross proceeds $ 230,000,000 Less: Issuance costs allocated to Class A Common Stock (13,181,867 ) Plus: Remeasurement of carrying value to redemption value 13,181,867 Class A Common Stock subject to possible redemption $ 230,000,000
Offering Costs Associated with the Initial Public Offering		Offering Costs Associated with the Initial Public Offering The Company complies with the requirements of ASC 340-10-S99-1 incurred related to the Initial Public Offering. Offering costs directly attributable to the issuance of an equity contract to be classified in equity are recorded as a reduction in equity. Offering costs for equity contracts that are classified as assets and liabilities are expensed immediately. The Company incurred offering costs amounting to $13,198,430 as a result of the Initial Public Offering (consisting of a $4,600,000 underwriting fee, $8,050,000 of deferred underwriting fees, and $548,430 of other offering costs). The Company recorded $13,181,867 of offering costs as a reduction of temporary equity in connection with the issuance of the Public Shares. The Company recorded $16,563 of offering costs as a reduction of permanent equity in connection with the issuance of the Private Placement Shares.
Income Taxes	Income Taxes The Company follows the asset and liability method of accounting for income taxes under ASC Topic 740, Income Taxes ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of March 31, 2022 and December 31, 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since incep tion.	Income Taxes The Company follows the asset and liability method of accounting for income taxes under ASC Topic 740, Income Taxes ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of December 31, 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception.
Net Loss Per Share		Net Loss Per Share of Common Stock Net loss per common share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. As the Public Shares are considered to be redeemable at fair value, and a redemption at fair value does not amount to a distribution different than other stockholders, Class A Common Stock and Class B Common Stock are presented as one class of stock in calculating net loss per share. As a result, the calculated net loss per share is the same for Class A Common Stock and Class B Common Stock. As of December 31, 2021, the Company did not have any dilutive securities and other contracts that could, potentially, be exercised or converted into shares of common stock and then share in the earnings of the Company. As a result, diluted loss per share is the same as basic loss per share for the periods presented. The following table reflects the calculation of basic and diluted net loss per common share (in dollars, except per share amounts): For the Period from March 1, 2021 Class A Class B Basic and diluted net loss per share: Numerator: Net loss $ (2,919,481 ) $ (937,607 ) Denominator: Basic and diluted weighted average shares outstanding 16,872,995 5,418,853 Basic and diluted net loss per share $ (0.17 ) $ (0.17 )
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company applies ASC Topic 820, Fair Value Measurement measurement date. The fair value hierarchy established in ASC 820 generally requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs reflect the assumptions that market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the reporting entity. Unobservable inputs reflect the entity’s own assumptions based on market data and the entity’s judgments about the assumptions that market participants would use in pricing the asset or liability and are to be developed based on the best information available in the circumstances. The carrying amounts reflected in the unaudited condensed consolidated balance sheet for current assets and current liabilities approximate fair value due to their short-term nature. Level 1 — Assets and liabilities with unadjusted, quoted prices listed on active market exchanges. Inputs to the fair value measurement are observable inputs, such as quoted prices in active markets for identical assets or liabilities. Level 2 — Inputs to the fair value measurement are determined using prices for recently traded assets and liabilities with similar underlying terms, as well as direct or indirect observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals. Level 3 — Inputs to the fair value measurement are unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no market data exists for the assets or liabilities. See Note 8 for additional information on assets and liabilities measured at fair value.	Fair Value of Financial Instruments The Company applies ASC Topic 820, Fair Value Measurement The carrying amounts reflected in the consolidated balance sheet for current assets and current liabilities approximate fair value due to their short-term nature. Level 1 — Assets and liabilities with unadjusted, quoted prices listed on active market exchanges. Inputs to the fair value measurement are observable inputs, such as quoted prices in active markets for identical assets or liabilities. Level 2 — Inputs to the fair value measurement are determined using prices for recently traded assets and liabilities with similar underlying terms, as well as direct or indirect observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals. Level 3 — Inputs to the fair value measurement are unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no market data exists for the assets or liabilities. See Note 9 for additional information on assets and liabilities measured at fair value.
Recently Adopted Accounting Pronouncements	Recent Accounting Standards Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company’s financial statements.	Recent Accounting Standards In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-06, Debt — Debt with Conversion and Other Options (Subtopic 470-20) 815-40) 2020-06”) 2020-06 2020-06 if-converted 2020-06 2020-06 2020-06 Management does not believe that any other recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company’s consolidated financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	3 Months Ended	10 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2021
Accounting Policies [Line Items]
Summary of Basic and Diluted Net Earnings (loss) Per Common Share	A reconciliation of net loss available to common stockholders and the number of shares in the calculation of basic and diluted loss per share is as follows: Three Months Ended March 31, 2022 2021 Net loss $ (11,808 ) $ (21,002 ) Weighted-average shares used in computing net loss per share, basic and diluted 16,204,614 14,602,926 Net loss per share attributable to common stockholders, basic and diluted $ (0.73 ) $ (1.44 )		A reconciliation of net loss available to common stockholders and the number of shares in the calculation of basic and diluted loss per share is as follows: Year Ended December 31, 2021 2020 Net loss $ (55,319 ) $ (19,862 ) Denominator: Weighted-average shares used in computing net loss per share, basic and diluted 14,881,325 13,862,582 Net loss per share attributable to common stockholders, basic and diluted $ (3.72 ) $ (1.43 )
Schedule Of Cash Cash Equivalents And Short Term Investments			The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that total to the amounts shown in the consolidated statements of cash flows for the Company: December 31, 2021 2020 Cash and cash equivalents 56,034 30,537 Restricted cash 3,257 497 Total $ 59,291 $ 31,034
summary Of Property Plant And Equipment			Property and equipment, net is stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, which are as follows: Small equipment 2 years Computer equipment and software 3 years Laboratory equipment 5-7 Furniture and fixtures 5-7 Leasehold improvements Shorter of the lease term and the useful life
DYNAMICS SPECIAL PURPOSE [Member]
Accounting Policies [Line Items]
Summary of Reconciliation of Condensed Balance Sheet		As of December 31, 2021, the Class A Common Stock subject to redemption reflected in the consolidated balance sheet is reconciled in the following table: Gross proceeds $ 230,000,000 Less: Issuance costs allocated to Class A Common Stock (13,181,867 ) Plus: Remeasurement of carrying value to redemption value 13,181,867 Class A Common Stock subject to possible redemption $ 230,000,000
Summary of Basic and Diluted Net Earnings (loss) Per Common Share		The following table reflects the calculation of basic and diluted net loss per common share (in dollars, except per share amounts): For the Period from March 1, 2021 Class A Class B Basic and diluted net loss per share: Numerator: Net loss $ (2,919,481 ) $ (937,607 ) Denominator: Basic and diluted weighted average shares outstanding 16,872,995 5,418,853 Basic and diluted net loss per share $ (0.17 ) $ (0.17 )

Other Financial Statement inf_2

Other Financial Statement information (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Other Financial Statement Information [Abstract]
Summary of Prepaid Expense and Other Current Assets	Prepaid expenses and other current assets consisted of the following (in thousands): March 31, December 31, Deposits $ 1,324 $ 1,157 SPAC deferred offering costs 3,073 1,446 Prepaid expenses (including prepaid rent) 1,003 798 Other 648 275 Total prepaid expenses and other current assets $ 6,048 $ 3,676	Prepaid expenses and other current assets consisted of the following (in thousands): December 31, 2021 2020 Deposits $ 1,157 $ 25 SPAC deferred offering costs 1,446 — Unbilled contract — 229 Other 1,073 830 Total prepaid expenses and other current assets $ 3,676 $ 1,084
Summary of Property and Equipment, Net	Property and equipment, net consisted of the following (in thousands): March 31, December 31, Lab equipment $ 5,301 $ 4,988 Leasehold improvements 431 431 Computer equipment and software 309 262 Furniture and fixtures 294 294 Construction in progress 19,599 8,048 Property and equipment at cost 25,934 14,023 Less: accumulated depreciation (1,867 ) (1,655 ) Property and equipment, net $ 24,067 $ 12,368	Property and equipment, net consisted of the following (in thousands): December 31, 2021 2020 Lab equipment $ 4,988 $ 3,459 Leasehold improvements 431 158 Computer equipment and software 262 214 Furniture and fixtures 294 232 Construction in progress 8,048 231 Property and equipment at cost 14,023 4,294 Less: accumulated depreciation (1,655 ) (982 ) Property and equipment, net $ 12,368 $ 3,312
Summary of Accrued Expenses and Other Liabilities	Accrued expenses and other liabilities consisted of the following (in thousands): March 31, December 31, Accrued professional and service fees $ 7,680 $ 2,555 Accrued employee-related expenses 1,247 2,665 Other accrued expenses 52 111 Total accrued expenses and other current liabilities $ 8,979 $ 5,331	Accrued expenses and other liabilities consisted of the following (in thousands): December 31, 2021 2020 Accrued professional and service fees $ 2,555 $ 54 Accrued employee related expenses 2,665 1,933 Other accrued expenses 111 11 Total accrued expenses and other current liabilities $ 5,331 $ 1,998

Redeemable Convertible Prefer_2

Redeemable Convertible Preferred Stock (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Temporary Equity Disclosure [Abstract]
Summary of Redeemable Convertible Preferred Stock	The Company’s redeemable convertible preferred stock consisted of the following (in thousands, except per share amounts) as of March 31, 2022 and December 31, 2021: Issue Price Shares Shares Issued Net Carrying Aggregate Series A $ 1.6427 35,199,610 35,199,610 $ 57,408 $ 57,822 Series B $ 1.6427 64,534,944 64,534,933 $ 114,425 $ 106,012 Total 99,734,554 99,734,543 $ 171,833 $ 163,834	The Company’s redeemable convertible preferred stock consisted of the following (in thousands, except per share amounts): December 31, 2021 Issue Price Shares Shares Issued Net Carrying Aggregate Series A $ 1.6427 35,199,610 35,199,610 $ 57,408 $ 57,822 Series B $ 1.6427 64,534,944 64,534,933 $ 114,425 $ 106,012 Total 99,734,554 99,734,543 $ 171,833 $ 163,834 December 31, 2020 Issue Price Shares Shares Issued Net Carrying Aggregate Series A $ 1.6427 35,199,610 35,199,610 $ 57,408 $ 57,822 Series B $ 1.6427 64,534,944 23,748,457 $ 32,254 $ 39,012 Total 99,734,554 58,948,067 $ 89,662 $ 96,834

Common Stock (Tables)

Common Stock (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Common Stock Disclosure [Abstract]
Schedule of Stock Options Reserved for Future Issuance	At March 31, 2022 and December 31, 2021, the Company was authorized to issue 138,000,000 shares of common stock, all at a par value of $0.0001 per share, and had reserved the following shares for future issuance: March 31, December 31, Series A and B redeemable convertible preferred stock 99,734,543 99,734,543 Stock options to purchase common stock 9,273,083 11,711,174 Common stock options available for future grant under stock option plan 5,646,099 3,666,927 Total 114,653,725 115,112,644	At December 31, 2021 and 2020, the Company was authorized to issue 138,000,000 shares of common stock, all at a par value of $0.0001 per share, and had reserved the following shares for future issuance: December 31, 2021 2020 Series A and B redeemable convertible preferred stock 99,734,543 58,948,067 Stock options to purchase common stock 11,711,174 4,173,285 Common stock options available for future grant under stock option plan 3,666,927 12,857,369 Total 115,112,644 75,978,721

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Abstract]
Summary of stock-based compensation expense	Total stock-based compensation expense was as follows (in thousands): Three Months Ended March 31, 2022 2021 General and administrative $ 458 $ 317 Research and development 203 55 Total stock-based compensation expense $ 661 $ 372	Total stock-based compensation expense was as follows (in thousands): Year Ended 2021 2020 General and administrative $ 1,940 $ 201 Research and development 355 71 Total stock-based compensation expense $ 2,295 $ 272
Summary of fair value of stock options granted to grantees	The assumptions used to determine the grant date fair value of stock options granted to grantees were as follows, presented on a weighted-average basis: Three Months Ended March 31, 2022 2021 Expected term (in years) — 6.03 Expected volatility — % 82.9% Risk-free interest rate — % 0.6% Dividend yield — % — %	The assumptions used to determine the grant date fair value of stock options granted to grantees were as follows, presented on a weighted-average basis: Year Ended 2021 2020 Expected term (in years) 6.03 6.03 Expected volatility 82.3% 83.3% Risk-free interest rate 0.9% 0.7% Dividend yield — % — %
Summary of stock option activity	The following table summarizes the Company’s stock option activity, excluding performance and market awards: Number of Weighted- Weighted- Remaining Aggregate Outstanding at December 31, 2021 11,711,174 $ 0.86 9.1 $ 11,304 Exercised (881,993 ) 0.48 — — Forfeited (1,556,098 ) 0.53 — — Outstanding at March 31, 2022 9,273,083 $ 0.95 8.6 $ 8,130 Vested and exercisable at March 31, 2022 1,978,319 $ 0.54 6.8 $ 2,541	The following table summarizes the Company’s stock option activity, excluding performance and market awards: Number of Weighted- Weighted- Remaining Aggregate Outstanding at December 31, 2020 4,173,285 $ 0.49 8.9 $ 199 Granted 10,800,000 $ 0.89 Exercised (3,103,769 ) $ 0.43 Forfeited (158,342 ) $ 0.65 Expired — Outstanding at December 31, 2021 11,711,174 $ 0.86 9.1 $ 11,304 Vested and exercisable at December 31, 2021 1,381,326 $ 0.48 7.7 $ 1,781

Operating Leases (Tables)

Operating Leases (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Leases [Abstract]
Schedule of Operating Lease Supplemental Cash Flow Information	Supplemental cash flow and noncash information related to the operating leases were as follows (in thousands): Three Months Ended March 31, 2022 2021 Supplemental cash flow information: Operating cash flows from operating lease $ 1,874 $ (653 ) Remeasurement of ROU and lease liabilities due to changes in the timing of receipt of lease incentives $ 239 $ —	Supplemental cash flow and noncash information related to the operating leases were as follows (in thousands): Year Ended 2021 2020 Supplemental cash flow information: Operating cash flows from operating lease $ (2,669 ) $ (2,577 ) ROU assets obtained in exchange for operating lease obligations 10,153 513
Schedule of Supplemental Additional Information Related to Operating Leases	The following summarizes additional information related to the operating leases as of March 31, 2022 and 2021: March 31, 2022 2021 Weighted-average remaining lease term 7.91 years 6.08 years Weighted-average discount rate 9.08% 8.91%	The following summarizes additional information related to the operating leases as of December 31, 2021 and 2020: December 31, 2021 2020 Weighted-average remaining lease term 7.76 years 6.33 years Weighted-average discount rate 9.06 % 8.91 %
Summary of Maturities of Lease Liabilities	Maturities of the Company’s lease liabilities as of March 31, 2022, were as follows (in thousands): 2022 $ 2,090 2023 6,272 2024 7,265 2025 7,489 2026 7,723 Thereafter 30,229 Total undiscounted lease payments 61,068 Less imputed interest (20,759 ) Tenant improvement reimbursements (14,914 ) Total lease liabilities $ 25,395	Maturities of the Company’s lease liabilities as of December 31, 2021, were as follows (in thousands): 2022 $ 2,770 2023 6,272 2024 7,266 2025 7,489 2026 7,723 Thereafter 30,229 Total undiscounted lease payments 61,749 Less imputed interest (21,555 ) Tenant improvement reimbursements (17,463 ) Total lease liabilities $ 22,731

Income Tax (Tables)

Income Tax (Tables)	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Schedule of Deferred Tax Assets and Liabilities	For the calendar years ended December 31, 2021 and 2020, the tax effects of significant items comprising the Company’s deferred taxes are as follows: December 31, 2021 2020 Deferred tax assets: Net operating losses $ 23,104 $ 15,543 Tax credits 4,915 2,775 Lease Liability 6,350 3,930 Accruals and reserves 738 526 Stock-based compensation 28 17 Other 600 2 Total deferred tax assets 35,735 22,793 Deferred tax liabilities: Operating lease right-of-use (5,789 ) (3,590 ) Fixed asset basis (236 ) (178 ) Total deferred tax liabilities (6,025 ) (3,768 ) Valuation allowance (29,710 ) (19,025 ) Net deferred taxes $ — $ —
Summary of Net Operating Losses And Tax Credit Carryforwards	Net operating losses and tax credit carryforwards as of December 31, 2021 are as follows (in thousands): Amount Expiration Years Net operating losses, federal (Post December 31, 2017) $ 86,602 Do Not Expire Net operating losses, federal (Pre January 1, 2018) $ 3,508 12/31/2031 Net operating losses, state $ 55,023 12/31/2032 Tax credits, federal $ 3,573 12/31/2032 Tax credits, state $ 3,120 Do Not Expire Net operating losses, foreign $ 1,146 Do Not Expire
Schedule of Components of Income Tax Expense (Benefit)	The effective tax rate of the Company’s provision (benefit) for income taxes differs from the federal statutory rate as follows: December 31, 2021 2020 Statutory rate 21.00 % 21.00 % State tax 2.98 % 11.68 % Other (0.80 )% (0.05 )% Tax credits 2.29 % 2.81 % Fair value of series B preferred stock tranche liability (5.60 )% 6.04 % Valuation allowance (19.87 )% (41.48 )% Total 0.00 % 0.00 %

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Earnings Per Share [Abstract]
Schedule of reconciliation of net loss available to common stockholders and the computation of basic and diluted loss per share	A reconciliation of net loss available to common stockholders and the number of shares in the calculation of basic and diluted loss per share is as follows: Three Months Ended March 31, 2022 2021 Net loss $ (11,808 ) $ (21,002 ) Weighted-average shares used in computing net loss per share, basic and diluted 16,204,614 14,602,926 Net loss per share attributable to common stockholders, basic and diluted $ (0.73 ) $ (1.44 )	A reconciliation of net loss available to common stockholders and the number of shares in the calculation of basic and diluted loss per share is as follows: Year Ended December 31, 2021 2020 Net loss $ (55,319 ) $ (19,862 ) Denominator: Weighted-average shares used in computing net loss per share, basic and diluted 14,881,325 13,862,582 Net loss per share attributable to common stockholders, basic and diluted $ (3.72 ) $ (1.43 )
Schedule of antidilutive securities excluded from computation of earnings per share	The following potential common shares securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been anti-dilutive (on an as-converted Three Months Ended March 31, 2022 2021 Series A and B redeemable convertible preferred stock 99,734,543 60,368,493 Potential issuance of Series B redeemable convertible preferred stock under Tranche 2 — 19,683,025 Potential issuance of Series B redeemable convertible preferred stock under Tranche 3 — 19,683,025 Stock options to purchase common stock 9,273,083 8,119,579 Unvested early exercised options 1,685,478 — Total 110,693,104 107,854,122	The following potential common shares securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been anti-dilutive (on an as-converted Year Ended December 31, 2021 2020 Series A and B redeemable convertible preferred stock 99,734,543 58,948,067 Potential issuance of Series B redeemable convertible preferred stock under Tranche 2 — 19,683,025 Potential issuance of Series B redeemable convertible preferred stock under Tranche 3 — 19,683,025 Stock options to purchase common stock 11,711,174 4,173,285 Unvested early exercised options 2,418,871 — Total 113,864,588 102,487,402

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended	10 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2021
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Summary Of Assets And Liabilities Measured at Fair Value Recurring Basis	The following table presents information about the Company’s financial assets that are measured at fair value on a recurring basis as of March 31, 2022 and December 31, 2021, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: Description Amount at Fair Level 1 Level 2 Level 3 March 31, 2022 Assets Investments held in Trust Account: U.S. Treasury Securities $ 230,031,946 $ 230,031,946 $ — $ — December 31, 2021 Assets Investments held in Trust Account: U.S. Treasury Securities $ 230,008,784 $ 230,008,784 $ — $ —
Summary of Estimated Value of Cash Equivalents and Restricted Cash	The following tables summarize the estimated value of cash equivalents and restricted cash (in thousands): March 31, 2022 Amortized Unrealized Unrealized Estimated Fair Cash equivalents: Money market fund $ 38,140 $ — $ — $ 38,140 Restricted cash: Money market fund 3,257 — — 3,257 Total $ 41,397 $ — $ — $ 41,397 December 31, 2021 Amortized Unrealized Unrealized Estimated Fair Cash equivalents: Money market fund $ 56,034 $ — $ — $ 56,034 Restricted cash: Money market fund 3,257 — — 3,257 Total $ 59,291 $ — $ — $ 59,291		The following tables summarize the estimated value of cash equivalents, restricted cash and short-term investments (in thousands): December 31, 2021 Amortized Unrealized Unrealized Estimated Fair Cash equivalents: Money market fund $ 56,034 $ — $ — $ 56,034 Restricted cash: Money market fund 3,257 $ — $ — 3,257 Total $ 59,291 $ — $ — $ 59,291 December 31, 2020 Amortized Unrealized Unrealized Estimated Fair Cash equivalents: Money market fund $ 30,387 $ — $ — $ 30,387 Restricted cash: Money market fund 497 — — 497 Total $ 30,884 $ — $ — $ 30,884
Summary of Significant Quantitative Inputs Used in the Valuation of the Preferred Stock Tranche Liability	The following reflects the significant quantitative inputs used in the valuation of the preferred stock tranche liability for fiscal year 2020 on initial closing on October 22, 2020, second closing on December 28, 2020 and subsequent measurement as of December 31, 2020 using a Monte Carlo valuation model and/or Black-Scholes option pricing model: October 22, 2020 Initial Measurement Date December 28 and December 31, 2020 Subsequent Measurement Dates Tranche 2 Call Tranche 3 Call Tranche Features Option Tranche 2 and Estimated fair value of Series B redeemable convertible preferred stock(1) $ 1.25 $ 1.25 $ 1.62 $ 1.62 Discount rate 0.12 % 0.17 % 0.11 % 0.11 % Time to liquidity (years) 0.9 2.2 0.5 0.5 Expected volatility 54.9 % 54.9 % 73.8 % N/A Probability of call option and forward contract N/A N/A 10 % 90 % Strike Price $ 1.6427 $ 1.6427 $ 1.6427 $ 1.6427 Value of each tranche feature $ 0.143 $ 0.199 $ 0.326 $ (0.023 ) (1) Fair value of the Series B redeemable convertible preferred stock was estimated using the Backsolve method. March 31, 2021 (unaudited) Tranche 2 Tranche 3 (Public) Tranche 3 (Staying Private) Forward Call No Value Call Forward No Value Estimated fair value of Series B redeemable convertible preferred stock(1) $ 2.0796 $ 2.3386 N/A $ 1.3023 $ 1.3023 N/A Discount rate 0.03 % 0.05 % N/A 0.06 % 0.06 % N/A Time to liquidity (years) 0.08 0.50 N/A 0.75 0.75 N/A Probability of call option and forward contract 100.0 % 25.0 % 75.0 % 45.0 % 5.0 % 50.0 % Strike price $ 1.6427 $ 1.6427 N/A $ 1.6427 $ 1.6427 N/A Expected volatility N/A 80.00 % N/A 80.00 % N/A N/A Value of each tranche feature $ 0.437 $ 0.873 $ — $ 0.251 $ (0.340 ) $ — Total value of tranche feature (in millions) $ 8.6 $ 4.3 $ 1.9 (1) Fair value of the Series B redeemable convertible preferred stock for Tranche 3 was estimated using guideline IPO transactions for the public scenario and the Black-Scholes based option pricing model for the staying-private scenario, and for Tranche 2 was based on a weighting of the public and staying-private scenarios used for Tranche 3.
Summary of Financial assets and liabilities measured and recognized at fair value			Financial assets and liabilities measured and recognized at fair value are as follows (in thousands): December 31, 2021 Level 1 Level 2 Level 3 Total Assets: Cash equivalents: Money market fund $ 56,034 $ — $ — $ 56,034 Restricted cash: Money market fund 3,257 — — 3,257 Total Assets $ 59,291 $ — $ — $ 59,291 December 31, 2020 Level 1 Level 2 Level 3 Total Assets: Cash equivalents: Money market fund $ 30,387 $ — $ — $ 30,387 Restricted cash: Money market fund 497 497 Total Assets $ 30,884 $ — $ — $ 30,884 Liabilities: Preferred stock tranche liability $ — $ — $ 435 $ 435 Total Liabilities $ — $ — $ 435 $ 435
Summary of significant quantitative inputs used to fair value the convertible notes			On Issuance Interest rate 8.00 % Discount rate 6.78 % Time to maturity (years) 0.49 Probability of automatic conversion upon qualified financing 95.0 % Probability of optional conversion 2.5 % Probability of no conversion 2.5 % Conversion Price $ 1.4784
Summary of fair value of the convertible notes			The following table provides a roll-forward of the fair value of the convertible notes (in thousands): Fair Value Proceeds from issuance in August 2020 $ 8,000 Change in fair value of convertible notes 720 Conversion to Series B redeemable convertible preferred stock (7,940 ) Recognition of preferred stock tranche liability (780 ) Balance as of December 31, 2020 $ —
Summary of significant quantitative inputs used in the valuation of the preferred stock tranche liability			The following reflects the significant quantitative inputs used in the valuation of the preferred stock tranche liability for fiscal year 2020 on initial closing on October 22, 2020, second closing on December 28, 2020 and subsequent measurement as of December 31, 2020 using a Monte Carlo valuation model and/or Black-Scholes option pricing model: October 22, 2020 Initial Measurement Date December 28 and December 31, 2020 Subsequent Measurement Dates Tranche 2 Call Tranche 3 Call Tranche Features Tranche 2 and 3 Estimated fair value of Series B redeemable convertible preferred stock (1) $1.25 $1.25 $1.62 $1.62 Discount rate 0.12% 0.17% 0.11% 0.11% Time to liquidity (years) 0.9 2.2 0.5 0.5 Expected volatility 54.9% 54.9% 73.8% N/A Probability of call option and forward contract N/A N/A 10% 90% Strike Price $1.6427 $1.6427 $1.6427 $1.6427 Value of each tranche feature $0.143 $0.199 $0.326 $(0.023)
Summary of a weighted comparable guideline IPO (high and low) and SPAC transactions			The value of the tranche rights acquired on May 14, 2021 was determined using the current value method as both tranches were called by the Company on the valuation date. The following reflects the significant quantitative inputs used in the valuation of the preferred stock tranche liability as of May 14, 2021 using a weighted comparable guideline IPO (high and low) and SPAC transactions for the public scenario and the Black-Scholes pricing model for the staying private scenario: May 14, 2021 Tranches 2 and 3 Public Scenario Staying Private Call Call Estimated fair value of Series B redeemable convertible preferred stock $2.18 $1.58 Scenario weighting 75.0% 25.0% Value of each tranche feature $1.637 $0.395 Weighted-average value of Series B redeemable convertible preferred stock $2.032
Summary of table provides a roll-forward of the change in the preferred stock tranche liability			The following table provides a roll-forward of the change in the preferred stock tranche liability (in thousands): Preferred Stock Initial closing on October 22, 2020 $ 6,120 Forfeiture of tranche rights (780 ) Change in fair value (4,968 ) Second closing on December 28, 2020 $ 63 Balance as of December 31, 2020 435 Recognition of tranche rights from January 2021 issuance 33 Change in fair value 14,742 Tranche liability extinguishment (15,210 ) Balance as of December 31, 2021 $ —
DYNAMICS SPECIAL PURPOSE [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Summary Of Assets And Liabilities Measured at Fair Value Recurring Basis		The following table presents information about the Company’s financial assets that are measured at fair value on a recurring basis as of December 31, 2021, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: Description Amount at Fair Level 1 Level 2 Level 3 December 31, 2021 Assets Investments held in Trust Account: U.S. Treasury Securities $ 230,008,784 $ 230,008,784 $ 0 $ 0

Organization and Description _2

Organization and Description of Business and Basis of Presentation - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 19, 2021	Dec. 31, 2019
Nature Of Operations [Line Items]
Proceeds from redeemable convertible preferred stock	$ 0	$ 2,333	$ 67,000	$ 30,000
Proceeds from convertible debt			0	8,000
Retained earnings accumulated deficit	(126,884)		(115,076)	(59,757)
Cash cash equivalents and restricted cash	$ 41,397	$ 26,021	59,291	$ 31,034		$ 5,798
Dynamic Special Purpose Acquisition Corp [Member]
Nature Of Operations [Line Items]
Combined enterprise value on merger			276,000		$ 276,000
Funding of the merger through cash held in trust			$ 230,000		230,000
Common stock shares subscriptions value					$ 66,800
Sale of stock issue price per share			$ 10
Prospective Private Placement [Member] | Dynamic Special Purpose Acquisition Corp [Member]
Nature Of Operations [Line Items]
Common stock shares subscriptions value			$ 66,800
Sale of stock issue price per share			$ 10

Description of Organization, _2

Description of Organization, Business Operations, and Going Concern - Additional Information (Details)					1 Months Ended	3 Months Ended	10 Months Ended
	Dec. 19, 2021 USD ($) $ / shares shares	Dec. 16, 2021	May 28, 2021 USD ($) $ / shares shares	Dec. 17, 2017 USD ($)	Dec. 31, 2021 USD ($) $ / shares shares	Mar. 31, 2022 USD ($) $ / shares shares	Dec. 31, 2021 USD ($) $ / shares shares	May 09, 2022	Apr. 29, 2022 shares	Dec. 31, 2020 $ / shares shares
Number of consecutive trading days determining share price
Common stock, par value | $ / shares					$ 0.0001	$ 0.0001	$ 0.0001			$ 0.0001
Common stock, shares outstanding					15,189,091	16,804,476	15,189,091			14,504,193
Cash | $					$ 889,323		$ 889,323
Shares subject to possible redemption					99,734,543	99,734,543	99,734,543			58,948,067
Common stock, shares issued					15,189,091	16,804,476	15,189,091			14,504,193
Maximum [Member]
Number of consecutive trading days determining share price
Anniversary period determining trading days	3 years
Minimum [Member]
Number of consecutive trading days determining share price
Anniversary period determining trading days	2 years
DYNAMICS SPECIAL PURPOSE [Member]
Number of consecutive trading days determining share price
State of incorporation						DE	DE
Date of incorporation						Mar. 01, 2021	Mar. 01, 2021
Stock shares issued during the period | shares							715,500
Gross proceeds from initial public offering | $							$ 225,400,000
Gross proceeds from private placement | $							7,155,000
Payment to acquire restricted investments | $			$ 230,000,000				$ 230,000,000
Cash deposited in Trust Account per share | $ / shares			$ 10
Term of restricted investments			185 days
Percentage of Public Shares that can be redeemed without prior consent					15%	15%	15%
Percentage of public shares to be redeemed in case business combination is not consummated					100%	100%	100%
Period to complete business combination from closing of initial public offering						24 months	24 months
Expenses payable on dissolution						100,000	100,000
Actual amount per share to be maintained in the trust account | $ / shares					$ 10	$ 10	$ 10
Underwriting fee | $			$ 4,600,000			$ 4,600,000	$ 4,600,000
Deferred underwriting fee payable | $			8,050,000		$ 7,050,000	7,050,000	7,050,000
Other Offering Costs | $			548,430			548,430	548,430
Minimum netwoth needed to effect business combination | $	$ 5,000,001				5,000,001	5,000,001	5,000,001
Number of hours following the effectiveness of the registration statement within which written consent shall be executed and delivered	48 days
Cash | $					889,323	396,693	889,323
Working capital (deficit) | $					$ 1,984,816	3,224,077	1,984,816
Transaction costs related to initial public offering | $			13,198,430			13,198,430	$ 13,198,430
DYNAMICS SPECIAL PURPOSE [Member] | Subsequent To Initial Public Offering [Member]
Number of consecutive trading days determining share price
Deferred underwriting fee payable | $				$ 7,050,000		$ 7,050,000
Deferred underwriting fees waived | $				1,000,000
Deferred underwrting fees payable before waive off | $				8,050,000
Transaction costs related to initial public offering | $				$ 12,198,430
DYNAMICS SPECIAL PURPOSE [Member] | Business Combination Agreement [Member] | Senti Business Combination [Member]
Number of consecutive trading days determining share price
Business acquisition, Equity interest issued or issuable, Value assigned | $	$ 240,000,000
DYNAMICS SPECIAL PURPOSE [Member] | Non RedemptionAgreement [Member] | Public Shares [Member]
Number of consecutive trading days determining share price
Equity method investment ownership percentage								11.111%
DYNAMICS SPECIAL PURPOSE [Member] | Sponsor Support Agreement [Member]
Number of consecutive trading days determining share price
Lock up period to sell assign or transfer of any common stock	1 year
DYNAMICS SPECIAL PURPOSE [Member] | Sponsor Support Agreement [Member] | Lock Up Period [Member] | Share Price Greater Than Or Equal To Twelve USD [Member]
Number of consecutive trading days determining share price
Share Price | $ / shares	$ 12
Number of trading days determining share price	20 days
Number of consecutive trading days determining share price	30 days
Threshold number of trading days determining share price	150 days
DYNAMICS SPECIAL PURPOSE [Member] | Minimum [Member]
Number of consecutive trading days determining share price
Number of operating businesses included in initial Business Combination						1	1
Fair market value as percentage of net assets held in Trust Account included in initial Business Combination					80%	80%	80%
Equity method investment ownership percentage					50%	50%	50%
DYNAMICS SPECIAL PURPOSE [Member] | Minimum [Member] | Business Combination Agreement [Member]
Number of consecutive trading days determining share price
Threshold available cash balance required for consummation of merger | $	$ 150,000,000
DYNAMICS SPECIAL PURPOSE [Member] | DYNS Sponsor [Member] | Non RedemptionAgreement [Member] | DYNS Founder Share [Member]
Number of consecutive trading days determining share price
Shares subject to forfeiture and cancellation	965,728								965,728
DYNAMICS SPECIAL PURPOSE [Member] | Over-Allotment Option [Member]
Number of consecutive trading days determining share price
Common stock shares subscribed but not issued					3,000,000	3,000,000	3,000,000
DYNAMICS SPECIAL PURPOSE [Member] | Private Placement [Member]
Number of consecutive trading days determining share price
Stock shares issued during the period | shares						7,155,000	715,500
DYNAMICS SPECIAL PURPOSE [Member] | PIPE [Member] | Subscription Agreement [Member] | Additional Subscription Event [Member]
Number of consecutive trading days determining share price
Price per share sold | $ / shares	$ 10
DYNAMICS SPECIAL PURPOSE [Member] | Common Class A [Member]
Number of consecutive trading days determining share price
Gross proceeds from initial public offering | $			$ 230,000,000
Common stock, par value | $ / shares					$ 0.0001	$ 0.0001	$ 0.0001
Price per share sold | $ / shares			$ 10		$ 10	$ 10	$ 10
Common stock, shares outstanding					715,500	715,500	715,500
Shares subject to possible redemption					23,000,000	23,000,000	23,000,000
Common stock, shares issued					23,715,500	23,715,500	23,715,500		885,377
DYNAMICS SPECIAL PURPOSE [Member] | Common Class A [Member] | Business Combination Agreement [Member] | Share Price Greater Than Or Equal To Fifteen USD [Member]
Number of consecutive trading days determining share price
Stock issued during period, Shares, Acquisitions	1,000,000
Volume weighted average share price | $ / shares	$ 15
Number of trading days determining volume weighted average share price	20 days
Number of consecutive trading days determining volume weighted average share price	30 days
DYNAMICS SPECIAL PURPOSE [Member] | Common Class A [Member] | Business Combination Agreement [Member] | Share Price Greater Than Or Equal To Twenty USD [Member]
Number of consecutive trading days determining share price
Stock issued during period, Shares, Acquisitions	1,000,000
Volume weighted average share price | $ / shares	$ 20
Number of trading days determining volume weighted average share price	20 days
Number of consecutive trading days determining volume weighted average share price	30 days
DYNAMICS SPECIAL PURPOSE [Member] | Common Class A [Member] | Business Combination Agreement [Member] | Senti Business Combination [Member]
Number of consecutive trading days determining share price
Common stock, par value | $ / shares	$ 0.0001
DYNAMICS SPECIAL PURPOSE [Member] | Common Class A [Member] | Non RedemptionAgreement [Member]
Number of consecutive trading days determining share price
Shares subject to possible redemption									7,968,483
DYNAMICS SPECIAL PURPOSE [Member] | Common Class A [Member] | Non RedemptionAgreement [Member] | Investor Shares [Member]
Number of consecutive trading days determining share price
Shares, Outstanding	8,691,655
DYNAMICS SPECIAL PURPOSE [Member] | Common Class A [Member] | Investor Rights Agreement [Member]
Number of consecutive trading days determining share price
Lock up period	1 year
DYNAMICS SPECIAL PURPOSE [Member] | Common Class A [Member] | Investor Rights Agreement [Member] | 12 Month Lock-Up [Member]
Number of consecutive trading days determining share price
Lock up period	18 months
DYNAMICS SPECIAL PURPOSE [Member] | Common Class A [Member] | Investor Rights Agreement [Member] | Share Price Greater Than Or Equal To Twelve USD [Member] | 12 Month Lock-Up [Member]
Number of consecutive trading days determining share price
Share Price | $ / shares	$ 12
Number of trading days determining share price	20 days
Number of consecutive trading days determining share price	30 days
Threshold number of trading days determining share price	150 days		330 days
DYNAMICS SPECIAL PURPOSE [Member] | Common Class A [Member] | Investor Rights Agreement [Member] | Share Price Greater Than Or Equal To Twelve USD [Member] | 18 Month Lock-Up [Member]
Number of consecutive trading days determining share price
Number of trading days determining share price	20 days
Number of consecutive trading days determining share price	30 days
Threshold number of trading days determining share price	330 days
DYNAMICS SPECIAL PURPOSE [Member] | Common Class A [Member] | Investor Rights Agreement [Member] | Senti Business Combination [Member] | 12 Month Lock-Up [Member]
Number of consecutive trading days determining share price
Lock up period	12 months
DYNAMICS SPECIAL PURPOSE [Member] | Common Class A [Member] | Senti Support Agreement [Member]
Number of consecutive trading days determining share price
Lock up period	18 months
Lock up period based on meeting of certain criteria	12 months
General lock up period	12 months
DYNAMICS SPECIAL PURPOSE [Member] | Common Class A [Member] | Senti Support Agreement [Member] | Extended Lock Up Period [Member] | Share Price Greater Than Or Equal To Twelve USD [Member]
Number of consecutive trading days determining share price
Share Price | $ / shares	$ 12
Number of trading days determining share price	20 days
Number of consecutive trading days determining share price	30 days
Threshold number of trading days determining share price					330 days
DYNAMICS SPECIAL PURPOSE [Member] | Common Class A [Member] | Senti Support Agreement [Member] | General Lock Up Period [Member] | Share Price Greater Than Or Equal To Twelve USD [Member]
Number of consecutive trading days determining share price
Share Price | $ / shares	$ 12
Number of trading days determining share price	20 days
Number of consecutive trading days determining share price	30 days
Threshold number of trading days determining share price		150 days
DYNAMICS SPECIAL PURPOSE [Member] | Common Class A [Member] | IPO [Member]
Number of consecutive trading days determining share price
Stock shares issued during the period | shares			23,000,000
DYNAMICS SPECIAL PURPOSE [Member] | Common Class A [Member] | Over-Allotment Option [Member]
Number of consecutive trading days determining share price
Stock shares issued during the period | shares			3,000,000
DYNAMICS SPECIAL PURPOSE [Member] | Common Class A [Member] | Private Placement [Member] | Sponsor [Member]
Number of consecutive trading days determining share price
Stock shares issued during the period | shares			715,500
Gross proceeds from private placement | $			$ 7,155,000
Price per share sold | $ / shares			$ 10
DYNAMICS SPECIAL PURPOSE [Member] | Common Class A [Member] | PIPE [Member] | Subscription Agreement [Member]
Number of consecutive trading days determining share price
Common stock shares subscribed but not issued	6,680,000
Price per share sold | $ / shares	$ 10
Common stock, Value, Subscriptions | $	$ 66,800,000
DYNAMICS SPECIAL PURPOSE [Member] | Common Class B [Member]
Number of consecutive trading days determining share price
Common stock, par value | $ / shares					$ 0.0001	$ 0.0001	$ 0.0001
Common stock, shares outstanding					5,750,000	5,750,000	5,750,000
Shares subject to possible redemption					5,750,000		5,750,000
Common stock, shares issued					5,750,000	5,750,000	5,750,000
DYNAMICS SPECIAL PURPOSE [Member] | Common Class B [Member] | DYNS Sponsor [Member]
Number of consecutive trading days determining share price
Common stock, par value | $ / shares	$ 0.0001
Common stock, shares outstanding	5,750,000

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)			3 Months Ended	10 Months Ended	12 Months Ended
	May 28, 2021	Dec. 17, 2017	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Accounting Policies [Line Items]
Cash equivalents				$ 0	$ 0
Cash				889,323	889,323
Unrecognized tax benefits						$ 1,300,000
Unrecognized tax benefits income tax penalties and interest accrued				0	0	0
Deferred offering costs			$ 3,073,000	$ 1,446,000	$ 1,446,000	$ 0
Percentage of tax benefit to be realized for recognition in the income statement					50%	50%
General and Administrative Expense [Member]
Accounting Policies [Line Items]
Deferred offering costs expensed					$ 2,200,000
US Government Securities [Member]
Accounting Policies [Line Items]
Restricted Investments Term				185 days
DYNAMICS SPECIAL PURPOSE [Member]
Accounting Policies [Line Items]
Cash equivalents			0
Cash			396,693	$ 889,323	889,323
Unrecognized tax benefits				0	0
Unrecognized tax benefits income tax penalties and interest accrued			0	0	0
Transaction costs related to initial public offering	$ 13,198,430		13,198,430	13,198,430
Underwriting fee	4,600,000		4,600,000	4,600,000
Deferred underwriting fee payable	8,050,000		7,050,000	7,050,000	7,050,000
Deferred underwriting fee payable			8,050,000	8,050,000	8,050,000
Other Offering Costs	$ 548,430		548,430	548,430
Federal Depository Insurance Coverage amount			250,000	250,000	250,000
Offering Costs Temporary Equity			13,181,867	13,181,867
Offering Costs Permanent Equity			16,563	16,563
Deferred offering costs			13,181,867	$ 13,181,867	$ 13,181,867
DYNAMICS SPECIAL PURPOSE [Member] | Subsequent To Initial Public Offering [Member]
Accounting Policies [Line Items]
Transaction costs related to initial public offering		$ 12,198,430
Deferred underwriting fee payable		7,050,000	$ 7,050,000
Deferred Underwriting Fees Waived		1,000,000
Deferred Underwriting Fee Payable Before Waive Off Noncurrent		$ 8,050,000
DYNAMICS SPECIAL PURPOSE [Member] | US Government Securities [Member]
Accounting Policies [Line Items]
Restricted Investments Term			185 days

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Summary of Reconciliation of Condensed Balance Sheet (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Condensed Cash Flow Statements, Captions [Line Items]
Issuance costs allocated to Class A common stock	$ (3,073,000)	$ (1,446,000)	$ 0
DYNAMICS SPECIAL PURPOSE [Member]
Condensed Cash Flow Statements, Captions [Line Items]
Gross proceeds	230,000,000	230,000,000
Issuance costs allocated to Class A common stock	(13,181,867)	(13,181,867)
Remeasurement of carrying value to redemption value	13,181,867	13,181,867
Class A common stock subject to possible redemption	$ 230,000,000	$ 230,000,000

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Basic and Diluted Net Earnings (loss) Per Common Share (Details) - USD ($)	1 Months Ended	3 Months Ended		10 Months Ended	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Denominator:
Basic and diluted weighted average shares outstanding		16,204,614	14,602,926		14,881,325	13,862,582
Basic and diluted net loss per share		$ (0.73)	$ (1.44)		$ (3.72)	$ (1.43)
Common Class B [Member]
Numerator:
Net loss				$ (1,178)
DYNAMICS SPECIAL PURPOSE [Member] | Common Class A [Member]
Numerator:
Net loss		$ (1,054,241)		$ (2,919,481)
Denominator:
Basic and diluted weighted average shares outstanding	0	23,715,500		16,872,995
Basic and diluted net loss per share	$ 0	$ (0.04)		$ (0.17)
DYNAMICS SPECIAL PURPOSE [Member] | Common Class B [Member]
Numerator:
Net loss		$ (255,608)		$ (937,607)
Denominator:
Basic and diluted weighted average shares outstanding	5,000,000	5,750,000		5,418,853
Basic and diluted net loss per share	$ 0	$ (0.04)		$ (0.17)

Summary of Significant Accoun_7

Summary of Significant Accounting Policies and Basis of Presentation - Schedule Of Property Plant And Equipment (Detail)	12 Months Ended
	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	Shorter of the lease term and the useful life
Small Equipment
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	2 years
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Maximum | Laboratory Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	7 years
Maximum | Furniture and Fixtures
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	7 years
Minimum | Laboratory Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Minimum | Furniture and Fixtures
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years

Summary of Significant Accoun_8

Summary of Significant Accounting Policies and Basis of Presentation - Schedule Of Cash Cash Equivalents And Short Term Investments (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Accounting Policies [Abstract]
Cash and cash equivalents	$ 38,140	$ 56,034	$ 25,524	$ 30,537
Restricted cash		3,257		497
Total	$ 41,397	$ 59,291	$ 26,021	$ 31,034	$ 5,798

Initial Public Offering - Addit

Initial Public Offering - Additional Information (Details) - DYNAMICS SPECIAL PURPOSE [Member] - USD ($)		10 Months Ended
	May 28, 2021	Dec. 31, 2021	Mar. 31, 2022
Issuance of Series B redeemable convertible preferred stock, net of preferred stock tranche liability of $5.4 million and issuance costs of $0.3 million Shares		715,500
Gross proceeds from initial public offering		$ 225,400,000
Common Class A [Member]
Price per share sold	$ 10	$ 10	$ 10
Gross proceeds from initial public offering	$ 230,000,000
IPO [Member] | Common Class A [Member]
Issuance of Series B redeemable convertible preferred stock, net of preferred stock tranche liability of $5.4 million and issuance costs of $0.3 million Shares	23,000,000
Over-Allotment Option [Member] | Common Class A [Member]
Issuance of Series B redeemable convertible preferred stock, net of preferred stock tranche liability of $5.4 million and issuance costs of $0.3 million Shares	3,000,000

Private Placement - Additional

Private Placement - Additional Information (Details) - DYNAMICS SPECIAL PURPOSE [Member] - USD ($)		3 Months Ended	10 Months Ended
	May 28, 2021	Mar. 31, 2022	Dec. 31, 2021
Class of Stock [Line Items]
Stock shares issued during the period | shares			715,500
Gross proceeds from private placement			$ 7,155,000
Private Placement [Member]
Class of Stock [Line Items]
Stock shares issued during the period | shares		7,155,000	715,500
Private Placement [Member] | Sponsor [Member] | Common Class A [Member]
Class of Stock [Line Items]
Stock shares issued during the period | shares	715,500
Price per share sold | $ / shares	$ 10
Gross proceeds from private placement	$ 7,155,000

Other Financial Statement inf_3

Other Financial Statement information - Summary of Prepaid Expense and Other Current Assets (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Prepaid Expense and Other Assets, Current [Abstract]
Deposits	$ 1,324	$ 1,157	$ 25
SPAC deferred offering costs	3,073	1,446	0
Unbilled contract		0	229
Prepaid expenses (including prepaid rent)	1,003	798
Other		1,073	830
Other	648	275
Total prepaid expenses and other current assets	$ 6,048	$ 3,676	$ 1,084

Other Financial Statement inf_4

Other Financial Statement information - Summary of Property and Equipment, Net (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Property and equipment at cost	$ 25,934	$ 14,023	$ 4,294
Less: accumulated depreciation	(1,867)	(1,655)	(982)
Property and equipment, net	24,067	12,368	3,312
Lab equipment
Property, Plant and Equipment [Line Items]
Property and equipment at cost	5,301	4,988	3,459
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property and equipment at cost	431	431	158
Computer equipment and software
Property, Plant and Equipment [Line Items]
Property and equipment at cost	309	262	214
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property and equipment at cost	294	294	232
Construction in progress
Property, Plant and Equipment [Line Items]
Property and equipment at cost	$ 19,599	$ 8,048	$ 231

Other Financial Statement inf_5

Other Financial Statement information - Summary of Accrued Expenses and Other Liabilities (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Payables and Accruals [Abstract]
Accrued professional and service fees	$ 7,680	$ 2,555	$ 54
Accrued employee-related expenses	1,247	2,665	1,933
Other accrued expenses	52	111	11
Total accrued expenses and other current liabilities	$ 8,979	$ 5,331	$ 1,998

Other Financial Statement inf_6

Other Financial Statement information - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Other Financial Statement Information [Line Items]
Depreciation	$ 240	$ 165	$ 769	$ 564
Impairment losses	0	0	22	238
Minimum [Member]
Other Financial Statement Information [Line Items]
Depreciation	$ 200	$ 200
Impairment losses			$ 100	$ 200

Convertible Notes - Additional

Convertible Notes - Additional Information (Detail) - USD ($) $ in Millions	1 Months Ended		12 Months Ended
	Oct. 31, 2020	Aug. 31, 2020	Dec. 31, 2020
Convertible Debt [Member]
Debt Instrument [Line Items]
Debt Instrument Face, Amount		$ 8
Series B Redeemable Convertible Preferred Stock [Member]
Debt Instrument [Line Items]
Debt instrument convertible number of shares issued	5,485,858
Series B Redeemable Convertible Preferred Stock [Member] | Convertible Debt [Member]
Debt Instrument [Line Items]
Debt instrument amount due at the time of conversion	$ 8.1
Debt instrument convertible number of shares issued	5,485,858
Convertible Debt [Member]
Debt Instrument [Line Items]
Debt Instrument Interest Rate Stated Percentage		8%
Debt instrument maturity month year		2021-02
Minimum threshold qualified financing on sale of preferred stock		$ 25
Debt instrument conversion price percentage over fixed price per share		90%
Change in fair value of convertible notes			$ 0.7

Redeemable Convertible Prefer_3

Redeemable Convertible Preferred Stock - Summary of Redeemable Convertible Preferred Stock (Detail) - USD ($) $ / shares in Units, $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Jan. 19, 2021	Dec. 31, 2020	Dec. 28, 2020	Oct. 01, 2020
Temporary Equity [Line Items]
Shares Authorized	99,734,554	99,734,554		99,734,554
Shares Issued	99,734,543	99,734,543		58,948,067
Shares Outstanding	99,734,543	99,734,543		58,948,067
Net Carrying Value	$ 171,833	$ 171,833		$ 89,662
Aggregate Liquidation Preference	$ 163,834	$ 163,834		$ 96,834
Series A
Temporary Equity [Line Items]
Issue Price	$ 1.6427	$ 1.6427		$ 1.6427
Shares Authorized	35,199,610	35,199,610		35,199,610
Shares Issued	35,199,610	35,199,610		35,199,610
Shares Outstanding	35,199,610	35,199,610		35,199,610
Net Carrying Value	$ 57,408	$ 57,408		$ 57,408
Aggregate Liquidation Preference	$ 57,822	$ 57,822		$ 57,822
Series B
Temporary Equity [Line Items]
Issue Price	$ 1.6427	$ 1.6427	$ 1.6427	$ 1.6427	$ 1.6427	$ 1.6427
Shares Authorized	64,534,944	64,534,944		64,534,944
Shares Issued	64,534,933	64,534,933		23,748,457
Shares Outstanding	64,534,933	64,534,933		23,748,457
Net Carrying Value	$ 114,425	$ 114,425		$ 32,254
Aggregate Liquidation Preference	$ 106,012	$ 106,012		$ 39,012

Redeemable Convertible Prefer_4

Redeemable Convertible Preferred Stock - Additional Information (Detail) $ / shares in Units, $ in Thousands				1 Months Ended	3 Months Ended		12 Months Ended
	May 14, 2021 USD ($) shares	Jan. 19, 2021 USD ($) $ / shares shares	Dec. 28, 2020 USD ($) $ / shares shares	Oct. 31, 2020 USD ($) shares	Mar. 31, 2022 USD ($) $ / shares	Mar. 31, 2021 USD ($)	Dec. 31, 2021 USD ($) Directors $ / shares shares	Dec. 31, 2020 USD ($) $ / shares	Oct. 01, 2020 $ / shares shares
Temporary Equity [Line Items]
Proceeds from redeemable convertible preferred stock | $					$ 0	$ 2,333	$ 67,000	$ 30,000
Estimated minimum gross proceeds in a qualified public offering for conversion of temporary equity into permanent equity | $							$ 50,000
Series B Redeemable Convertible Preferred Stock [Member]
Temporary Equity [Line Items]
Temporary equity stock shares issued during the period shares		1,420,426	2,637,929	15,624,670
Temporary equity issue price per share | $ / shares		$ 1.6427	$ 1.6427		$ 1.6427		$ 1.6427	$ 1.6427	$ 1.6427
Proceeds from redeemable convertible preferred stock | $		$ 2,300	$ 4,300	$ 25,700
Payment of stock issuance costs for redeemable convertible preferred stock | $		$ 6	$ 200	$ 100
Debt instrument converted into equity number of shares issued				5,485,858
Number of directors entitled to be elected through vote | Directors							2
Temporary equity dividend rate							8%
Temporary equity conversion price per share | $ / shares							$ 1.6427
Conversion ratio from temporary equity to permanent equity							1	1
Temporary equity shares redeemable contingently							2,435,016
Series B Redeemable Convertible Preferred Stock [Member] | Obligation To Issue Tranche One [Member]
Temporary Equity [Line Items]
Temporary equity shares subscribed but not issued									16,842,176
Temporary equity rights to purchase shares forfeited			1,217,506
Series B Redeemable Convertible Preferred Stock [Member] | Obligation To Issue Tranche Two [Member]
Temporary Equity [Line Items]
Temporary equity shares subscribed but not issued									18,668,438
Temporary equity rights to purchase shares forfeited			3,043,768
Series B Redeemable Convertible Preferred Stock [Member] | Obligation To Issue Additional Shares Tranche Two [Member]
Temporary Equity [Line Items]
Temporary equity shares subscribed but not issued		1,420,426	2,637,929
Series B Redeemable Convertible Preferred Stock [Member] | Obligation To Issue Additional Shares Tranche Three [Member]
Temporary Equity [Line Items]
Temporary equity shares subscribed but not issued		1,420,426	2,637,929
Series B Redeemable Convertible Preferred Stock [Member] | Call Tranche Two And Three [Member]
Temporary Equity [Line Items]
Temporary equity stock shares issued during the period shares	39,366,050
Proceeds from redeemable convertible preferred stock | $	$ 64,700
Series A Redeemable Convertible Preferred Stock [Member]
Temporary Equity [Line Items]
Temporary equity issue price per share | $ / shares					$ 1.6427		$ 1.6427	$ 1.6427
Number of directors entitled to be elected through vote | Directors							2
Temporary equity dividend rate							8%
Temporary equity conversion price per share | $ / shares							$ 1.6427
Conversion ratio from temporary equity to permanent equity							1	1
Common Stock [Member]
Temporary Equity [Line Items]
Number of directors entitled to be elected through vote | Directors							2
Redeemable Convertible Preferred Stock And Common Stock [Member]
Temporary Equity [Line Items]
Number of remainning directors entitled to be eleted through vote | Directors							7

Common Stock - Summary of Stock

Common Stock - Summary of Stock Options Reserved for Future Issuance (Detail) - shares	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Schedule Of Stock Options Reserved For Future Issuance [Line Items]
Common Stock	114,653,725	115,112,644	75,978,721
Series A and B redeemable convertible preferred stock [Member]
Schedule Of Stock Options Reserved For Future Issuance [Line Items]
Common Stock	99,734,543	99,734,543	58,948,067
Stock options to purchase common stock [Member]
Schedule Of Stock Options Reserved For Future Issuance [Line Items]
Common Stock	9,273,083	11,711,174	4,173,285
Common stock options available for future grant under stock option plan [Member]
Schedule Of Stock Options Reserved For Future Issuance [Line Items]
Common Stock	5,646,099	3,666,927	12,857,369

Common Stock - Summary of Sto_2

Common Stock - Summary of Stock Options Reserved for Future Issuance (Parenthetical) (Detail) - $ / shares	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Common Stock Disclosure [Abstract]
Common stock, shares authorized	138,000,000	138,000,000	138,000,000
Common stock, par value	$ 0.0001	$ 0.0001	$ 0.0001

Revenue - Additional Informatio

Revenue - Additional Information (Detail) $ in Thousands	1 Months Ended			3 Months Ended		12 Months Ended
	Dec. 31, 2021 USD ($)	Apr. 30, 2021 USD ($) Month	May 31, 2019 USD ($)	Mar. 31, 2022 USD ($)	Mar. 31, 2021 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2018 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Fixed consideration of development agreement			$ 300
Variable consideration of development agreement			$ 300
Contract asset reversal amount	$ 300					$ 300
Upfront payment received		$ 3,000
Evaluation period of agreement | Month		24
Fixed upfront amount of transaction price		$ 3,000
Revenue from collaborative agreement				$ 400	$ 0	0	$ 200
Unbilled revenue	$ 0			0	0	0	200
Grant income				$ 250	$ 28	470	$ 172	$ 200
Customer A [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Grant income						$ 2,000
Customer Concentration Risk [Member] | Customer A [Member] | Revenue Benchmark [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Concentration risk percentage				77%		84.30%
Customer Concentration Risk [Member] | Customer B [Member] | Revenue Benchmark [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Concentration risk percentage				23%	39%	15.70%	30.40%
Customer Concentration Risk [Member] | Customer C [Member] | Revenue Benchmark [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Concentration risk percentage					61%		69.60%

Stockholders' Equity (Deficit)

Stockholders' Equity (Deficit) - Additional Information (Details) - $ / shares	3 Months Ended	10 Months Ended
	Mar. 31, 2022	Dec. 31, 2021	Apr. 29, 2022	May 28, 2021	Mar. 08, 2021	Dec. 31, 2020
Subsidiary or Equity Method Investee [Line Items]
Common stock shares authorized	138,000,000	138,000,000				138,000,000
Common stock par or stated value per share	$ 0.0001	$ 0.0001				$ 0.0001
Common stock shares issued	16,804,476	15,189,091				14,504,193
Common stock shares outstanding	16,804,476	15,189,091				14,504,193
Shares subject to possible redemption	99,734,543	99,734,543				58,948,067
DYNAMICS SPECIAL PURPOSE [Member]
Subsidiary or Equity Method Investee [Line Items]
Preferred stock shares authorized	1,000,000	1,000,000
Preferred stock par or stated value per share	$ 0.0001	$ 0.0001
Preferred stock shares issued	0	0
Preferred stock shares outstanding	0	0
Founder Share [Member] | DYNAMICS SPECIAL PURPOSE [Member]
Subsidiary or Equity Method Investee [Line Items]
Shares subject to possible redemption				750,000
Common Class A [Member] | DYNAMICS SPECIAL PURPOSE [Member]
Subsidiary or Equity Method Investee [Line Items]
Common stock shares authorized	100,000,000	100,000,000
Common stock par or stated value per share	$ 0.0001	$ 0.0001
Common Stock, Voting Rights	one vote	one vote
Common stock shares issued	23,715,500	23,715,500	885,377
Common stock shares outstanding	715,500	715,500
Shares subject to possible redemption	23,000,000	23,000,000
Common Class A [Member] | Founder Share [Member] | DYNAMICS SPECIAL PURPOSE [Member]
Subsidiary or Equity Method Investee [Line Items]
Shares subject to possible redemption	750,000
Common Class B [Member] | DYNAMICS SPECIAL PURPOSE [Member]
Subsidiary or Equity Method Investee [Line Items]
Common stock shares authorized	10,000,000	10,000,000
Common stock par or stated value per share	$ 0.0001	$ 0.0001
Common Stock, Voting Rights	one vote	one vote
Common stock shares issued	5,750,000	5,750,000
Common stock shares outstanding	5,750,000	5,750,000
Shares subject to possible redemption		5,750,000
Common Class B [Member] | Founder Share [Member] | DYNAMICS SPECIAL PURPOSE [Member]
Subsidiary or Equity Method Investee [Line Items]
Shares subject to possible redemption	10,000,000	750,000			750,000
Common Class B [Member] | Sponsor [Member] | DYNAMICS SPECIAL PURPOSE [Member]
Subsidiary or Equity Method Investee [Line Items]
Percentage of the common stock issued and outstanding	20%	20%			20%

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of stock-based compensation expense (Detail) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	$ 661	$ 372	$ 2,295	$ 272
General and administrative [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	458	317	1,940	201
Research and development [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	$ 203	$ 55	$ 355	$ 71

Stock-Based Compensation - Su_2

Stock-Based Compensation - Summary of fair value of stock options granted to grantees (Detail)	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Expected term (in years)		6 years 10 days	6 years 10 days	6 years 10 days
Expected volatility	0%	82.90%	82.30%	83.30%
Risk-free interest rate	0%	0.60%	0.90%	0.70%
Dividend yield	0%	0%	0%	0%

Stock-Based Compensation - Su_3

Stock-Based Compensation - Summary of stock option activity (Detail) - USD ($) $ / shares in Units, $ in Thousands			3 Months Ended	12 Months Ended
	Dec. 31, 2021	Dec. 19, 2021	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share-based Payment Arrangement [Abstract]
Number of Options Outstanding			11,711,174	11,711,174	4,173,285
Number of options granted					10,800,000
Early exercise of common stock options Shares			(881,993)		(3,103,769)
Number of Options Forfeited			(1,556,098)		(158,342)
Number of Options Expired					0
Number of Options Outstanding	11,711,174		9,273,083	11,711,174	11,711,174
Number of Options Vested and exercisable	1,381,326		1,978,319	1,381,326
Weighted- Average Exercise Price Outstanding			$ 0.86	$ 0.86	$ 0.49
Weighted- Average Exercise Price Granted					0.89
Weighted- Average Exercise Price Exercised			0.48		0.43
Weighted- Average Exercise Price Forfeited			0.53		0.65
Weighted- Average Exercise Price Outstanding	$ 0.86		0.95	0.86	$ 0.86
Weighted- Average Exercise Price Vested and exercisable	$ 0.48		$ 0.54	$ 0.48
Weighted- Average Remaining Contractual Life (Years)	9 days 2 hours	8 days 14 hours		9 days 2 hours	8 days 21 hours
Weighted- Average Remaining Contractual Life (Years) Vested and exercisable			6 days 19 hours	7 days 16 hours
Aggregate Intrinsic Value Outstanding			$ 11,304	$ 11,304	$ 199
Aggregate Intrinsic Value Outstanding	$ 11,304		8,130	11,304	$ 11,304
Aggregate Intrinsic Value Vested and exercisable	$ 1,781		$ 2,541	$ 1,781

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions		3 Months Ended		12 Months Ended
	Dec. 19, 2021	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number		1,978,319		1,381,326
Unrecognized stock-based compensation		$ 7.2		$ 9.2
Weighted-average period		3 years		3 years 1 month 6 days
Performance Awards [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock Issued During Period, Shares, Restricted Stock Award, Gross	42,927,654	42,486,017		42,909,091
Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award	four-year
Stock Issued During Period, Shares, Restricted Stock Award, Forfeited		423,074
Market Awards [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock Issued During Period, Shares, Restricted Stock Award, Gross	3,093,776
Percentage of vesting of award under share-based payment arrangement	25%
Twenty Sixteen Stock Incentive Plan [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Percentage of Minimum estimated fair value of the shares on the date of grant				100%
Percentage of exercise price of an ISO granted to a stockholder		10%		10%
Percentage of Maximum estimated fair value of the shares on the date of grant		110%		110%
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period		4 years		4 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period		10 years		10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value		$ 1.2	$ 0.5	$ 0.8	$ 0.2
Weighted-average grant-date fair values of options granted		$ 0	$ 0.9	$ 0.96	$ 0.38
Number of shares issued under share-based payment arrangement.		65,551,165	2,619,677	2,418,871	2,619,677
Stock Repurchased During Period, Value		$ 0.9		$ 1.2
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number					0
Number of Shares Authorized				65,551,165
Twenty Sixteen Stock Incentive Plan [Member] | Performance Awards [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Number of shares issued under share-based payment arrangement.		100
Stock Issued During Period, Shares, Restricted Stock Award, Gross				18,563

Operating Leases - Summary of O

Operating Leases - Summary of Operating Lease Supplemental Cash Flow Information (Detail) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Leases [Abstract]
Operating cash flows from operating lease	$ (1,874)	$ (653)	$ (2,669)	$ (2,577)
ROU assets obtained in exchange for operating lease obligations			$ 10,153	$ 513
Remeasurement of ROU and lease liabilities due to changes in the timing of receipt of lease incentives	$ 239	$ 0

Operating Leases - Summary of S

Operating Leases - Summary of Supplemental Additional Information Related to Operating Leases (Detail)	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021	Dec. 31, 2020
Leases [Abstract]
Weighted-average remaining lease term	7 years 10 months 28 days	7 years 9 months 3 days	6 years 29 days	6 years 3 months 29 days
Weighted-average discount rate	9.08%	9.06%	8.91%	8.91%

Operating Leases - Summary of M

Operating Leases - Summary of Maturities of Lease Liabilities (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Lessee, Operating Lease, Liability, Payment, Due [Abstract]
2022	$ 2,090
2022	6,272	$ 2,770
2023	7,265	6,272
2024	7,489	7,266
2025	7,723	7,489
2026		7,723
Thereafter	30,229
Thereafter		30,229
Total undiscounted lease payments	61,068	61,749
Less imputed interest	(20,759)	(21,555)
Tenant improvement reimbursements	(14,914)	(17,463)
Total lease liabilities	$ 25,395	$ 22,731

Operating Leases - Additional I

Operating Leases - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Lessee, Lease, Description [Line Items]
Payments for proceeds from tenant allowance			$ 0	$ 0
Operating lease cost	$ 1,300	$ 700	3,800	2,700
Variable lease payment	200	200	700	600
Tenant Improvements	2,500
Tenant Improvement Reimbursements	(14,914)		(17,463)
Short-term lease expense	$ 0	$ 0	$ 0	$ 0
Corporate Headquarters Lease [Member]
Lessee, Lease, Description [Line Items]
Lessee operating lease term of contract	8 years		8 years
Lease expiration year	2027		2027
Alameda Lease [Member]
Lessee, Lease, Description [Line Items]
Lessee operating lease term of contract	11 years		11 years
Lease expiration year	2032		2032
Operating lease renewal description	two additional terms of five years		two additional terms of five years
Tenant Improvement Reimbursements	$ 17,500		$ 17,500

Related Parties - Additional In

Related Parties - Additional Information (Details) - USD ($)			1 Months Ended			3 Months Ended		10 Months Ended	12 Months Ended
	May 21, 2021	Mar. 08, 2021	Apr. 30, 2021	Mar. 31, 2021	[1]	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Apr. 29, 2022	Dec. 19, 2021	May 28, 2021	May 14, 2021
Related Party Transaction [Line Items]
Temporary Equity, Shares Outstanding						99,734,543		99,734,543	99,734,543	58,948,067
Accrued bonuses						$ 100,000		$ 200,000	$ 200,000
Related party transaction , reimbursement of cost and expenses						$ 10,000,000
Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Compensation expense, excluding cost of good and service sold									400,000	$ 400,000
Accrued bonuses								$ 200,000	$ 200,000	$ 200,000
Series A Redeemable Convertible Preferred Stock [Member]
Related Party Transaction [Line Items]
Temporary Equity, Shares Outstanding						35,199,610		35,199,610	35,199,610	35,199,610
Series B Redeemable Convertible Preferred Stock [Member]
Related Party Transaction [Line Items]
Temporary Equity, Shares Outstanding						64,534,933		64,534,933	64,534,933	23,748,457
NEA [Member] | Series A Redeemable Convertible Preferred Stock [Member]
Related Party Transaction [Line Items]
Stock issued during the period shares for services						13,505,035			13,505,035	13,505,035
NEA [Member] | Series B Redeemable Convertible Preferred Stock [Member]
Related Party Transaction [Line Items]
Stock issued during the period shares for services									2,742,931	2,742,931
EightVC [Member] | Series A Redeemable Convertible Preferred Stock [Member]
Related Party Transaction [Line Items]
Stock issued during the period shares for services						9,052,387			9,052,387	9,052,387
EightVC [Member] | Series B Redeemable Convertible Preferred Stock [Member]
Related Party Transaction [Line Items]
Stock issued during the period shares for services									1,662,398	1,662,398
Timothy Lu [Member] | Redeemable Convertible Preferred Stock [Member]
Related Party Transaction [Line Items]
Stock issued during the period shares for services						158,950			158,950	158,950
Timothy Lu and Family [Member] | Common Stock [Member]
Related Party Transaction [Line Items]
Stock issued during the period shares for services									8,100,000	8,100,000
Timothy Lu, NEA, and 8VC [Member]
Related Party Transaction [Line Items]
Stock issued during the period value for services						$ 100,000	$ 100,000
BlueRock Therapeutics LP [Member] | Option Agreement [Member]
Related Party Transaction [Line Items]
Related party transaction research term	3 years
BlueRock Therapeutics LP [Member] | Research and Development Arrangement [Member]
Related Party Transaction [Line Items]
Related party transaction , reimbursement of cost and expenses	$ 10,000,000
BlueRock Therapeutics LP [Member] | Research and Development Arrangement [Member] | Option Agreement [Member]
Related Party Transaction [Line Items]
Related party transaction, expenses from transactions with related party	$ 10,000,000
BlueRock [Member]
Related Party Transaction [Line Items]
Related party transaction , reimbursement of cost and expenses						$ 10,000,000
BlueRock [Member] | Series B Redeemable Convertible Preferred Stock [Member]
Related Party Transaction [Line Items]
Stock issued during the period shares for services									27,393,924	9,131,308
Shares issued, price per share														$ 1.6427
Fair value of shares price per share														$ 2.03
Bayer Healthcare LLC
Related Party Transaction [Line Items]
Stock issued during the period shares for services						27,393,924
DYNAMICS SPECIAL PURPOSE [Member]
Related Party Transaction [Line Items]
Stock issued during the period value for services				$ 25,000				$ 25,000
Proceeds from related party debt								$ 250,000
Working Capital Loan Outstanding						$ 0			$ 0
DYNAMICS SPECIAL PURPOSE [Member] | Founder Share [Member]
Related Party Transaction [Line Items]
Temporary Equity, Shares Outstanding													750,000
DYNAMICS SPECIAL PURPOSE [Member] | Common Class B [Member]
Related Party Transaction [Line Items]
Temporary Equity, Shares Outstanding								5,750,000	5,750,000
DYNAMICS SPECIAL PURPOSE [Member] | Common Class B [Member] | Founder Share [Member]
Related Party Transaction [Line Items]
Temporary Equity, Shares Outstanding		750,000				10,000,000		750,000	750,000
DYNAMICS SPECIAL PURPOSE [Member] | Common Class B [Member] | Common Stock [Member]
Related Party Transaction [Line Items]
Stock issued during the period shares for services				5,750,000				5,750,000
Stock issued during the period value for services				$ 575				$ 575
DYNAMICS SPECIAL PURPOSE [Member] | Common Class A [Member]
Related Party Transaction [Line Items]
Temporary Equity, Shares Outstanding						23,000,000		23,000,000	23,000,000
Shares issued, price per share						$ 10		$ 10	$ 10				$ 10
DYNAMICS SPECIAL PURPOSE [Member] | Common Class A [Member] | Non RedemptionAgreement [Member]
Related Party Transaction [Line Items]
Temporary Equity, Shares Outstanding											7,968,483
DYNAMICS SPECIAL PURPOSE [Member] | Common Class A [Member] | Founder Share [Member]
Related Party Transaction [Line Items]
Temporary Equity, Shares Outstanding						750,000
DYNAMICS SPECIAL PURPOSE [Member] | Common Class A [Member] | Common Stock [Member]
Related Party Transaction [Line Items]
Stock issued during the period shares for services				0				0
Stock issued during the period value for services				$ 0				$ 0
DYNAMICS SPECIAL PURPOSE [Member] | Sponsor [Member] | Founder Share [Member] | Non RedemptionAgreement [Member]
Related Party Transaction [Line Items]
Shares subject to forfeiture and cancellation												965,728	885,377
DYNAMICS SPECIAL PURPOSE [Member] | Sponsor [Member] | Promissory Note [Member]
Related Party Transaction [Line Items]
Debt instrument face value		$ 300,000
Proceeds from related party debt			$ 250,000
DYNAMICS SPECIAL PURPOSE [Member] | Sponsor [Member] | Working capital loans [Member]
Related Party Transaction [Line Items]
Working capital loans convertible into equity value						$ 2,000,000		$ 2,000,000
Debt instrument conversion price per share						$ 10		$ 10	$ 10
DYNAMICS SPECIAL PURPOSE [Member] | Sponsor [Member] | Administrative Services Agreement [Member]
Related Party Transaction [Line Items]
Related party transaction amount payable per month for office space administration and support services						$ 10,000		$ 10,000	$ 10,000
DYNAMICS SPECIAL PURPOSE [Member] | Sponsor [Member] | Common Class B [Member]
Related Party Transaction [Line Items]
Stock issued during the period shares for services		5,750,000
Stock issued during the period value for services		$ 25,000
Percentage of the common stock issued and outstanding		20%				20%		20%	20%
DYNAMICS SPECIAL PURPOSE [Member] | Sponsor [Member] | Common Class A [Member] | Founder Share [Member] | Non RedemptionAgreement [Member]
Related Party Transaction [Line Items]
Shares forfeited and cancelled and concurrent issuance of an equivalent stock						0		0	0
[1]The period from March 1, 2021 (inception) through March 31, 2021 includes up to 750,000 shares of Class B common stock which were subject to forfeiture if the over-allotment option was not exercised in full or in part by the underwriter. The over-allotment option was exercised in full on May 28, 2021; thus, these shares are no longer subject to forfeiture (see Notes 5 and 7).

Net Loss Per Share - Schedule o

Net Loss Per Share - Schedule of Reconciliation Of Net Loss Available To Common Stockholders And The Computation Of Bsic And Diluted Loss Per Share (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Net loss	$ (11,808)	$ (21,002)	$ (55,319)	$ (19,862)
Weighted-average shares used in computing net loss per share, basic and diluted	16,204,614	14,602,926	14,881,325	13,862,582
Net loss per share, basic and diluted	$ (0.73)	$ (1.44)	$ (3.72)	$ (1.43)

Net Loss Per Share - Schedule_2

Net Loss Per Share - Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share (Detail) - shares	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	110,693,104	107,854,122	113,864,588	102,487,402
Series A and B redeemable convertible preferred stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	99,734,543	60,368,493	99,734,543	58,948,067
Potential issuance of Series B redeemable convertible preferred stock under Tranche 2 [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	0	19,683,025	0	19,683,025
Potential issuance of Series B redeemable convertible preferred stock under Tranche 3 [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	0	19,683,025	0	19,683,025
Stock options to purchase common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	9,273,083	8,119,579	11,711,174	4,173,285
Unvested early exercised options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	1,685,478	0	2,418,871	0

Commitments And Contingencies -

Commitments And Contingencies - Additional Information (Details) - USD ($)					3 Months Ended		10 Months Ended	12 Months Ended
	Sep. 21, 2021	Aug. 31, 2021	Jun. 03, 2021	May 28, 2021	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2021
Other Commitments [Line Items]
Payment of underwriter discount					$ 0	$ 42,000
Lessee operating lease, liability to be paid					61,068,000		$ 61,749,000	$ 61,749,000
Licence agreements annual maintenance payments payable					100,000		$ 100,000	$ 100,000
DYNAMICS SPECIAL PURPOSE [Member]
Other Commitments [Line Items]
Issuance of Series B redeemable convertible preferred stock, net of preferred stock tranche liability of $5.4 million and issuance costs of $0.3 million Shares							715,500
Payment of underwriter discount							$ 523,430
Collaboration and Option Agreement [Member] | BlueRock Therapeutics LP [Member]
Other Commitments [Line Items]
Long term purchase commitment period								3 years
Long-term purchase commitment amount					10,000,000			$ 10,000,000
Sponsored Research Agreements [Member]
Other Commitments [Line Items]
Long-term purchase commitment amount					2,100,000			$ 2,200,000
cGMP Facility Alameda California [Member]
Other Commitments [Line Items]
Lease expiration year			2032					2032
Lessee operating lease, liability to be paid			$ 46,000,000
Lease term			11 years
cGMP Facility Alameda California [Member] | Capital Addition Purchase Commitments [Member]
Other Commitments [Line Items]
Aggregate construction costs paid					8,200,000		$ 2,600,000	$ 2,600,000
Long-term purchase commitment amount					$ 35,500,000			$ 35,500,000
Financial Advisor Agreement [Member] | DYNAMICS SPECIAL PURPOSE [Member]
Other Commitments [Line Items]
Accrued professional fees		$ 1,000,000
Agreement, Termination date		Dec. 16, 2022
Placement Agent Agreement [Member] | DYNAMICS SPECIAL PURPOSE [Member]
Other Commitments [Line Items]
Agreement, Termination date	Aug. 28, 2022
Percentage of fee payable to agents to aggregate price at which the shares of common stock sold to investors	4%
Percentage of fee receive by agents	33.30%
Over-Allotment Option [Member] | DYNAMICS SPECIAL PURPOSE [Member]
Other Commitments [Line Items]
Overallotment Option Vesting Period					45 days		45 days
Common stock shares subscribed but not issued					3,000,000		3,000,000	3,000,000
Underwriter discount per unit				$ 0.2
Payment of underwriter discount				$ 4,600,000
Deferred underwriting fee payable per unit				$ 0.35
Deferred underwriting commissions				$ 8,050,000	$ 7,050,000		$ 7,050,000	$ 7,050,000
Deferred underwriting commissions, Waived					$ 1,000,000		$ 1,000,000
Over-Allotment Option [Member] | Common Class A [Member] | DYNAMICS SPECIAL PURPOSE [Member]
Other Commitments [Line Items]
Issuance of Series B redeemable convertible preferred stock, net of preferred stock tranche liability of $5.4 million and issuance costs of $0.3 million Shares				3,000,000

Income Tax - Schedule of Defer

Income Tax - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)	Dec. 31, 2021	Dec. 19, 2021	Dec. 31, 2020
Deferred tax assets:
Start-up costs	$ 551,466,000
Net operating losses	32,562,000
Tax credits	4,915,000		$ 2,775,000
Lease Liability	6,350,000		3,930,000
Accruals and reserves	738,000		526,000
Stock-based compensation	28,000		17,000
Other	600,000		2,000
Total deferred tax assets	584,028,000
Deferred tax liabilities:
Operating lease right-of-use assets	(5,789,000)		(3,590,000)
Fixed asset basis	(236,000)		(178,000)
Total deferred tax liabilities	(6,025,000)		(3,768,000)
Valuation allowance	(584,028,000)	$ (584,028)
Deferred tax assets, net of allowance	0
Net deferred taxes	0		0
Deferred Taxes [Member]
Deferred tax assets:
Net operating losses	23,104,000		15,543,000
Total deferred tax assets	35,735,000		22,793,000
Deferred tax liabilities:
Valuation allowance	$ (29,710,000)		$ (19,025,000)

Income Tax - Schedule Of Compon

Income Tax - Schedule Of Components Of Income Tax Expense Benefit (Details) - USD ($)	10 Months Ended	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Federal
Current	$ 0
Deferred	(584,028)
State
Current	0
Deferred	0
Change in valuation allowance	584,028	$ 10,700,000	$ 7,900,000
Income tax provision	$ 0	$ 0	$ 0

Income Tax - Summary of Net Ope

Income Tax - Summary of Net Operating Losses And Tax Credit Carryforwards (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 19, 2021
Domestic Tax Authority [Member]
Operating Losses And Tax Credit Carryforwaards [Line Items]
Net operating losses, amount		$ 155,000
Domestic Tax Authority [Member] | Indefinitely Carryforward [Member]
Operating Losses And Tax Credit Carryforwaards [Line Items]
Net operating losses, amount	$ 86,602,000
Net operating losses, description of expiration	Do Not Expire
Domestic Tax Authority [Member] | Tax Period Two Thousand And Thirty One [Member]
Operating Losses And Tax Credit Carryforwaards [Line Items]
Net operating losses, amount	$ 3,508,000
Net operating losses, expiration date	Dec. 31, 2031
Domestic Tax Authority [Member] | Tax Period Two Thousand And Thirty Two [Member]
Operating Losses And Tax Credit Carryforwaards [Line Items]
Tax credits, amount	$ 3,573,000
Tax credits, expiration date	Dec. 31, 2032
State and Local Jurisdiction [Member] | Indefinitely Carryforward [Member]
Operating Losses And Tax Credit Carryforwaards [Line Items]
Tax credits, amount	$ 3,120,000
Tax credits, description of expiration	Do Not Expire
State and Local Jurisdiction [Member] | Tax Period Two Thousand And Thirty Two [Member]
Operating Losses And Tax Credit Carryforwaards [Line Items]
Net operating losses, amount	$ 55,023,000
Net operating losses, expiration date	Dec. 31, 2032
Foreign Tax Authority [Member] | Indefinitely Carryforward [Member]
Operating Losses And Tax Credit Carryforwaards [Line Items]
Net operating losses, amount	$ 1,146,000
Net operating losses, description of expiration	Do Not Expire

Income Tax - Schedule Of Effec

Income Tax - Schedule Of Effective Income Tax Rate Reconciliation (Details)	10 Months Ended	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Effective Income Tax Rate Reconciliation, Percent [Abstract]
Statutory rate	21%	21%	21%
State tax	0%	2.98%	11.68%
Other	0%	(0.80%)	(0.05%)
Tax credits		2.29%	2.81%
Fair value of series B preferred stock tranche liability		(5.60%)	6.04%
Valuation allowance	(15.10%)	(19.87%)	(41.48%)
Business combination transaction costs	(5.90%)
Total	0%	0%	0%

Income Tax - Additional Informa

Income Tax - Additional Information (Details) - USD ($)	10 Months Ended	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 19, 2021
Deferred tax assets, Valuation allowance	$ 584,028,000	$ 584,028,000		$ 584,028
Increase valuation allowance	584,028	10,700,000	$ 7,900,000
Income tax provision	0	0	0
Gross unrecognized tax benefits			1,300,000
Accrued interest and penalties related to unrecognized tax benefits	$ 0	$ 0	$ 0
Domestic Tax Authority [Member]
Operating loss carry forwards				$ 155,000
Operating Loss Carry Forwards Term	indefinitely

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Assets And Liabilities Measured at Fair Value Recurring Basis (Details) - Fair Value, Recurring [Member] - US Treasury Securities [Member] - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments held in Trust Account	$ 230,031,946	$ 230,008,784
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments held in Trust Account	230,031,946	230,008,784
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments held in Trust Account	0	0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments held in Trust Account	$ 0	$ 0

Fair Value Measurements - Sum_2

Fair Value Measurements - Summary of Estimated Value of Cash Equivalents and Restricted Cash (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Amortized Cost	$ 41,397	$ 59,291	$ 30,884
Unrealized Gain	0	0	0
Unrealized Loss	0	0	0
Estimated Fair Value	41,397	59,291	30,884
Cash And Cash Equivalents Money Market Fund Investments [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Amortized Cost	38,140	56,034	30,387
Unrealized Gain	0	0	0
Unrealized Loss	0	0	0
Estimated Fair Value	38,140	56,034	30,387
Restricted Cash And Cash Equivalents Money Market Fund Invesments [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Amortized Cost	3,257	3,257	497
Unrealized Gain	0	0	0
Unrealized Loss	0	0	0
Estimated Fair Value	$ 3,257	$ 3,257	$ 497

Fair Value Measurements - Sum_3

Fair Value Measurements - Summary of Financial Assets and Liabilities Measured and Recognized at Fair Value (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure In Tabular Form Of Fair Value Of Financial Assets And Liabilities [Line Items]
Cash equivalents, Money market fund	$ 38,140	$ 56,034	$ 30,387
Restricted cash, Money market fund	3,257	3,257	497
Total	41,397	59,291	30,884
Total Liabilities			435
Preferred Stock Tranche Liability [Member]
Disclosure In Tabular Form Of Fair Value Of Financial Assets And Liabilities [Line Items]
Preferred stock tranche liability			435
Level 1
Disclosure In Tabular Form Of Fair Value Of Financial Assets And Liabilities [Line Items]
Cash equivalents, Money market fund	38,140	56,034	30,387
Restricted cash, Money market fund	3,257	3,257	497
Total	41,397	59,291	30,884
Total Liabilities			0
Level 1 | Preferred Stock Tranche Liability [Member]
Disclosure In Tabular Form Of Fair Value Of Financial Assets And Liabilities [Line Items]
Preferred stock tranche liability			0
Level 2
Disclosure In Tabular Form Of Fair Value Of Financial Assets And Liabilities [Line Items]
Cash equivalents, Money market fund	0	0	0
Restricted cash, Money market fund	0	0
Total	0	0	0
Total Liabilities			0
Level 2 | Preferred Stock Tranche Liability [Member]
Disclosure In Tabular Form Of Fair Value Of Financial Assets And Liabilities [Line Items]
Preferred stock tranche liability			0
Level 3
Disclosure In Tabular Form Of Fair Value Of Financial Assets And Liabilities [Line Items]
Cash equivalents, Money market fund	0	0	0
Restricted cash, Money market fund	0	0
Total	$ 0	$ 0	0
Total Liabilities			435
Level 3 | Preferred Stock Tranche Liability [Member]
Disclosure In Tabular Form Of Fair Value Of Financial Assets And Liabilities [Line Items]
Preferred stock tranche liability			$ 435

Fair Value Measurements - Sum_4

Fair Value Measurements - Summary of Significant Quantitative Inputs Used in the Valuation of the Preferred Stock Tranche Liability (Detail) - Preferred Stock Tranche Liability [Member]

Mar. 31, 2021 d

Mar. 31, 2021 shares

Mar. 31, 2021

Dec. 31, 2020 d

Dec. 31, 2020 shares

Dec. 31, 2020

Dec. 31, 2020 yr

Dec. 28, 2020 d

Dec. 28, 2020 shares

Dec. 28, 2020

Dec. 28, 2020 yr

Oct. 22, 2020 d

Oct. 22, 2020 shares

Oct. 22, 2020

Oct. 22, 2020 yr

Value of each tranche feature

Disclosure In Tabular Form Of Significant Unobservable Inputs Used In The Measurement Of Preferred Stock Tranche Liability [Line Items]

Embedded Derivative Liability, Measurement Input

(0.023)

Tranche Two Call Option [Member] | Estimated fair value of Series B redeemable convertible preferred stock

Disclosure In Tabular Form Of Significant Unobservable Inputs Used In The Measurement Of Preferred Stock Tranche Liability [Line Items]

Embedded Derivative Liability, Measurement Input

1.25

[1]

1.25

Tranche Two Call Option [Member] | Discount rate

Disclosure In Tabular Form Of Significant Unobservable Inputs Used In The Measurement Of Preferred Stock Tranche Liability [Line Items]

Embedded Derivative Liability, Measurement Input

0.12

0.12

Tranche Two Call Option [Member] | Time to liquidity

Disclosure In Tabular Form Of Significant Unobservable Inputs Used In The Measurement Of Preferred Stock Tranche Liability [Line Items]

Embedded Derivative Liability, Measurement Input

0.9

0.9

Tranche Two Call Option [Member] | Expected volatility

Disclosure In Tabular Form Of Significant Unobservable Inputs Used In The Measurement Of Preferred Stock Tranche Liability [Line Items]

Embedded Derivative Liability, Measurement Input

54.9

54.9

Tranche Two Call Option [Member] | Strike Price

Disclosure In Tabular Form Of Significant Unobservable Inputs Used In The Measurement Of Preferred Stock Tranche Liability [Line Items]

Embedded Derivative Liability, Measurement Input

1.6427

1.6427

Tranche Two Call Option [Member] | Value of each tranche feature

Disclosure In Tabular Form Of Significant Unobservable Inputs Used In The Measurement Of Preferred Stock Tranche Liability [Line Items]

Embedded Derivative Liability, Measurement Input

0.143

Tranche Three Call Option [Member] | Estimated fair value of Series B redeemable convertible preferred stock

Disclosure In Tabular Form Of Significant Unobservable Inputs Used In The Measurement Of Preferred Stock Tranche Liability [Line Items]

Embedded Derivative Liability, Measurement Input

1.25

[1]

1.25

Tranche Three Call Option [Member] | Estimated fair value of Series B redeemable convertible preferred stock | Public Scenario [Member]

Disclosure In Tabular Form Of Significant Unobservable Inputs Used In The Measurement Of Preferred Stock Tranche Liability [Line Items]

Embedded Derivative Liability, Measurement Input

2.3386

Tranche Three Call Option [Member] | Estimated fair value of Series B redeemable convertible preferred stock | Staying Private Scenario [Member]

Disclosure In Tabular Form Of Significant Unobservable Inputs Used In The Measurement Of Preferred Stock Tranche Liability [Line Items]

Embedded Derivative Liability, Measurement Input

1.3023

Tranche Three Call Option [Member] | Discount rate

Disclosure In Tabular Form Of Significant Unobservable Inputs Used In The Measurement Of Preferred Stock Tranche Liability [Line Items]

Embedded Derivative Liability, Measurement Input

0.17

0.17

Tranche Three Call Option [Member] | Discount rate | Public Scenario [Member]

Disclosure In Tabular Form Of Significant Unobservable Inputs Used In The Measurement Of Preferred Stock Tranche Liability [Line Items]

Embedded Derivative Liability, Measurement Input

0.05

Tranche Three Call Option [Member] | Discount rate | Staying Private Scenario [Member]

Disclosure In Tabular Form Of Significant Unobservable Inputs Used In The Measurement Of Preferred Stock Tranche Liability [Line Items]

Embedded Derivative Liability, Measurement Input

0.06

Tranche Three Call Option [Member] | Time to liquidity

Disclosure In Tabular Form Of Significant Unobservable Inputs Used In The Measurement Of Preferred Stock Tranche Liability [Line Items]

Embedded Derivative Liability, Measurement Input

2.2

2.2

Tranche Three Call Option [Member] | Time to liquidity | Public Scenario [Member]

Disclosure In Tabular Form Of Significant Unobservable Inputs Used In The Measurement Of Preferred Stock Tranche Liability [Line Items]

Embedded Derivative Liability, Measurement Input

0.5

Tranche Three Call Option [Member] | Time to liquidity | Staying Private Scenario [Member]

Disclosure In Tabular Form Of Significant Unobservable Inputs Used In The Measurement Of Preferred Stock Tranche Liability [Line Items]

Embedded Derivative Liability, Measurement Input

0.75

Tranche Three Call Option [Member] | Expected volatility

Disclosure In Tabular Form Of Significant Unobservable Inputs Used In The Measurement Of Preferred Stock Tranche Liability [Line Items]

Embedded Derivative Liability, Measurement Input

54.9

54.9

Tranche Three Call Option [Member] | Expected volatility | Public Scenario [Member]

Disclosure In Tabular Form Of Significant Unobservable Inputs Used In The Measurement Of Preferred Stock Tranche Liability [Line Items]

Embedded Derivative Liability, Measurement Input

80

Tranche Three Call Option [Member] | Expected volatility | Staying Private Scenario [Member]

Disclosure In Tabular Form Of Significant Unobservable Inputs Used In The Measurement Of Preferred Stock Tranche Liability [Line Items]

Embedded Derivative Liability, Measurement Input

80

Tranche Three Call Option [Member] | Probability of call option and forward contract | Public Scenario [Member]

Disclosure In Tabular Form Of Significant Unobservable Inputs Used In The Measurement Of Preferred Stock Tranche Liability [Line Items]

Embedded Derivative Liability, Measurement Input

25

Tranche Three Call Option [Member] | Probability of call option and forward contract | Staying Private Scenario [Member]

Disclosure In Tabular Form Of Significant Unobservable Inputs Used In The Measurement Of Preferred Stock Tranche Liability [Line Items]

Embedded Derivative Liability, Measurement Input

45

Tranche Three Call Option [Member] | Strike Price

Disclosure In Tabular Form Of Significant Unobservable Inputs Used In The Measurement Of Preferred Stock Tranche Liability [Line Items]

Embedded Derivative Liability, Measurement Input

1.6427

1.6427

Tranche Three Call Option [Member] | Strike Price | Public Scenario [Member]

Disclosure In Tabular Form Of Significant Unobservable Inputs Used In The Measurement Of Preferred Stock Tranche Liability [Line Items]

Embedded Derivative Liability, Measurement Input | shares

1.6427

Tranche Three Call Option [Member] | Strike Price | Staying Private Scenario [Member]

Disclosure In Tabular Form Of Significant Unobservable Inputs Used In The Measurement Of Preferred Stock Tranche Liability [Line Items]

Embedded Derivative Liability, Measurement Input | shares

1.6427

Tranche Three Call Option [Member] | Value of each tranche feature

Disclosure In Tabular Form Of Significant Unobservable Inputs Used In The Measurement Of Preferred Stock Tranche Liability [Line Items]

Embedded Derivative Liability, Measurement Input

0.199

Tranche Three Call Option [Member] | Value of each tranche feature | Public Scenario [Member]

Disclosure In Tabular Form Of Significant Unobservable Inputs Used In The Measurement Of Preferred Stock Tranche Liability [Line Items]

Embedded Derivative Liability, Measurement Input

0.873

Tranche Three Call Option [Member] | Value of each tranche feature | Staying Private Scenario [Member]

Disclosure In Tabular Form Of Significant Unobservable Inputs Used In The Measurement Of Preferred Stock Tranche Liability [Line Items]

Embedded Derivative Liability, Measurement Input

0.251

Tranche Two And Three Call Option [Member] | Estimated fair value of Series B redeemable convertible preferred stock

Disclosure In Tabular Form Of Significant Unobservable Inputs Used In The Measurement Of Preferred Stock Tranche Liability [Line Items]

Embedded Derivative Liability, Measurement Input

1.62

1.62

[1]

1.62

Tranche Two And Three Call Option [Member] | Discount rate

Disclosure In Tabular Form Of Significant Unobservable Inputs Used In The Measurement Of Preferred Stock Tranche Liability [Line Items]

Embedded Derivative Liability, Measurement Input

0.11

0.11

0.11

Tranche Two And Three Call Option [Member] | Time to liquidity

Disclosure In Tabular Form Of Significant Unobservable Inputs Used In The Measurement Of Preferred Stock Tranche Liability [Line Items]

Embedded Derivative Liability, Measurement Input

0.5

0.5

Tranche Two And Three Call Option [Member] | Expected volatility

Disclosure In Tabular Form Of Significant Unobservable Inputs Used In The Measurement Of Preferred Stock Tranche Liability [Line Items]

Embedded Derivative Liability, Measurement Input

73.8

73.8

73.8

Tranche Two And Three Call Option [Member] | Probability of call option and forward contract

Disclosure In Tabular Form Of Significant Unobservable Inputs Used In The Measurement Of Preferred Stock Tranche Liability [Line Items]

Embedded Derivative Liability, Measurement Input

10

10

10

Tranche Two And Three Call Option [Member] | Strike Price

Disclosure In Tabular Form Of Significant Unobservable Inputs Used In The Measurement Of Preferred Stock Tranche Liability [Line Items]

Embedded Derivative Liability, Measurement Input

1.6427

1.6427

1.6427

Tranche Two And Three Call Option [Member] | Value of each tranche feature

Disclosure In Tabular Form Of Significant Unobservable Inputs Used In The Measurement Of Preferred Stock Tranche Liability [Line Items]

Embedded Derivative Liability, Measurement Input

0.326

0.326

Tranche Two And Three Forward Contract [Member] | Estimated fair value of Series B redeemable convertible preferred stock

Disclosure In Tabular Form Of Significant Unobservable Inputs Used In The Measurement Of Preferred Stock Tranche Liability [Line Items]

Embedded Derivative Liability, Measurement Input

1.62

[1]

1.62

Tranche Two And Three Forward Contract [Member] | Discount rate

Disclosure In Tabular Form Of Significant Unobservable Inputs Used In The Measurement Of Preferred Stock Tranche Liability [Line Items]

Embedded Derivative Liability, Measurement Input

0.11

0.11

0.11

Tranche Two And Three Forward Contract [Member] | Time to liquidity

Disclosure In Tabular Form Of Significant Unobservable Inputs Used In The Measurement Of Preferred Stock Tranche Liability [Line Items]

Embedded Derivative Liability, Measurement Input

0.5

0.5

0.5

Tranche Two And Three Forward Contract [Member] | Probability of call option and forward contract

Disclosure In Tabular Form Of Significant Unobservable Inputs Used In The Measurement Of Preferred Stock Tranche Liability [Line Items]

Embedded Derivative Liability, Measurement Input

90

90

90

Tranche Two And Three Forward Contract [Member] | Strike Price

Disclosure In Tabular Form Of Significant Unobservable Inputs Used In The Measurement Of Preferred Stock Tranche Liability [Line Items]

Embedded Derivative Liability, Measurement Input

1.6427

1.6427

1.6427

Tranche Two And Three Forward Contract [Member] | Value of each tranche feature

Disclosure In Tabular Form Of Significant Unobservable Inputs Used In The Measurement Of Preferred Stock Tranche Liability [Line Items]

Embedded Derivative Liability, Measurement Input

0.023

0.023

Tranche Two Forward Contract [Member]

Disclosure In Tabular Form Of Significant Unobservable Inputs Used In The Measurement Of Preferred Stock Tranche Liability [Line Items]

Embedded Derivative Liability, Measurement Input

8,600,000

8,600,000

Tranche Two Forward Contract [Member] | Estimated fair value of Series B redeemable convertible preferred stock

Disclosure In Tabular Form Of Significant Unobservable Inputs Used In The Measurement Of Preferred Stock Tranche Liability [Line Items]

Embedded Derivative Liability, Measurement Input

2.0796

Tranche Two Forward Contract [Member] | Estimated fair value of Series B redeemable convertible preferred stock | Staying Private Scenario [Member]

Disclosure In Tabular Form Of Significant Unobservable Inputs Used In The Measurement Of Preferred Stock Tranche Liability [Line Items]

Embedded Derivative Liability, Measurement Input

1.3023

Tranche Two Forward Contract [Member] | Discount rate

Disclosure In Tabular Form Of Significant Unobservable Inputs Used In The Measurement Of Preferred Stock Tranche Liability [Line Items]

Embedded Derivative Liability, Measurement Input

0.03

Tranche Two Forward Contract [Member] | Discount rate | Staying Private Scenario [Member]

Disclosure In Tabular Form Of Significant Unobservable Inputs Used In The Measurement Of Preferred Stock Tranche Liability [Line Items]

Embedded Derivative Liability, Measurement Input

0.06

Tranche Two Forward Contract [Member] | Time to liquidity

Disclosure In Tabular Form Of Significant Unobservable Inputs Used In The Measurement Of Preferred Stock Tranche Liability [Line Items]

Embedded Derivative Liability, Measurement Input

0.08

Tranche Two Forward Contract [Member] | Time to liquidity | Staying Private Scenario [Member]

Disclosure In Tabular Form Of Significant Unobservable Inputs Used In The Measurement Of Preferred Stock Tranche Liability [Line Items]

Embedded Derivative Liability, Measurement Input

0.75

Tranche Two Forward Contract [Member] | Probability of call option and forward contract

Disclosure In Tabular Form Of Significant Unobservable Inputs Used In The Measurement Of Preferred Stock Tranche Liability [Line Items]

Embedded Derivative Liability, Measurement Input

100

Tranche Two Forward Contract [Member] | Probability of call option and forward contract | Staying Private Scenario [Member]

Disclosure In Tabular Form Of Significant Unobservable Inputs Used In The Measurement Of Preferred Stock Tranche Liability [Line Items]

Embedded Derivative Liability, Measurement Input

5

Tranche Two Forward Contract [Member] | Strike Price

Disclosure In Tabular Form Of Significant Unobservable Inputs Used In The Measurement Of Preferred Stock Tranche Liability [Line Items]

Embedded Derivative Liability, Measurement Input | shares

1.6427

Tranche Two Forward Contract [Member] | Strike Price | Staying Private Scenario [Member]

Disclosure In Tabular Form Of Significant Unobservable Inputs Used In The Measurement Of Preferred Stock Tranche Liability [Line Items]

Embedded Derivative Liability, Measurement Input | shares

1.6427

Tranche Two Forward Contract [Member] | Value of each tranche feature

Disclosure In Tabular Form Of Significant Unobservable Inputs Used In The Measurement Of Preferred Stock Tranche Liability [Line Items]

Embedded Derivative Liability, Measurement Input

0.437

Tranche Two Forward Contract [Member] | Value of each tranche feature | Staying Private Scenario [Member]

Disclosure In Tabular Form Of Significant Unobservable Inputs Used In The Measurement Of Preferred Stock Tranche Liability [Line Items]

Embedded Derivative Liability, Measurement Input

(0.34)

Tranche Three No Value [Member] | Public Scenario [Member]

Disclosure In Tabular Form Of Significant Unobservable Inputs Used In The Measurement Of Preferred Stock Tranche Liability [Line Items]

Embedded Derivative Liability, Measurement Input

4,300,000

Tranche Three No Value [Member] | Staying Private Scenario [Member]

Disclosure In Tabular Form Of Significant Unobservable Inputs Used In The Measurement Of Preferred Stock Tranche Liability [Line Items]

Embedded Derivative Liability, Measurement Input

1,900,000

Tranche Three No Value [Member] | Probability of call option and forward contract | Public Scenario [Member]

Disclosure In Tabular Form Of Significant Unobservable Inputs Used In The Measurement Of Preferred Stock Tranche Liability [Line Items]

Embedded Derivative Liability, Measurement Input

75

Tranche Three No Value [Member] | Probability of call option and forward contract | Staying Private Scenario [Member]

Disclosure In Tabular Form Of Significant Unobservable Inputs Used In The Measurement Of Preferred Stock Tranche Liability [Line Items]

Embedded Derivative Liability, Measurement Input

50

[1]Fair value of the Series B redeemable convertible preferred stock was estimated using the Backsolve method.

Fair Value Measurements- Summar

Fair Value Measurements- Summary of significant quantitative inputs used to fair value the convertible notes (Detail) - Convertible Debt [Member]	Dec. 31, 2021 d
Interest rate
Disclosure In Tabular Form Of Significant Unobservable Input Used In Calculation Of Fair Value Of Convertible Notes [Line Items]
Convertible Notes at Issuance	8
Discount rate
Disclosure In Tabular Form Of Significant Unobservable Input Used In Calculation Of Fair Value Of Convertible Notes [Line Items]
Convertible Notes at Issuance	6.78
Time to maturity (years)
Disclosure In Tabular Form Of Significant Unobservable Input Used In Calculation Of Fair Value Of Convertible Notes [Line Items]
Convertible Notes at Issuance	0.49
Probability of automatic conversion upon qualified financing
Disclosure In Tabular Form Of Significant Unobservable Input Used In Calculation Of Fair Value Of Convertible Notes [Line Items]
Convertible Notes at Issuance	95
Probability of optional conversion
Disclosure In Tabular Form Of Significant Unobservable Input Used In Calculation Of Fair Value Of Convertible Notes [Line Items]
Convertible Notes at Issuance	2.5
Probability of no conversion
Disclosure In Tabular Form Of Significant Unobservable Input Used In Calculation Of Fair Value Of Convertible Notes [Line Items]
Convertible Notes at Issuance	2.5
Conversion Price
Disclosure In Tabular Form Of Significant Unobservable Input Used In Calculation Of Fair Value Of Convertible Notes [Line Items]
Convertible Notes at Issuance	1.4784

Fair Value Measurements- Summ_2

Fair Value Measurements- Summary of fair value of the convertible notes (Detail) $ in Thousands	5 Months Ended
	Dec. 31, 2020 USD ($)
Disclosure In Tabular Form Of Change In The Fair Value Of Convertible Notes [Line Items]
Total preferred stock tranche liability	$ 400
Convertible Debt [Member]
Disclosure In Tabular Form Of Change In The Fair Value Of Convertible Notes [Line Items]
Proceeds from issuance in August 2020	8,000
Change in fair value of the preferred stock tranche liability	720
Conversion to Series B redeemable convertible preferred stock	(7,940)
Recognition of preferred stock tranche liability	(780)
Total preferred stock tranche liability	$ 0

Fair Value Measurements - Sum_5

Fair Value Measurements - Summary of Significant Quantitative Inputs Used in the Valuation of the Preferred Stock Tranche Liability (Parenthetical) (Detail) - $ / shares	Mar. 31, 2021	Dec. 31, 2020	Dec. 28, 2020	Oct. 22, 2020
Disclosure In Tabular Form Of Significant Unobservable Inputs Used In The Measurement Of Preferred Stock Tranche Liability [Line Items]
Weighted Fair Value Of The Tranche Feature			$ 0.012	$ 0.172
Preferred Stock Tranche Liability [Member]
Disclosure In Tabular Form Of Significant Unobservable Inputs Used In The Measurement Of Preferred Stock Tranche Liability [Line Items]
Weighted Fair Value Of The Tranche Feature	$ 0.312	$ 0.012	$ 0.012	$ 0.172

Fair Value Measurements - Sum_6

Fair Value Measurements - Summary of a weighted comparable guideline IPO (high and low) and SPAC transactions (Detail) - Tranche Rights Acquired [Member]	May 14, 2021 d
Estimated Fair Value Of Series B Redeemable Convertible Preferred Stock [Member] | Public Scenario [Member]
Disclosure In Tabular Form Of Significant Unobservable Inputs Used In Measurement Of Fair Value Of Tranche Rights Acquired [Line Items]
Embedded Derivative Liability, Measurement Input	2.18
Estimated Fair Value Of Series B Redeemable Convertible Preferred Stock [Member] | Staying Private Scenario [Member]
Disclosure In Tabular Form Of Significant Unobservable Inputs Used In Measurement Of Fair Value Of Tranche Rights Acquired [Line Items]
Embedded Derivative Liability, Measurement Input	1.58
Value Of Each Tranche Feature [Member] | Public Scenario [Member]
Disclosure In Tabular Form Of Significant Unobservable Inputs Used In Measurement Of Fair Value Of Tranche Rights Acquired [Line Items]
Embedded Derivative Liability, Measurement Input	1.637
Value Of Each Tranche Feature [Member] | Staying Private Scenario [Member]
Disclosure In Tabular Form Of Significant Unobservable Inputs Used In Measurement Of Fair Value Of Tranche Rights Acquired [Line Items]
Embedded Derivative Liability, Measurement Input	0.395
Weighted Average Fair Value Of Series B Redeemable Convertible Preferred Stock [Member] | Public Scenario [Member]
Disclosure In Tabular Form Of Significant Unobservable Inputs Used In Measurement Of Fair Value Of Tranche Rights Acquired [Line Items]
Embedded Derivative Liability, Measurement Input	2.032
Weighted Average Fair Value Of Series B Redeemable Convertible Preferred Stock [Member] | Staying Private Scenario [Member]
Disclosure In Tabular Form Of Significant Unobservable Inputs Used In Measurement Of Fair Value Of Tranche Rights Acquired [Line Items]
Embedded Derivative Liability, Measurement Input	2.032

Fair Value Measurements - Sum_7

Fair Value Measurements - Summary of a weighted comparable guideline IPO (high and low) and SPAC transactions (Parenthetical) (Detail) - Series B Redeemable Convertible Preferred Stock [Member] $ / shares in Units, $ in Millions	May 14, 2021 USD ($) $ / shares
Disclosure In Tabular Form Of Significant Unobservable Inputs Used In Measurement Of Fair Value Of Tranche Rights Acquired [Line Items]
Weighted average value of redeemable convertible preferred stock	$ 2.032
Weighted average exercise price of redeemable convertible preferred stock	1.6427
Tranche Rights Acquired [Member]
Disclosure In Tabular Form Of Significant Unobservable Inputs Used In Measurement Of Fair Value Of Tranche Rights Acquired [Line Items]
Weighted average fair value of the tranche feature	$ 0.3893
Fair value with unobservable input reconciliation recurring basis liability settlements | $	$ 15.2

Fair Value Measurements - Sum_8

Fair Value Measurements - Summary of table provides a roll-forward of the change in the preferred stock tranche liability (Detail) - USD ($) $ in Thousands	2 Months Ended	3 Months Ended	12 Months Ended
	Dec. 28, 2020	Mar. 31, 2021	Dec. 31, 2021
Disclosure In Tabular Form Of Change In The Fair Value Of Preferred Stock Tranche Liability Using Significant Unobservable Input [Line Items]
Beginning balance		$ 400	$ 400
Ending Balance
Preferred Stock Tranche Liability [Member]
Disclosure In Tabular Form Of Change In The Fair Value Of Preferred Stock Tranche Liability Using Significant Unobservable Input [Line Items]
Initial closing on October 22, 2020	$ 6,120
Forfeiture of tranche rights	(780)
Change in fair value	(4,968)	11,800	14,742
Second closing on December 28, 2020	$ 63
Beginning balance		435	435
Recognition of tranche rights from January 2021 issuance			33
Tranche liability extinguishment			(15,210)
Ending Balance		$ 12,300	$ 0

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) $ / shares in Units, $ in Thousands, d in Millions

1 Months Ended

2 Months Ended

3 Months Ended

5 Months Ended

12 Months Ended

May 14, 2021 shares

Oct. 01, 2020 USD ($) shares

Jan. 31, 2021 USD ($)

Oct. 31, 2020 shares

Aug. 31, 2020 USD ($)

Dec. 28, 2020 USD ($) $ / shares

Mar. 31, 2021 USD ($)

Dec. 31, 2020 USD ($) $ / shares

Dec. 31, 2021 USD ($)

Aug. 31, 2020 USD ($)

Mar. 31, 2021 d

Mar. 31, 2021 $ / shares

Mar. 31, 2021

Oct. 22, 2020 $ / shares

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Gain loss on convertible notes issued

$ 900

Weighted average fair value of the tranche feauture | $ / shares

$ 0.012

$ 0.172

Total preferred stock tranche liability

$ 400

Convertible Debt [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Fair value of convertible notes issued

$ 8,900

Total preferred stock tranche liability

0

Change in fair value of the preferred stock tranche liability

$ 720

Preferred Stock Tranche Liability [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Weighted average fair value of the tranche feauture | $ / shares

$ 0.012

$ 0.012

$ 0.312

$ 0.172

Total preferred stock tranche liability

$ 12,300

$ 435

$ 0

Change in fair value of the preferred stock tranche liability

$ (4,968)

11,800

$ 14,742

Preferred Stock Tranche Liability [Member] | Tranche Two Forward Contract [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Total forward contract

8.6

8,600,000

Preferred Stock Tranche Liability [Member] | Public Scenario [Member] | Tranche Three NoValue [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Total forward contract

4,300,000

Preferred Stock Tranche Liability [Member] | Staying Private Scenario [Member] | Tranche Three NoValue [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Total forward contract

1,900,000

Tranche Rights Acquired [Member] | Tranche Three NoValue [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Total forward contract

3,700,000

Tranche Rights Acquired [Member] | Public Scenario [Member] | Scenario Weighing [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Embedded derivative liability, measurement input percentage

75%

Tranche Rights Acquired [Member] | Staying Private Scenario [Member] | Scenario Weighing [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Embedded derivative liability, measurement input percentage

25%

Series B Redeemable Convertible Preferred Stock [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Debt instrument convertible number of shares issued | shares

5,485,858

Recognition of liability in connection with issue of redeemable convertible preferred stock

$ 33

Series B Redeemable Convertible Preferred Stock [Member] | Convertible Debt [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Debt instrument amount due at the time of conversion

$ 8,100

Debt instrument convertible number of shares issued | shares

5,485,858

Debt instrument fair value at the time of conversion

$ 8,700

Series B Redeemable Convertible Preferred Stock [Member] | Preferred Stock Tranche Liability [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Recognition of liability in connection with issue of redeemable convertible preferred stock

$ 33

Series B Redeemable Convertible Preferred Stock [Member] | Acheivement Of Milestone [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Temporary equity stock shares issued during the period shares | shares

39,366,050

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands		12 Months Ended
	May 19, 2022	Dec. 31, 2021	Dec. 31, 2020	Jun. 08, 2022
Subsequent Event [Line Items]
Proceeds from convertible debt		$ 0	$ 8,000
Subsequent Event [Member] | PIPE [Member]
Subsequent Event [Line Items]
Common stock, Value, Subscriptions				$ 66,800
Subsequent Event [Member] | Convertible Debt [Member] | Bayer HealthCare LLC [Member]
Subsequent Event [Line Items]
Proceeds from convertible debt	$ 5,200
Debt Instrument Interest Rate Stated Percentage	3%
Debt instrument, term	2 years
Debt instrument conversion price per share	$ 10

Events (Unreviewed) Subsequent

Events (Unreviewed) Subsequent - Additional Information (Detail)	Jun. 08, 2022 USD ($) $ / shares shares	May 19, 2022 shares	Mar. 31, 2022 $ / shares	Dec. 31, 2021 $ / shares	Dec. 31, 2020 $ / shares
Subsequent Event [Line Items]
Common stock, par value | $ / shares			$ 0.0001	$ 0.0001	$ 0.0001
Subsequent Event [Member] | Convertible Note Exchange [Member]
Subsequent Event [Line Items]
Debt conversion, original debt, amount	$ 5,175,000
Stock issued during period, shares, conversion of convertible debt | shares		517,500
Subsequent Event [Member] | PIPE [Member]
Subsequent Event [Line Items]
Common stock shares subscriptions value	$ 66,800,000
Subsequent Event [Member] | Business Combination Agreement [Member]
Subsequent Event [Line Items]
Business combination common stock exchange ratio	0.1957
Business combination preferred stock exchange ratio	1
Business combination contingent consideration common stock shares issuable | shares	2,000,000
Common stock, par value | $ / shares	$ 0.0001
Business combination gross proceeds received	$ 140,300,000
Business combination aggregate proceeds receivable	156,500,000
Business combination funding through cash held In trust net of redemptions	84,500,000
Subsequent Event [Member] | Business Combination Agreement [Member] | Bayer HealthCare LLC [Member]
Subsequent Event [Line Items]
Debt instrument face value	5,200,000
Subsequent Event [Member] | Business Combination Agreement [Member] | PIPE [Member]
Subsequent Event [Line Items]
Sale of stock consideration received on transaction	50,600,000
Common stock shares subscriptions value	$ 66,800,000
Number of new stock issued during the period | shares	5,060,000
Sale of stock, price per share | $ / shares	$ 10
Common stock shares proceeds receivable	$ 16,200,000